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Abstract 
Nrf2 is a transcription factor that plays a vital role in the cytoprotective response to 
oxidative stress. Under basal conditions Nrf2 is sequestered in the cytosol by Keap1, a 
molecule which targets Nrf2 for ubiquitination and subsequent proteasomal degradation. 
Following oxidative insult, Keap1 is no longer able to facilitate the breakdown of Nrf2. Nrf2 
accumulates in the cell and is free to translocate to the nucleus where it binds to the 
antioxidant response element (ARE) in a range of genes resulting in their expression. Nrf2 
regulates genes encoding phase II enzymes, proteins important for glutathione synthesis 
and antioxidants. Nrf2 knockout (KO) mice have been shown to be more susceptible to the 
toxicity associated with a range of different compounds, in the liver as well as in other 
organs. Conversely, pharmacological activation of Nrf2 has been shown to be protective in 
mouse models of hepatotoxicity.   
Drug induced liver injury (DILI) is a major concern for the pharmaceutical industry, and 
there is a clear imperative to improve existing preclinical models of DILI.  Oxidative stress is 
known to result from the administration of a number of model hepatotoxins and has also 
been associated with cases of idiosyncratic DILI.  Biomarkers of Nrf2 activity have potential 
utility in preclinical models investigating the role of oxidative stress in hepatotoxicity.  
Furthermore, such biomarkers could also have applications in studies determining the 
importance and variability of Nrf2 in the human population.  Consequently the aim of the 
work described in this thesis was to characterise the hepatic profiles of mice in which Nrf2 
activity had been modulated in order to identify candidate biomarkers of Nrf2 activity.   
iTRAQ analysis was employed in order to identify the proteins that were differentially 
expressed in the livers of wild type (WT) and Nrf2 KO mice.  Subsequent pathway analysis 
identified cytoprotection and lipid metabolism as the processes that were most 
significantly perturbed in the livers of KO animals, with lipid metabolism found to be 
negatively regulated by Nrf2. The development of an LC-MS/MS assay for the 
determination of hepatic GSH and GSSG levels in liver homogenates showed that basal GSH 
levels were reduced by 21.5% in Nrf2 KO mice when compared to their WT counterparts.  
GC-FID analysis identified a number of fatty acids with levels that differed in the livers of 
WT and Nrf2 KO animals, constitutively and following carbohydrate restriction. Preliminary 
lipidomic analysis also identified differences in the wider hepatic lipid profile of the 
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animals.  iTRAQ was further employed to investigate the hepatic proteomic profile of mice 
following the administration of a single 3mg/kg dose of the Nrf2 inducer, CDDO-Me. Five 
proteins were found to be regulated at both the basal and inducible level and so have 
significant potential to be used in the development of biomarkers indicative of Nrf2 
activity.   
The work described in this thesis highlights the importance of the roles that Nrf2 plays in 
the regulation of hepatic homeostasis in terms of both cytoprotection and lipid 
metabolism. Furthermore, it has identified proteins and pathways that have potential 
applications in the development of biomarkers of Nrf2 activity. Such biomarkers would 
have utility in preclinical assays and in investigations into the importance of the 
transcription factor in the human population.    
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1.1 Drug-induced liver injury 
1.1.1 Drug-induced damage of the liver 
 The liver is a vital organ for the maintenance of homeostasis within the body, and has a 
diverse range of functions in processes including digestion, protein synthesis and immunity.  
It has key roles in lipid metabolism and glucose regulation and protects organisms from 
systemic exposure to exogenous toxins through a variety of detoxification pathways.   
However, as the primary site for the processing of environmental toxins and drugs, the liver 
is particularly susceptible to drug-related toxicity. 
Drug induced liver injury (DILI) encompasses a heterogeneous set of conditions and can 
result from both acute and chronic exposure to drugs. DILI can be broadly divided into 
hepatocellular and cholestatic injury. Damage to cells in the liver can lead to hepatic 
necrosis, the development of fibrosis and hepatitis and in some cases, cancer. In its most 
serious form, hepatocellular damage can result in fulminant hepatic failure. Cholestatic 
liver injury occurs when bile flow is perturbed. It is usually reversible, and consequently has 
less propensity to result in severe liver injury (FDA, 2009).   
While drug administration can result in acute liver damage, chronic conditions may also 
develop as a result of drug toxicity, including non-alcoholic fatty liver disease (NAFLD) and 
steatosis.  In such cases, attributing liver injury to drug administration can be problematic, 
as both forms of liver disease are closely associated with metabolic syndrome and 
hyperlipidaemia. 20% of the adult population are estimated to have NAFLD (Chowdhry et 
al., 2010), consequently it is difficult to monitor the development of drug-induced fatty 
liver and to distinguish it from lifestyle-related disease. However, in a limited number of 
cases including that of valproic acid, a link between drug administration and NAFLD has 
been established (Sato et al., 2005; Verrotti et al., 2009). 
1.1.2 The impact of DILI on drug development  
Hepatotoxicity is a major concern for the pharmaceutical industry.  More than 600 drugs 
have been linked to cases of liver injury (Park et al., 2005a; Suh et al., 2003) and DILI is the 
reason most commonly cited for the withdrawal of an approved drug from the market (Lee, 
2003).   Greater than 50% of cases of acute liver failure in the USA can be attributed to DILI 
(Antoine et al., 2008) with the majority of patients requiring a liver transplant in order to 
survive.  Given that there is a 60 to 80% mortality rate in patients with acute liver failure 
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who do not receive a transplant (Bjornsson et al., 2005), together with the contribution of 
hepatotoxicity to instances of drug withdrawal, it is clear that DILI poses a significant threat 
to public health.  
The problem of DILI is also severe in terms of the cost to the pharmaceutical industry. It is 
estimated that in the last decade, the cost of developing a drug has risen to in excess of 
$800 million (DiMasi et al., 2003).  This highlights how crucial it is that the potential for 
toxicity is identified as early in the development process as possible. While the 
identification of potential hepatotoxins is vital, preclinical assays should also be sufficiently 
robust to enable the identification of compounds that are safe. If a signal from an assay 
cannot be definitively interpreted, continued development of the drug may be deemed to 
be too much of a risk, and potentially beneficial compounds are lost.  Consequently there is 
a clear imperative for the development of improved predictive preclinical models of 
hepatotoxicity in order to allow the confident identification of compounds that are likely to 
result in liver damage and crucially, those that are safe.   
An understanding of the mechanisms by which liver damage occurs is important for the 
development of such models. While drug toxicity can have a dose dependent profile and 
relate to the primary pharmacology of a drug, some of the most severe cases of DILI are 
idiosyncratic, with the mechanisms by which liver injury occurs poorly understood (Park et 
al., 2005b). Research investigating the mechanisms by which DILI occurs can be invaluable 
in informing the drug development process and identifying potentially hepatotoxic 
compounds, while also contributing to the identification of candidate translational 
biomarkers of DILI.  
1.1.3 Mechanisms of DILI – Reactive metabolite formation and oxidative stress 
Although the exact mechanisms of DILI often remain elusive, reactive metabolite formation 
has been identified as a common step in a significant number of cases of idiosyncratic 
toxicity (Antoine et al., 2008; Walgren et al., 2005; Zhou et al., 2005). In general, the drug 
metabolism processes that occur in the liver result in the detoxification and safe excretion 
of compounds.  However, in some instances, metabolism can lead to the generation of 
species that are more reactive than the parent compound.  This is widely documented 
following cytochrome P450 (CYP450) mediated phase I oxidative metabolism (Antoine et 
al., 2008; Park et al., 1995) , but can also occur following phase II conjugative metabolism 
Chapter 1 
5 
 
as has been noted with the formation of protein reactive acyl glucuronide metabolites of 
some nonsteroidal anti-inflammatory drugs (NSAIDs) including diclofenac (Hargus et al., 
1995; Kretz-Rommel et al., 1993). 
Reactive metabolite production can result in covalent modification of proteins and damage 
to mitochondria and DNA. Such pathological processes are closely associated with 
glutathione depletion and oxidative stress. The toxicity resulting from paracetamol 
overdose is widely studied as a model of chemically reactive metabolite (CRM)-mediated 
DILI, and glutathione depletion and oxidative stress are characteristic of paracetamol-
induced hepatotoxicity (Hazelton et al., 1986; Lores Arnaiz et al., 1995).  
When a therapeutic dose of paracetamol is taken, the majority of the drug undergoes 
conjugative metabolism via glucuronidation and sulphation pathways, and is safely 
excreted. Paracetamol toxicity involves the bioactivation of the parent compound to the 
highly reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) (Dahlin et al., 1984).  
This occurs via the action of three CYP450 enzymes, CYP2E1, CYP1A2 and CYP3A4 (Dai et 
al., 1995; Manyike et al., 2000; Nelson, 1995; Tonge et al., 1998). NAPQI is also formed 
following a therapeutic dose but is readily conjugated to reduced glutathione, either 
spontaneously or through a glutathione-S-transferase (GST) catalysed mechanism, and is 
safely excreted.  
In cases of paracetamol overdose, the levels of NAPQI that are produced result in 
glutathione depletion such that cellular defence mechanisms are overwhelmed and 
oxidative damage to proteins, lipids and DNA can occur. Necrosis can result, although 
apoptotic cell death has also been shown following paracetamol overdose (Ferret et al., 
2001; Ray et al., 2000; Ray et al., 1999; Ray et al., 1996).  Significant levels of cell death can 
lead to severe liver injury, and paracetamol overdose is currently the most frequent cause 
of acute liver failure in the USA (Larson et al., 2005), and in the UK (Ryder et al., 2001). 
In the case of many other compounds, the mechanism by which DILI occurs is less well 
characterised. While the toxicity of some drugs is known to be associated with CRM 
formation or the parent compound itself, in other cases, the relative contribution of the 
metabolite and parent compound to toxicity is not clear.  For example, nefazodone, a drug 
that was withdrawn due to instances of rare but severe hepatitis, has been associated with 
CRM formation (Kalgutkar et al., 2005), transporter inhibition (Kostrubsky et al., 2006) as 
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well as oxidative stress and glutathione depletion (Dykens et al., 2008; Xu et al., 2008a), 
however the mechanism that results in the severe liver damage remains undetermined. 
One study using imaging of primary hepatocytes treated with a range of 344 drugs, 
including many compounds associated with DILI, concluded that the most important 
contributors to hepatotoxicity are mitochondrial damage, intracellular glutathione 
depletion and oxidative stress  (Xu et al., 2008a).  Drugs that are known to cause severe 
idiosyncratic hepatotoxicity including nefazodone, troglitazone and nimesulide were 
associated with one or more of the parameters, whereas drugs with superior safety profiles 
had consistently negative results in the assays.  While the role of CRM formation in toxicity 
associated with the drugs investigated was often unclear, oxidative stress and glutathione 
depletion were consistently associated with known hepatotoxins. 
Other studies evaluating the NSAID nimesulide (Singh et al., 2010) and the anti-epileptic 
drug, valproic acid (Chang et al., 2006) have also associated hepatotoxicity with oxidative 
stress. This would suggest that investigations into the role of oxidative stress in DILI could 
contribute significantly to understanding the mechanisms by which the injury occurs as well 
as to the identification of potentially hepatotoxic compounds.  Characterisation of the 
pathways associated with the oxidative stress response has the potential to inform the 
identification of reliable biomarkers of DILI as well as the development of predictive 
preclinical in vitro and in vivo models. Biomarkers that are indicative of oxidative stress 
would have valuable applications in the drug development process and translational value 
in the clinic, given that the pathologies associated with DILI often reflect natural disease 
processes (Park et al., 2005a).   
1.2 The oxidative stress response  
1.2.1 Oxidative and electrophilic stress 
Oxidative stress occurs when there is an imbalance in a cell between the pro-oxidant 
species that can damage key macromolecules, and the anti-oxidative mechanisms that 
have evolved to protect the body from these potentially harmful species. The redox 
balance can be perturbed by radicals including reactive oxygen species (ROS), as well as 
peroxides and electrophiles.  
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Radical species are constantly produced in the body as a by-product of mitochondrial 
oxidative phosphorylation and have physiological roles in the immune system and signalling 
processes. They can also be formed by the actions of enzymes on substrates, including 
exogenous drugs and toxins. For example, carbon tetrachloride is widely studied as a model 
compound that is metabolised by the action of CYP450 enzymes to form radical species 
that result in hepatotoxicity (Weber et al., 2003). 
Pathologically, the production of radicals can arise as the result of injury or inflammation, 
and oxidative stress has been associated with a number of disease processes including 
neurodegenerative conditions, cancer, and cardiovascular disease (Ames, 1983; Dhalla et 
al., 2000; Miller, 1970; Valko et al., 2007).  Radical species have a single unpaired electron 
and can cause damage to proteins, lipids and DNA, resulting in reduced function. If the 
damage is severe, cell death can result.  
While some exogenous compounds can be metabolised to form radical species, others 
have intrinsic electrophilic properties or can be metabolised to form electrophiles thus 
increasing their reactivity towards nucleophilic centres in macromolecules.  Consequently, 
electrophilic stress can also lead to cellular damage and reduced function.       
1.2.2 The cytoprotective response 
Cellular defence mechanisms have evolved in a way that allows organisms to manage the 
basal levels of oxidative stress but also respond robustly to acute oxidative insult. The 
processes by which cells act to prevent damage to macromolecules by oxidative and 
electrophilic stress can be broadly categorised into five groups [adapted from (Kensler et 
al., 2007)]:  
 Oxidation and reduction of hydrophobic compounds, whereby functional groups 
are exposed, often by the action of CYP450 enzymes, facilitating further 
metabolism. 
 Nucelophilic trapping processes, including conjugative metabolism by enzymes 
such as GSTs and UDP-glucuronosyltransferases (UGTs), as well as inactivation of 
ROS by catalase, superoxide dismutases (SODs) and glutathione peroxidases 
(GPXs).  
 The export of toxic metabolites via efflux transporters.  
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 The action of anti-oxidants including vitamin E, vitamin C, β-carotene (the 
precursor of vitamin A) and bilirubin, which all have the ability to scavenge free 
radicals.   
 The maintenance of reducing capacity by the thiol-containing molecules 
glutathione and thioredoxin. 
A range of cytoprotective proteins are important for mediating this oxidative stress 
response, these include enzymes that are required for glutathione synthesis as well as 
Phase I and Phase II metabolism proteins and drug efflux transporters.  While these 
proteins are expressed constitutively, their expression can also be up-regulated following 
an oxidative insult (Primiano et al., 1997), thereby helping to restore intracellular 
homeostasis through mechanisms such as glutathione repletion and the direct 
detoxification of electrophiles. One of the most important mediators of this up-regulation 
is a transcription factor that belongs to the CNC-bZIP transcription factor family (Jaiswal, 
2004) and is termed nuclear factor-erythroid 2–related factor 2 (Nrf2). The role of Nrf2 is 
described below in section 1.2.3.   
The multi-faceted defence response allows cells to successfully prevent damage by 
oxidative stress and electrophilic species in most instances.  However, the ability of a cell to 
repair damage to macromolecules when it does occur represents an important further tier 
of the defence response. Repair to proteins is mediated by the thioredoxin and 
glutaredoxin enzymes, while DNA repair occurs by base or nucleotide excision.  
When a toxic insult is severe, cellular defence mechanisms can be overwhelmed.  If 
intracellular damage is of a sufficient magnitude, normal cellular processes including cell 
division cease, and proteins that are significantly damaged are targeted for proteasomal 
degradation or autophagic mechanisms.  If damage to the cell is irreparable, apoptosis is 
initiated. The level of damage can be such that the cytoprotective proteins themselves are 
damaged and can no longer function successfully.  Depletion of glutathione following a 
paracetamol overdose is associated with a reduction in the activity of many of the enzymes 
that are key in the oxidative stress response, including, glutathione reductase, glutathione 
peroxidase, γ-glutamylcysteinyl synthase, catalase and superoxide dismutase (Acharya et 
al., 2010; O'Brien et al., 2000).  Such damage has the potential to result in necrotic cell 
death and severe liver damage. 
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1.2.3 The role of Nrf2 in the cytoprotective response 
The role of Nrf2 in the response to oxidative stress is well established.  Following oxidative 
insult, the transcription factor mediates the regulation of the inducible expression of 
cytoprotective genes containing a common sequence termed the antioxidant response 
element (ARE) in their promoter regions (Itoh et al., 1997).  Nrf2 is also known to play a 
significant role in the constitutive regulation of some ARE-containing genes. A list of 
cytoprotective genes that are constitutively and inducibly regulated by Nrf2 is given in table 
1.1.  
The Nrf2 gene was first isolated in 1994 (Moi et al., 1994). While the transcription factor is 
expressed in the majority of tissues, its levels are highest in organs such as the liver and the 
skin which play the most significant role in detoxification or are most commonly exposed to 
exogenous compounds.   
The level and functional capacity of Nrf2 is regulated at the post-transcriptional level, 
primarily through its association with an actin-associated protein, kelch-like ECH associated 
protein 1 (Keap 1).  The Nrf2 protein is a high turnover molecule, with a half-life of less than 
twenty minutes (Itoh et al., 2003; Kobayashi et al., 2004). The rapid turnover rate of the 
Nrf2 protein means that the transcription factor is difficult to detect under basal 
conditions.  In the absence of oxidative stress, Nrf2 is bound to a Keap1 homodimer, which 
sequesters Nrf2 in the cytosol. (Itoh et al., 1999).  Through interaction with a cullin-
dependent E3 ubiquitin ligase complex (cul3), Keap1 targets Nrf2 for ubiquitination 
(Cullinan et al., 2004; Furukawa et al., 2005), and subsequent proteasomal degradation.  
However, under conditions of oxidative stress, the interaction of Nrf2 with Keap1 is 
disrupted. This prevents the turnover of Nrf2, and the transcription factor rapidly 
accumulates in the cell, thus enabling the transcription of downstream genes.  A summary 
of Nrf2 regulation and activation is shown in figure 1.1. 
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Table 1.1: Cytoprotective enzymes regulated by Nrf2 (Adapted from Copple et al.; 2008). 
Full name Abbreviation Reference 
 
Aldo-keto reductases AKR Lou et al.; 2006, Nishinaka et al.; 2005 
Biliverdin reductase B 
 
BLVRB Wu et al.; 2011 
Ferritin 
 
 Pietsch  et al.; 2003 
Glutamate cysteine ligase, 
catalytic subunit 
 
GCLC Chan et al.; 2000, Jeyapaul  et al.; 2000, 
Sekhar  et al.; 2000 
Glutamate cysteine ligase, 
modifier subunit  
 
GCLM Chan et al.; 2000, Moinova  et al.; 1999, 
Wild  et al.; 1999 
Glutathione peroxidases 
 
GPX Wu et al.;2011 
Glutathione synthetase 
 
GS Lee  et al.; 2005 
Glutathione S-transferases GST Chanas  et al.; 2002, Hayes  et al.; 2000, 
McMahon  et al.; 2001, Thimmulappa  et al.; 
2002 
Haem-oxygenase 1 
 
HO-1 Alam  et al.; 1999, Ishii et al.; 2000 
Microsomal epoxide 
hydrolase 
mEH Ramos-Gomez et al.; 2001, Slitt  et al.; 2006, 
Thimmulappa  et al.; 2002 
NADPH: quinone 
oxidoreductases 
 
NQO Venugopal  et al.; 1996, Wang  et al.; 2006 
Peroxiredoxin 1 Prx 1 Kim  et al.;  2007, Wu et al.;2011 
Superoxide dismutases 
 
SOD Park  et al.; 2002 
Thioredoxin reductases 
 
TrxR Sakurai  et al.; 2005 
Thioredoxins Trx Kim  et al.; 2001, Kim  et al.; 2003 
UDP-
glucuronosyltransferases 
UGT Shelby  et al.; 2006, Yueh  et al.; 2007 
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1.2.4 The hinge and latch model of Nrf2 activation 
As a cysteine-rich molecule, Keap1 is well adapted to act as a sensor for electrophilic and 
oxidative stress.  Human Keap1 contains 27 cysteine residues, while Keap1 in mice and rats 
contains 25 cysteine residues (Dinkova-Kostova et al., 2002; Itoh et al., 1999). Indeed, a 
range of compounds including triterpenoids, isothiocynates and dithioethiones that are  
known to activate Nrf2 have been shown to react with Keap1, modifying different cysteine 
residues (Dinkova-Kostova et al., 2002; Hong et al., 2005; Luo et al., 2007; Yates et al., 
2009).  
Oxidative and electrophilic species can modify the sulfhydryl groups of Keap1, altering its 
conformation  (Kobayashi et al., 2006), and this is the basis for the hinge and latch model of 
Nrf2 activation (Tong et al., 2006). Two motifs in the Nrf2 protein are important for the 
binding of the transcription factor to Keap1: the high affinity ETGE and the lower affinity 
DLG. The conformational change that occurs in Keap1 following an oxidative insult results 
in the detachment of Nrf2 at the DLG domain (the latch), while the association at the ETGE 
is maintained (the hinge).  Keap1 is no longer able to target Nrf2 for ubiquitination and 
Keap1 molecules quickly become saturated with Nrf2. Aided by a nuclear localisation 
sequence (Jain et al., 2005), newly synthesised Nrf2 is free to translocate to the nucleus, 
where the transcription factor mediates the transcription of genes containing the ARE (Itoh 
et al., 1999).   
In order to bind to the ARE, Nrf2 must first form a heterodimer with other bZIP factors, 
typically small Maf proteins (Itoh et al., 1997).  Once bound, Nrf2 recruits coactivator 
proteins, most notably CREB-binding protein (CBP), and target gene transcription results 
(Katoh et al., 2001). CBP has intrinsic histone acetyltransferase (HAT) activity, but also 
interacts with other HAT proteins to facilitate gene transcription. 
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Figure 1.1: The regulation and activation of the transcription factor Nrf2.  (a) Under basal 
conditions, Nrf2 is bound to a Keap1 homodimer, which targets Nrf2 for ubiquitination and 
subsequent proteosomal degradation.  (b) Under conditions of oxidative stress, the interaction 
between Nrf2 and Keap1 is disrupted and Nrf2 is no longer targeted for degradation. Molecules of 
Keap1 become saturated and newly synthesised Nrf2 is free to translocate to the nucleus, where it 
dimerises with partners including small Maf protein (sMaf) and binds to the antioxidant response 
element (ARE) in a range of cytoprotective genes, mediating their transcription.  
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1.2.5 The regulation of Nrf2 is complex 
There is evidence to suggest that the hinge and latch model is not universally applicable to 
all instances of Nrf2 activation and that other mechanisms can also play a role in the 
regulation of the Keap1-Nrf2 interaction.  For example, studies have shown that some Nrf2 
inducers including the heavy metals result in the complete dissociation of Nrf2 from Keap1 
(He et al., 2008; He et al., 2007). Furthermore, other mechanisms may contribute to the 
modulation of the Keap1-Nrf2 pathway in parallel with those regulating the partial or 
complete dissociation of Nrf2.  Some inducers of Nrf2, including sulphoraphane and tert-
butylhydroquinone (tBHQ), have been shown to disrupt the interaction between Keap1 and 
Cul3 (Zhang et al., 2004), thus inhibiting the ubiquitination and enhancing the stability of 
the transcription factor.  
Evidence from in vivo studies suggests that there are further levels of Nrf2 regulation that 
are not explained by the hinge and latch model of Nrf2 activation. For example, studies in 
Nrf2 knockout (KO) mice highlight the importance of Nrf2 in the basal as well as inducible 
expression of target genes (Chanas et al., 2002; McMahon et al., 2001).  There is also 
evidence that Nrf2 inducers increase mRNA levels of the transcription factor (Ramos-
Gomez et al., 2001), whereas this increase has not been seen in many in vitro studies 
employing Nrf2 inducers (Itoh et al., 2003; McMahon et al., 2003; Stewart et al., 2003). 
While such increases in Nrf2 may not be important in the acute response to oxidative 
stress, they are likely to have more subtle long term implications for regulation of gene 
expression by the transcription factor. The hypothesis for autoregulation of Nrf2 is 
supported by the presence of an ARE in the Nrf2 promoter (Kwak et al., 2002).     
A range of signalling pathways have been implicated in the regulation of Nrf2, many 
involving protein kinases and the phosphorylation of the transcription factor. Often, these 
signalling pathways are hypothesised to be Keap1 independent, but function alongside 
Keap1 regulation of Nrf2.  Protein kinase C (PKC) activation has been shown to induce Nrf2-
mediated gene expression, with Ser40 identified as the residue important for Nrf2 
phosphorylation by PKC (Bloom et al., 2003; Huang et al., 2002; Huang et al., 2000).  
Mitogen-activated protein kinase (MAPK) and PI3K pathways have also been implicated in 
Nrf2 regulation (Alam et al., 2000; Lee et al., 2001; Reddy et al., 2008; Yu et al., 1999).  
However, Keap1 is fundamental to the regulation of Nrf2 activity in vivo, as studies 
employing organ-specific Keap1 knockdown show that when pharmacological activators of 
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Nrf2 are used in such models, further Nrf2 activation is limited (Yates et al., 2009).  
Furthermore when phosphorylation pathways implicated in Nrf2 signalling are inhibited, 
the effects on Nrf2 activation are modest when compared to Keap1 modulation (Sun et al., 
2009).    
1.2.6  The role of glutathione in cytoprotection  
Glutathione is an essential tripeptide (γ-Glu-Cys-Gly) that has a number of critical functions 
within cells, including electrophile conjugation and the scavenging of free radicals, and as 
such is an important molecule for defence against oxidative stress.  Glutathione is 
synthesised sequentially by the action of two enzymes, glutamate cysteine ligase (GCL) and 
glutathione synthetase (GS).  GCL catalyses the formation of a bond between glutamate 
and cysteine, while GS catalyses the addition of glycine to complete the tripeptide.  GCL is 
composed of two subunits, a catalytic subunit (GCLC) and a modifier subunit (GCLM) and is 
the rate limiting enzyme in glutathione synthesis. 
Glutathione can form covalent bonds with electrophilic species because of its nucleophilic 
cysteinyl thiol group.  Glutathione conjugation increases the solubility of a compound, 
facilitating excretion and can occur spontaneously or in a reaction catalysed by GST (Leslie 
et al., 2003).  On reaction with electrophiles, glutathione is oxidised non-enzymatically to a 
disulphide (GSSG), which is in turn reduced back to two molecules of glutathione (GSH) by 
the enzyme glutathione reductase. This process uses NADPH as an electron donor.  
Oxidised glutathione is also effluxed from cells, resulting in decreased intracellular 
glutathione levels. Consequently glutathione homeostasis is maintained by balancing the 
rate of synthesis of glutathione and reduction of the disulphide against the rate of 
glutathione conjugation and oxidation together with the transport of the disulphide out of 
the cell.  Glutathione synthesis and redox cycling are summarised in figure 1.2.  
While glutathione is present in organelles, including mitochondria and peroxisomes, 
between 85 and 90% of intracellular glutathione is located in the cytosol.  Extracellular 
concentrations of glutathione are generally low, for example 2-20 μmol/L in plasma (Wu et 
al., 2004), while levels in the liver are much higher at around 5 mM.   
Glutathione deficiency has a role to play in aging as well contributing to oxidative stress in 
disease pathology.  Depletion of glutathione is also associated with the toxicity of a number 
of drugs and is a hallmark event in paracetamol overdose-induced liver injury (Potter et al., 
Chapter 1 
15 
 
1974), during which, intracellular glutathione depletion facilitates the covalent modification 
of macromolecules by NAPQI. 
Nrf2 plays an important role in glutathione homeostasis following oxidative insult. Genes 
encoding enzymes, including GCL and GS, that are key for the synthesis and reduction of 
glutathione have been identified as Nrf2 targets (Chan et al., 2001; Li et al., 2009; Moinova 
et al., 1999).  While regulation of expression of glutathione synthesis is not exclusively 
Nrf2-mediated, (for example,  the gene encoding GCL has also been shown to contain 
binding sites for AP-1 and NF-κB (Yang et al., 2001)),  evidence from studies showing a 
significant delay in glutathione recovery in paracetamol treated Nrf2 KO mice (Chan et al., 
2001) highlights the importance of the transcription factor in glutathione repletion.  
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Figure 1.2: Glutathione synthesis and redox cycling. Glutathione is synthesised from glutamate, 
cysteine and glycine by the action of 2 enzymes, glutamate cysteine ligase and glutathione 
synthetase.  On reaction with electrophiles, glutathione (GSH) is oxidised to the disulphide (GSSG) 
spontaneously or in a reaction catalysed by glutathione peroxidase.  GSSG is reduced back to 2 
molecules of GSH in a glutathione reductase catalysed reaction, which requires NADPH as a cofactor.   
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1.3 In vivo models of Nrf2 modulation 
1.3.1 The Nrf2 knockout mouse model  
In vivo studies have been widely employed to characterise the cytoprotective role of Nrf2, 
and the Nrf2 KO mouse model has contributed significantly to the current understanding of 
the transcription factor. The first Nrf2 KO mice were successfully engineered in 1996 (Chan 
et al., 1996). Mice in which the gene for Nrf2 has been knocked out are viable and survive 
into adulthood. Young mice show no significant phenotype under basal conditions; 
however there are reports that aging Nrf2 KO mice develop lupus-like autoimmune disease, 
a problem that is more common in female mice (Suh et al.). Evidence from another study 
also suggests vacuolar leukoencephalopathy arises in all Nrf2 KO animals by the age of 10 
months, a condition characterised by the development of cavities in the brain and the 
deterioration of myelin sheaths (Hubbs et al., 2007).   
Phenotypic differences are in evidence when Nrf2 KO mice, regardless of age, are exposed 
to oxidative and chemical stress. Nrf2 KO animals are more vulnerable to the toxicity 
associated with a diverse range of compounds in a variety of organs with examples 
including hepatotoxicity following paracetamol administration (Chan et al., 2001; Enomoto 
et al., 2001), hepatic fibrosis on carbon tetrachloride treatment (Xu et al., 2008b), ethanol 
induced liver injury (Lamle et al., 2008), pulmonary fibrosis resulting from administration of 
bleomycin (Cho et al., 2004; Sriram et al., 2009), cisplatin-induced renal toxicity (Park et al., 
2008), and colitis following dextran sulphate administration (Khor et al., 2006). 
Gene array studies have been carried out to compare wild type (Yang et al.)  and Nrf2 KO 
mice in terms of mRNA expression both at the constitutive and inducible level following 
treatment with compounds known to activate Nrf2 including sulphoraphane, the 
isothiocyanate PEITC and tunicamycin (Hu et al., 2006; Nair et al., 2007; Nair et al., 2006; 
Thimmulappa et al., 2002). The studies have focussed on gene expression in the liver and 
small intestine and identified genes important for xenobiotic metabolism, glutathione 
synthesis, and NADPH generation, as being Nrf2 regulated.  Processes such as biosynthesis, 
metabolism and cell cycle control were also found to be modulated by Nrf2 at some level.  
Gene arrays provide an unbiased method of identifying mRNA expressional differences, 
however levels of mRNA do not directly correspond to protein synthesis levels in a cell and 
so do not always give an accurate representation of protein expression or activity 
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(Kitteringham et al., 2000). Consequently, the functional relevance of differences in mRNA 
expression levels is not always clear.   
Differences have also been identified in WT and Nrf2 KO mice at the protein level, with 
studies focussing on a single protein or a small group of proteins. Such studies often 
investigate the protein expression of enzymes that have been identified as differentially 
expressed at the mRNA level as a result of Nrf2-modulation or drug administration.      
However, there is a lack of work investigating the effect of Nrf2 modulation at a proteomic 
level, looking at global protein expression in a particular organ or system. Such studies 
would provide insight into pathways in which Nrf2 regulation has a functionally significant 
role. 
1.3.2 Genetic and pharmacological models of Nrf2 induction 
Keap1 KO mice have been engineered in order to study the consequences of enhanced 
Nrf2 activity in vivo. However, the mice did not survive beyond 20 days of age 
(Wakabayashi et al., 2003).  The authors suggest that this is the result of hyperkeratosis of 
the oesophagus and forestomach, a problem that is known to be linked to hyperactivity of 
Nrf2, with the phenotype being reversed in the offspring of Keap1 KO mice crossbred with 
Nrf2-null mice.   
Organ-specific Keap1 knockdown is however possible and this approach has allowed the 
development of viable in vivo models of Nrf2 hyper-expression. A Keap1-hepatocyte-
specific KO (Keap1-HKO) model was developed using the albumin-Cre loxP system, with 
mice showing resistance to paracetamol-induced hepatotoxicity (Okawa et al., 2006) and to 
acute inflammatory liver injury (Osburn et al., 2008).   
As well as models using genetic manipulation of the Keap1-Nrf2 system, in vivo models 
using pharmacological modulation of Nrf2 have also been employed. Triterpenoids, 
isothiocynates and dithioethiones are all known to activate Nrf2 (Dinkova-Kostova et al., 
2002; Hong et al., 2005; Luo et al., 2007; Yates et al., 2009).  The triterpenoid 2-cyano-3,12-
dioxooleana-1,9,-dien-28-oic acid (CDDO) and its derivatives are the most potent inducers 
of Nrf2 currently identified, and are widely used in studies investigating the effects of 
differential Nrf2 expression. This group of molecules is described in detail in section 1.4 
below.   
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Understanding how the profiles of pharmacological and genetic modulation of Nrf2 differ is 
important in the context of drug development and in determining the specificity of a given 
inducer, but also in giving a clearer picture of the adaptive changes that may occur in the 
mice that have been modified genetically.  A study by Yates et al. used the Keap1-HKO 
model alongside pharmacological activation of Nrf2 using the triterpenoid, CDDO-imidazole 
(CDDO-Im) in order to compare the role of genetic and pharmacological modulation of Nrf2 
(Yates et al., 2009).  CDDO-Im increased the expression of the Nrf2-regulated gene, 
NAD(P)H:quinone oxidoreductase 1 (NQO1) 6.5-fold in livers of WT mice at the level of 
mRNA expression, while it was increased 24.4-fold in Keap1-HKO mice.  Interestingly, in 
Keap1-HKO mice treated with CDDO-Im, further increases in NQO1 expression were 
minimal (Yates et al., 2009). While genetic manipulation results in maximal Nrf2 activation, 
triterpenoid administration is a valuable tool for achieving Nrf2 activation in vivo. 
Adaptation to genetic manipulation is one of the limitations associated with the use of in 
vivo animal models to study human health and disease, with chronic gene deficiency 
resulting in alterations in gene and protein expression profiles that differ from those arising 
from drug administration.  However there are other factors associated with the use of 
experimental animals regardless of whether the model has been genetically modified. 
Laboratory mouse strains are usually inbred, resulting in a population with little genetic 
variability.  Furthermore, the environment and diet of the animals is closely monitored and 
controlled, with exposure to pathogens limited. Such conditions are not reflective of a 
genetically diverse human population experiencing a wide range of environmental 
influences with highly varied diets and disease profiles. Consequently, these factors need to 
be taken into account when interpreting results from animal experiments and extrapolating 
to humans.  
1.3.3 NQO1 as a marker of Nrf2 activation  
NQO1 is often used as a marker of Nrf2 activation, as was the case in the study of Yates et 
al., described above.  NQO1 was one of the genes that was first identified as an Nrf2 target 
and the importance of Nrf2 in the regulation of both the basal and inducible expression of 
NQO1 is now well characterised (Itoh et al., 1997; Kwak et al., 2001; McMahon et al., 
2001), with a functional ARE identified in the murine Nqo1 gene (Nioi et al., 2003). NQO1 
works as an antioxidant and has a role in the detoxification of quinines, naphthoquinones, 
quinine imines, nitro and azo compounds, catalysing their two electron reduction and thus 
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preventing the formation of radical species (Chan et al., 2004; Siegel et al., 1997).  
Mutations in the NQO1 gene have been associated with an increased risk of developing 
cancers including breast (Menzel et al., 2004) and colon cancer (Begleiter et al., 2006).  
Regulation of NQO1 mRNA expression is not exclusively regulated by Nrf2, with 
transcription factors including AP-1 and NF-κB also having a role to play in NQO1 up-
regulation in response to lead, mercury and oltipraz (Korashy et al., 2008; Park et al., 2004; 
Yao et al., 1995). However, NQO1 mRNA, protein and activity levels have been widely used 
as a marker of Nrf2 activation and a measure of cytoprotective enzyme up-regulation.   
As a well-defined target of Nrf2, NQO1 is useful as a surrogate marker for the activation of 
a range of Nrf2-regulated enzymes.  It has a wide dynamic range of expression with NQO1 
mRNA expression being between 3.5- and 5-fold higher in livers of WT mice when 
compared with Nrf2 KO animals (Aleksunes et al., 2010b; Tanaka et al., 2008b).  Hepatic 
NQO1 mRNA levels are also significantly increased above those in basal animals by both 
genetic and pharmacological Nrf2 induction (Yates et al., 2009).  Furthermore NQO1 is 
expressed ubiquitously in tissues in the body, with expression levels in organs such as the 
liver, lung and kidney well established (Jaiswal, 2000). Consequently, the enzyme provides 
a useful marker of Nrf2 activation that is applicable in a range of tissues.  
1.4 The synthetic triterpenoids 
1.4.1 The development of CDDO and its derivatives  
The synthetic triterpenoid, CDDO and its derivatives including CDDO-Im and CDDO-methyl 
ester (CDDO-Me), have been shown to be potent inducers of Nrf2. The structures of the 
three compounds are shown in figure 1.3. The key role that Nrf2 target genes play in the 
response to oxidative stress, together with the anti-inflammatory and anti-proliferative 
properties of the triterpenoids, mean that CDDO-derived compounds have been widely 
investigated as potential chemotherapeutic as well as chemopreventive agents.  
CDDO is an analogue of the naturally occurring oleanolic acid.  Oleanolic acid and its 
isomer, ursolic acid, are two triterpenoids that are known to have weak anti-inflammatory 
and anti-carcinogenic properties (Huang et al., 1994; Nishino et al., 1988), and CDDO and 
its derivatives were originally developed as anti-inflammatory agents. However, 
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subsequent studies have also highlighted their anti-oxidant and anti-proliferative 
properties (Dinkova-Kostova et al., 2005; Suh et al., 1999).   
Initial work showed that the synthetic triterpenoids have anti-cancer properties in a variety 
of in vitro models including human breast cancer, lung cancer and leukaemia  cell lines (Ito 
et al., 2000; Konopleva et al., 2004; Lapillonne et al., 2003; Zou et al., 2004). CDDO-Im has 
been shown to have anti-proliferative properties and induce differentiation in cell models 
as well as to decrease tumour burden in a mouse model of melanoma (Place et al., 2003). 
Furthermore, CDDO and CDDO-Me have been used in Phase I clinical trials for treatment of 
leukaemia as well as for solid tumours (Vannini et al., 2007).  The potential utility of the 
triterpenoids extends beyond the treatment of cancer, with studies investigating the anti-
diabetic effects of CDDO-Me (Saha et al., 2010), as well as the potential benefits of CDDO 
analogues in the treatment of Huntington’s disease and emphysema (Stack et al., 2010; 
Sussan et al., 2009).   
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Figure 1.3: The structure of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its 
methyl ester (CDDO-Me) and imidazolide (CDDO-Im) derivatives.  All three compounds have been 
shown to be potent inducers of Nrf2.   
CDDO-Me 
CDDO-Im 
CDDO 
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1.4.2 The synthetic triterpenoids and Nrf2 induction  
Initial evidence for triterpenoid activation of Nrf2 came from a study in which CDDO was 
shown to potently induce the phase II response in embryonic fibroblasts (Dinkova-Kostova 
et al., 2005), a response that was abolished in cells from the Nrf2 null mouse. Results from 
the paper also strongly suggest that Keap1 is a molecular sensor for the triterpenoids. In 
subsequent work, Liby et al. demonstrated a time-dependent induction of mRNA levels of 
the Nrf2-regulated gene, haem oxygenase-1 (HO-1), following treatment of U937 human 
leukaemia cells with CDDO and CDDO-Im, and also an increase in Nrf2 protein levels (Liby 
et al., 2005). HO-1 protein induction was also seen in vivo via western blot in a variety of 
organs including the liver, lung and stomach in an experiment using CD-1 mice treated with 
2 μmol CDDO-Im.  
The parent compound oleanolic acid has also been shown to induce expression of Nrf2 
mRNA and the mRNA of Nrf2 target genes when dosed once daily for 4 days to mice and 
rats (Liu et al., 2008), while other triterpenoid compounds including the avicins, have been 
associated with induction of the Keap1-Nrf2 pathway (Haridas et al., 2004).   
In a 2007 paper by Yates et al., an NQO1-ARE-luciferase reporter gene assay was used in 
association with in vivo bioluminescent imaging to determine NQO1 transcriptional 
activation in a mouse model following treatment with CDDO derivatives.  CDDO-Me was 
seen to induce Nqo1 transcripts in the liver, small intestine and lung after a single dose, 
while CDDO-Me dosed on three consecutive days also maintained or further increased the 
levels of Nqo1 expression seen after a single dose, suggesting sustained induction of the 
Nrf2 pathway using CDDO-Me is possible.   
CDDO-Im has been shown to be protective against paracetamol-induced hepatotoxicity in 
WT but not in Nrf2 KO mice (Reisman et al., 2009).  CDDO-Im attenuated the rise in ALTs 
seen in WT mice 6h after administration of a 500mg/kg dose of paracetamol.  A 380% 
increase was detected in Nrf2 protein levels in nuclear extracts from livers of  WT mice 
treated with CDDO-Im dosed once daily for three days (1mg/kg; i.p.). The synthetic 
triterpenoids have also been shown to offer Nrf2-dependent protection against damage to 
other organs.  For example, CDDO-Im has been shown to induce an Nrf2-mediated 
protective response in the kidneys of mice treated with ferric nitrilotriacetate (FeNTA), a 
compound associated with a high incidence of renal adenocarcinomas in rodents (Tanaka 
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et al., 2008a).  Furthermore, CDDO-Im was protective in Nrf2 WT mice against cisplatin-
induced renal toxicity (Aleksunes et al., 2010a).  Nrf2 has a protective role against neuronal 
and capillary degeneration in retinal ischemia–reperfusion injury:  CDDO-Me is protective 
in WT but not in Nrf2 KO mice (Wei et al., 2011).   
1.4.3 The synthetic triterpenoids also modulate other signalling pathways 
A number of other signalling pathways have also been implicated in the documented 
effects of CDDO and its derivatives. The inflammatory properties are, in part, mediated 
through modulation of NF-κB signalling and CDDO, CDDO-Im and CDDO-Me have all been 
shown to inhibit both the constitutive as well as the inducible activation of NF-κB 
(Shishodia et al., 2006). This may be through inhibition of IKK-β as both CDDO-Me and 
CDDO-Im have been shown to inhibit IKK-β, an effect that is mediated by oxidation of Cys-
179 (Ahmad et al., 2006; Yore et al., 2006).  The inhibitory effects of the CDDO analogues 
on the transcription of TNF-α, INF-γ, inducible COX-2 and iNOS (Honda et al., 1998; Place et 
al., 2003; Suh et al., 1998; Suh et al., 1999), are also likely to  contribute to the potent anti-
inflammatory properties of the compounds.   
Other intracellular targets for the synthetic triterpenoids have also been identified 
including the PPAR-γ receptor (Wang et al., 2000) and  STAT signalling (Liby et al., 2006), 
with CDDO-Me shown to inhibit activation of the JAK1/STAT3 pathway (Ahmad et al., 
2008).    Consequently, while Nrf2 activation may have a role in the therapeutic properties 
of CDDO and its derivatives, the relative contribution of other pathways remains to be 
determined. 
1.5 Nrf2 in Man  
1.5.1 Nrf2 induction as a therapeutic strategy 
Given the role of oxidative stress in health and disease, compounds that induce Nrf2 have 
significant therapeutic potential.  The triterpenoid CDDO-Me (also known as bardoxolone 
methyl) has been used in a Phase I clinical trial for the treatment of advanced solid tumours 
and lymphomas. In the context of cancer treatment, use of the compound has not 
advanced further to clinical trials in larger patient populations. The role of Nrf2 in the 
pathology of cancer is complex, and expression of the transcription factor has been shown 
to be dysregulated in some cancers (Lister et al., 2011; Shibata et al., 2008; Stacy et al., 
2006).  Furthermore, induction of Nrf2 in cancer patients may not always be desirable, 
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given that enhanced resistance to oxidative stress may confer a survival advantage on 
cancer cells treated with chemotherapeutics. Consequently, while Nrf2 induction has 
shown promise as a chemopreventive strategy (Kwak et al., 2010; Liby et al., 2007), its 
potential as a cancer treatment agent may be limited.  
However, CDDO-Me was noted in clinical trials to have a beneficial effect on glomerular 
filtration rate (Hong et al., 2012) and its utility in the treatment of chronic kidney disease 
(CKD) was subsequently investigated.  In fact, CDDO-Me has recently entered phase III trials 
for the treatment of CKD in patients with type II diabetes.  Furthermore, Abbott have 
invested $400 million in Reata Pharmaceuticals for the development of second generation 
oral antioxidant inflammation modulators (AIMs), a class in which CDDO-Me is a first 
generation compound (Crunkhorn, 2012).  
1.5.2 Nrf2 in human disease 
Given this drive towards the clinical development of compounds known to induce Nrf2, it is 
becoming more important to understand the role that the transcription factor plays in 
human health and studies addressing this important issue are currently lacking. There are 
however, a number of studies that have investigated the importance of the transcription 
factor in the lung.  Studies have shown that Nrf2-regulated gene expression is induced in 
the lung by cigarette smoke (Hubner et al., 2009), while in patients with chronic obstructive 
pulmonary disorder (COPD) Nrf2 is down regulated in pulmonary macrophages.  This is also 
the case in lungs of aged smokers, but not in those of younger smokers (Suzuki et al., 
2008).   
Single nucleotide polymorphisms (SNPs) in the promoter region of the human Nrf2 gene 
have been identified in a range of ethnic groups (Marzec et al., 2007; Yamamoto et al., 
2004) with one SNP at position 617 (C to A),  linked  to an increase in the risk of acute lung 
injury after major trauma (Marzec et al., 2007).  Oxidative stress is postulated to contribute 
significantly to acute lung injury.   
The role of Nrf2 in children with severe asthma, a condition associated with redox 
perturbation and glutathione depletion, has also been investigated (Fitzpatrick et al., 2011).  
Nrf2 mRNA and protein levels were found to be increased in PBMCs taken from children 
with severe asthma, when compared to those with mild/moderate disease. Expression of 
downstream genes including GSTs, GCLC and GCLM were not different between groups, 
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however, glutathione levels were significantly lower in the plasma of children with severe 
asthma. The authors suggest that this indicates a dysregulation of the Nrf2 pathway, which 
may contribute to the disease process.   
Data from studies investigating the role of Nrf2 in respiratory diseases associated with 
oxidative stress is important as it shows that the transcription factor has a role to play in 
the context of human health, however work to determine the role of the transcription 
factor in other organs, including the liver is currently lacking.  Biomarkers of Nrf2 activity in 
humans would be invaluable in developing our understanding of the Keap1-Nrf2 system in 
disease and drug-induced toxicity and may serve to validate the use of preclinical in vivo 
models of Nrf2 modulation in toxicity testing. 
1.6 Biomarkers 
1.6.1 Biomarkers in drug safety 
A biomarker can be defined as a characteristic that is objectively measured as an indicator 
of normal biological processes, pathogenic processes or a pharmacological response to a 
therapeutic intervention (Biomarkers Definitions Working Group, 2001).  In the context of 
drug safety, biomarkers can be a change at the level of gene, epigenetic, protein or 
metabolite expression that is indicative of drug-induced injury.  Biomarkers have significant 
utility as tools to assess the safety of a drug, while at the same time having the potential to 
contribute to the understanding of the mechanisms that result in drug induced-toxicity.  
They can contribute to each stage of the drug development process: at a preclinical level 
they can be used to identify potential toxicity at an early stage of development, while 
further on in the process they can contribute towards the selection of the safest candidate. 
Biomarkers can be used to inform the dosing regimen that will be used in Phase I clinical 
trials and beyond, and have subsequent utility during clinical development in order to 
monitor safety throughout the early and late phases as well as having value in post 
marketing surveillance (Marrer et al., 2010).   
Biomarkers that are reflective of Nrf2 activity would have two important applications.  In 
the case of drug safety assessment they could be used as markers of oxidative stress in in 
vitro and animal models.  However, they would also have utility in studies exploring the 
significance of Nrf2 in the human population and defining the variability that exists in 
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expression and activity of the transcription factor.  As discussed in section 1.5.2, research in 
this area is currently lacking. 
The ideal characteristics of a biomarker depend on the circumstances under which it will be 
used. In a clinical study, an ideal biomarker would be non-invasive and hence easily 
accessible in blood or urine.  For preclinical assays, biomarker levels in tissues and cells can 
easily be determined.  For a biomarker to be useful as a marker of liver injury in the human 
population it would ideally be liver specific and reflective of the level of injury sustained, as 
well as being detectable prior to the occurrence of significant or irreparable liver damage 
(Antoine et al., 2008).  However, in a preclinical in vivo model investigating the propensity 
of a compound to cause liver damage, the need for an early marker of injury is less crucial.  
Ultimately however, an ideal biomarker would be translational and suitable for use in in 
vitro and in vivo models as well as in the clinic.  In order to have universal applicability, 
biomarkers would also need to be cost effective and easy to assess in a standard 
laboratory. 
1.6.2 Current biomarkers of DILI 
The functional significance of DILI biomarkers means that many potential candidates have 
been explored. However, there are only ten DILI biomarkers that are in use or have been 
validated for use in the USA by the FDA (Shi et al., 2010).  The most commonly used 
markers include serum alanine aminotransferase (ALT), aspartate amino transferase (AST) 
and alkaline phosphatase as well as total bilirubin (TBL) concentration.  Hy’s law states the 
criteria that are widely employed to define DILI and was employed by the FDA to provide 
the following guidelines to identify drugs in clinical development that are likely to be 
associated with DILI in the wider population (FDA, 2009):  
1. The drug causes hepatocellular injury, generally shown by a higher incidence of 3-fold or 
greater elevations above the upper limit of normal (ULN) of ALT or AST than the 
(nonhepatotoxic) control drug or placebo  
2. Among trial subjects showing such aminotransferase (AT) elevations, often with ATs 
much greater than 3xULN, one or more also show elevation of serum TBL to >2xULN, 
without initial findings of cholestasis (elevated serum ALP)  
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3. No other reason can be found to explain the combination of increased AT and TBL, such 
as viral hepatitis A, B, or C; pre-existing or acute liver disease; or another drug capable of 
causing the observed injury.  
ALT is a biomarker that is widely used because it has a number of useful characteristics. It is 
an enzyme that is abundant in the liver and will leak out of damaged hepatocytes. It is 
stable in serum with a relatively long half-life of 42 hours (Ozer et al., 2008), and is 
therefore easily detectable in biological assays.  However, it lacks specificity, as ALT levels 
can also rise following muscle injury, as well as showing evidence of circadian variation 
(Green et al., 2002).  Furthermore, levels only rise once hepatocyte damage has occurred, 
hence it can be indicative rather than predictive of liver injury.  When a rise in ALT does 
occur, it can be transient and subsequently return to normal levels without significant liver 
damage, as has been detected in some patients following the administration of aspirin and 
some statins (FDA, 2009).  However, small early rises in ALT can also be caused by drugs 
that have the potential to cause more severe injury and there is no way to determine which 
of the two outcomes will follow an early ALT rise.  
There is the potential to overcome some of the limitations associated with ALT by using 
assays that distinguish between the two isoforms of ALT, ALT1 and ALT2.  ALT2 has been 
shown to be more specific for the liver than the ALT1 isoform, while both isoforms increase 
in the serum in rat models of carbon tetrachloride and paracetamol injury (Yang et al., 
2009).  Evidence from the study also suggests that ALT2 may be indicative of mitochondrial 
damage, and consequently assays measuring both isoforms may provide additional 
information concerning the nature of the liver damage.   
Other markers of DILI have been investigated including GST-α, malate dehydrogenase and 
γ-glutamyl transpeptidase, a marker of cholestasis (Marrer et al., 2010).  One of the most 
promising markers to emerge has been microRNA-122 (miR-122), which has been identified 
as a biomarker of paracetamol-induced liver injury in both a mouse model and in overdose 
patients (Starkey Lewis et al., 2011; Wang et al., 2009). 
While there is an on-going drive to identify and investigate the potential of a range of 
biomarkers for DILI, it seems unlikely that a single biomarker will emerge that can be 
universally applied to determine drug safety.  A panel of biomarkers that can be used in 
combination and have different levels of specificity and sensitivity according to the 
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mechanism by which damage occurs is likely to have greater utility. Different markers may 
be employed at different stages of the drug development process, with some providing 
preclinical information on the mechanism by which damage occurs and the severity of the 
damage and others used in the clinical phase to predict and identify injury or to determine 
individuals who may be susceptible to the toxicity associated with a particular compound.  
1.6.3 Methods of biomarker discovery 
Different ‘omic’ approaches have been widely employed in the search for biomarkers 
looking at genetic, epigenetic, protein and metabolic profiles in order to identify drug- or 
disease-induced changes. One approach that has proved successful in the fields of 
proteomics and metabolomics is the use of mass spectrometry to perform unbiased 
profiling of serum, urine and tissue homogenates.  
The proteome describes the complete set of proteins produced by an organism or a system 
and takes into account post-translational modifications to proteins (Wilkins et al., 1996).  
Proteomic methods involve the large scale analysis of proteins within a given system and 
often employ mass spectrometric techniques. Quantification by direct mass spectrometry 
is associated with a high degree of variability and so results are not reproducible, however 
the use of stable isotope labelling employed by techniques such as stable isotope labelling 
by amino acids in cell culture (SILAC), isotope-coded affinity tags (ICAT) and isobaric tag for 
relative and absolute quantitation (iTRAQ) facilitates relative or absolute quantification of 
proteins in a manner that allows reliable comparisons to be made between samples.   
While SILAC is a method for quantifying protein in cultured cells, both ICAT and iTRAQ can 
be used for the analysis of in vivo samples, with iTRAQ having the additional advantage of 
facilitating the simultaneous quantification of proteins in up to 8 samples.   The iTRAQ 
method was originally developed as a 4-plex procedure (Ross et al., 2004) employing 4 
unique reporter tags (m/z 114-117), and was subsequently extended to include 4 further 
reporters.  Each reporter is associated with a balance, such that all tags have a total mass of 
145 Da. The tags were designed to include a peptide reactive group which binds covalently 
to the primary amines at the N-terminus and in peptide side chains. Prior to labelling, the 
proteins in each sample undergo trypsin digest to yield peptides.  Subsequently, each 
sample is incubated with a different tag, before all samples are combined.  
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Samples are fractionated by nano liquid chromatorgraphy and analysed by LC-MS/MS. The 
peptide fragmentation patterns are compared to a database in order to identify the 
peptides and hence the proteins present. The collision energy also results in the 
dissociation of the reporter ion and balance in each tag. The peak area of the reporter is 
used in order to allow the relative quantification of each peptide in one sample compared 
to another.  The labelling and quantification of proteins by iTRAQ is described in figure 1.4. 
Mass spectrometric methods are also widely employed in the global profiling of 
metabolites. Metabolomics can be defined as ‘the nonbiased identification and 
quantification of all metabolites in a biological system’ (Ellis et al., 2007).  Metabolites can 
be the products or the intermediates of metabolism, and the term is usually employed to 
describe a small molecule that falls into one of 3 classes of molecule: carbohydrate, lipid or 
amino acid.    Within the field of metabolomics, metabonomic studies analyse the changes 
in metabolite profiles that result from the administration of exogenous compounds 
including drugs or from genetic modification (Robertson, 2005).  Lipidomics focuses on the 
lipid profile of an organism, organ or cell and while it is broadly categorised within 
metabolomics, it is also considered a discipline in its own right. 
While genomic and proteomic approaches have been successfully employed to identify 
potential biomarkers, there is a consensus that, as the end points of biochemical processes, 
metabolite expression profiles are more likely to give an accurate representation of disease 
state because they are more reflective of an organism’s phenotype (Ellis et al., 2007). 
Furthermore, metabolites are highly conserved across species (Coen et al., 2008), and may 
therefore provide markers that can be directly translated between animal models and into 
man.  Consequently, metabolomic studies have significant potential to contribute to the 
search for biomarkers. However, if they can be used alongside studies investigating global 
gene and protein expression profiles then together, the three approaches can contribute 
significantly to the understanding of a disease process or mechanism of toxicity.  Crucially 
however, in order to be widely adopted in preclinical studies and clinical settings any 
biomarker needs to be validated as a sensitive, reproducible and quantitative measure 
indicative of a given condition or toxicity. 
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Figure 1.4: Labelling and analysis of iTRAQ samples. iTRAQ analysis allows the simultaneous 
quantification of peptides in up to eight samples. (a) Proteins in each sample undergo tryptic digest 
before peptides are labelled with a reporter tag.  After labelling all samples are combined into a 
single sample ready for LC-MS/MS analysis.  (b) Each reporter tag is associated with a balance, such 
that all tags have the same molecular mass. The balance and reporter dissociate during LC-MS/MS 
analysis permitting the relative quantification of peptides in each sample. The peptide 
fragmentation pattern facilitates the identification of the peptide and ultimately the protein by way 
of a database search.  
 
 
(a) 
(b) 
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1.6.4 Omic approaches in the identification of drug safety biomarkers 
Both metabolomic and proteomic approaches have led to the identification of potential 
biomarkers, for example a metabolic study identified ophthalmic acid as a potential 
biomarker for glutathione depletion (Soga et al., 2006).  Proteomic methods including 
iTRAQ have been used to identify potential biomarkers for ovarian cancer (Wang et al., 
2012) and metastatic disease in cases of prostate cancer (Rehman et al., 2012). The 
number of studies employing such methods is growing, and as mass spectrometry and 
other technologies associated with omic approaches advance, the potential for such 
approaches to successfully identify biomarkers increases.   
Serum and urine are optimal biofluids in which to identify potential biomarkers because 
both can be collected in a minimally invasive way in preclinical models and in the clinic.  
Furthermore, it is relatively easy to take repeat samples over the course of hours, days or 
weeks, as appropriate.  However, investigating the proteomic or metabolomic profile of an 
organ also has the potential to identify biomarkers that are indicative of damage to the 
organ and can thus be used in preclinical models and may translate to changes in protein or 
metabolite levels in biofluids, consequently yielding biomarkers that have utility in the 
clinic.  Furthermore, comparing the protein or metabolic profile of a particular organ under 
different conditions, for example control versus drug treated or gene knockout, can provide 
important information in the context of drug-induced injury or disease pathology within 
the organ studied. 
Consequently, the use of proteomic and metabolomic approaches in order to profile 
hepatic Nrf2 modulation, could provide important mechanistic insight into the pathways of 
oxidative stress while at the same time providing candidate biomarkers of Nrf2 activity with 
considerable potential for translational applications in characterising the role of Nrf2 in the 
human population.   
1.7 Aims 
Nrf2 is a transcription factor that plays a vital role in the cytoprotective response to 
oxidative stress.  Mice in which the Nrf2 gene has been knocked out are more susceptible 
to the toxicity associated with a range of different compounds, in the liver as well as in 
other organs.  Conversely, pharmacological activation of Nrf2 has been shown to be 
protective in mouse models of hepatotoxicity.   
Chapter 1 
33 
 
While a considerable body of research has characterised the role of Nrf2 in mice, work 
exploring the role of the transcription factor in man is limited.  Biomarkers that are 
indicative of hepatic Nrf2 activity would have significant utility in determining the 
importance and variability of Nrf2 in the human population.  Given that oxidative stress and 
glutathione depletion have been shown to be associated with the administration of both 
model hepatotoxins and compounds associated with idiosyncratic hepatotoxicity, 
biomarkers of Nrf2 activity would also have applications in the development of preclinical 
models of DILI. 
Consequently, the objectives of the work described in this thesis were: 
 to characterise the basal hepatic proteomic profile of WT and Nrf2 KO mice in 
order to construct a list of proteins that are constitutively regulated by Nrf2. 
 to identify the protein networks that are constitutively perturbed in the livers of 
mice in the absence of a functional Nrf2 gene.  
 to explore existing methods for the quantification of glutathione and to adapt 
these methods in order to produce a robust LC-MS/MS assay for the quantification 
of GSH and GSSG in mouse liver samples.  
 to use the LC-MS/MS assay to characterise hepatic glutathione homeostasis in the 
livers of WT and Nrf2 KO mice.  
 to characterise and compare the fatty acid and lipidomic profile of livers of WT and 
Nrf2 KO mice in order to contribute to the understanding of the role of Nrf2 in lipid 
homeostasis (a role identified in chapter 2). 
 to explore how WT and Nrf2 KO animals respond to the perturbations in hepatic 
fatty acid metabolism resulting from carbohydrate restriction. 
 to characterise the hepatic proteomic profile of Nrf2 induction in order to construct 
a list of proteins that are inducibly regulated by Nrf2 following the administration 
of a single dose of CDDO-Me 
 To investigate the dynamic range of the expression of proteins that have been 
identified as Nrf2-regulted  
Through the characterisation of the hepatic profiles of mice in which Nrf2 activity has been 
modulated, the ultimate aim of the work described in this thesis was the identification of 
candidate biomarkers of Nrf2 activity with potential utility in preclinical models 
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investigating the role of oxidative stress in DILI and translational value in studies defining 
the importance of Nrf2 in the human population. 
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Chapter 2 Proteomic analysis of the livers of WT and Nrf2 KO mice* 
 
 
 
 
 
 
 
 
 
*Much of the work described in this chapter has previously been published: 
Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, et al. (2010). Proteomic 
analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as 
primary Nrf2-dependent pathways in the liver. J Proteomics 73(8): 1612-1631. 
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2.1 Introduction 
We are constantly exposed to oxidative insult from endogenous and exogenous sources 
and the ability of a cell to defend itself against oxidative damage is vital for survival. The 
redox balance within a cell can be perturbed by electrophilic and oxidative stress resulting 
from drug administration, which can lead to damage to proteins, DNA and lipids. As the 
primary site for the processing of drugs in the body, the liver is at particular risk of drug-
induced toxicity, with DILI being the most common reason for withdrawal of a drug from 
the market (Lee, 2003). Oxidative stress and glutathione depletion are characteristic of the 
DILI associated with paracetamol overdose (Hazelton et al., 1986; Lores Arnaiz et al., 1995), 
and have also been implicated in the hepatotoxicity resulting from administration of a 
range of drugs including nefazadone and nimesulide (Xu et al., 2008a). 
The role of the transcription factor Nrf2 in the cytoprotective response to oxidative stress is 
well documented.  Nrf2 has a key role in regulating the expression of many genes 
associated with detoxification and defence against oxidative stress, including NQO1, HO-1, 
GSTs, GCLC and thioredoxin, as detailed in table 1.1 of this thesis. Under basal conditions, 
Nrf2 is sequestered in the cytosol by Keap1, which targets Nrf2 for ubiquitination and 
subsequent proteasomal degradation (Cullinan et al., 2004; Furukawa et al., 2005; Itoh et 
al., 1999).  However when the intracellular redox balance is disturbed, modifications to 
cysteine residues within the Keap1 homodimer result in a conformational change in the 
molecule (Kobayashi et al., 2006), and while Nrf2 remains bound to Keap1, it is no longer 
targeted for ubiquitination.  The high synthesis rate of Nrf2 means that Keap1 molecules 
quickly become saturated and newly synthesised Nrf2 is free to translocate to the nucleus, 
where it binds to the ARE in Nrf2 target genes, thus mediating their transcription (Itoh et 
al., 1999).     
While the transcription factor plays an important protective role in many organs, the vital 
role of Nrf2 in the hepatic cytoprotective response is highlighted by the fact that transgenic 
Nrf2 KO mice are more vulnerable to the hepatotoxic effects of a range of compounds. Nrf2 
null animals show reduced resistance to liver injury following administration of 
paracetamol (Chan et al., 2001; Enomoto et al., 2001), ethanol (Lamle et al., 2008), carbon 
tetrachloride (Xu et al., 2008b) and pyrazole (Lu et al., 2008).   
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Two key factors may play a role in the enhanced susceptibility of Nrf2 KO mice to drug-
induced toxicity.  Firstly, loss of Nrf2 may result in a reduction in the ability to mediate an 
adaptive response to a toxic insult through the up-regulation of cytoprotective gene 
expression.  However, the constitutive expression levels of genes important in the stress 
response may also impact on the ability of an animal to respond to the chemical stress 
associated with the administration of some drugs.  While the relative importance of these 
two factors may be a function of the mechanism by which toxicity occurs, and as such 
differs from compound to compound, the characterisation of constitutive differences in 
protein expression in the presence and absence of Nrf2 is of fundamental importance in 
understanding the role that the transcription factor plays in protecting the liver from drug-
induced toxicity.   
Studies using the Nrf2 KO mouse model together with known inducers of Nrf2 have 
identified a wide range of genes that are regulated by Nrf2 at an inducible and/or 
constitutive level.  For example, oligonucleotide microarray investigations have suggested a 
modulatory role for Nrf2 in the expression of more than 200 genes (Hu et al., 2006; Nair et 
al., 2007; Nair et al., 2006; Thimmulappa et al., 2002).   In some cases, the transcription 
factor regulates both basal and inducible expression of a given gene, while in others, 
expression of genes that are up-regulated on Nrf2 induction, remains largely unchanged at 
a constitutive level in the absence of Nrf2.     
Changes in gene expression do not always translate to an equivalent change at the protein 
level (Kitteringham et al., 2000), and consequently the functional significance of changes in 
gene expression remains to be determined in many cases. A number of the studies looking 
at gene expression have also investigated the effects of Nrf2 gene deletion and induction 
on expression levels of proteins, or the level of activity of enzymes important in the 
cytoprotective response (Chanas et al., 2002; Ramos-Gomez et al., 2001).  However, the 
number of proteins included in the studies is limited, and no global proteomic analysis has 
been performed to determine how hepatic protein expression profiles differ in WT and 
Nrf2 KO mice.   
Consequently, the aim of the work described in this chapter was to characterise and 
compare the constitutive proteomic profiles of WT and Nrf2 KO mouse livers using iTRAQ, 
and to identify the pathways that are differentially regulated in the livers of WT and Nrf2 
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KO animals. Ultimately, these proteins and pathways may provide candidate preclinical 
biomarkers of hepatic Nrf2 activation and oxidative stress and give mechanistic insight into 
the processes by which the cytoprotective response is mediated.   
2.2 Materials and methods 
2.2.1 Materials 
8-plex iTRAQ protein labelling kits were purchased from ABSciex (Warrington, UK).  
Sequencing grade trypsin, the GoTaq Flexi System and the ImProm-II™ Reverse 
Transcription System was obtained from Promega UK (Southampton, UK). Nitrocellulose 
and photographic film were from Amersham/GE Healthcare (Buckinghamshire, UK). Tris 
glycine, 4x Proto Gel Resolving Buffer, Proto Gel Stacking Buffer, and 30% acrylamide: 0.8% 
(w/v) Bis-acrylamide stock solution were purchased from Gene Flow (Staffordshire, UK). 
Protein assay reagent, rainbow molecular weight marker and non-fat dry milk were from 
BioRad (Hertfordshire, UK). Enhanced Chemiluminescence (ECL) substrate was from Perkin 
Elmer (Buckinghamshire, UK).   ATP citrate lyase (ACL) antibody was obtained from Abcam 
(Cambridge, UK). GST-P1 antibody was a gift from Lesley McLellan, University of Dundee. 
RNeasy Mini-kit and DNeasy blood and tissue kit were purchased from Qiagen (Crawley, 
UK).  The RNA 6000 Nano Kit was from Agilent (Berkshire UK).  100 bp ladder was from 
Invitrogen (Paisley, UK). All other reagents were from Sigma (Poole, UK), unless otherwise 
specified.  
2.2.2 Animal studies 
All experiments were undertaken in accordance with criteria outlined in a license granted 
under the Animals (Scientific Procedures) Act 1986, and approved by the Animal Ethics 
Committees of the University of Liverpool.  Male and female WT and Nrf2 KO 
C57BL6/SV129 mice were bred in house. Generation of the Nrf2 KO mouse has been 
described elsewhere (Itoh et al., 1997; McMahon et al., 2001). Mice were given free access 
to food and water and housed at a temperature of between 19°C - 23°C under 12 h 
light/dark cycles.   
For the ITRAQ study, animals (10-12 weeks) were killed at 10 am by exposure to a rising 
concentration of carbon dioxide, confirmed by cervical dislocation. Livers were removed, 
rinsed in 0.9% saline, snap frozen in liquid nitrogen and stored at -80°C. 
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For Microfluidic analysis, animals (22-24 weeks) were culled between 2 pm and 4 pm by 
exposure to a rising concentration of carbon dioxide, before cardiac puncture was 
performed. Livers were removed and stored as above.   
2.2.3 Genotyping of mice 
PCR was performed in order to confirm the genotype of mice in the Nrf2 colony.  DNA was 
isolated from approximately 25 mg of liver tissue from each mouse using the Qiagen 
DNeasy blood and tissue kit according to the manufacturer’s instructions with samples 
digested overnight, DNA bound to the spin column before being washed and subsequently 
eluted.   PCR was performed using the Promega GoTaq Flexi system with primers 1 to 3 as 
detailed in table 2.1.  The PCR conditions were 95 °C for 15 minutes followed by 35 cycles 
of 94 °C for 30 sec; 62 °C for 30 sec; 72 °C for 1 min.  The PCR products were run on a 2% 
agarose gel in 1x TAE buffer (100 V; 30 min), and viewed using a transilluminator.   
Table 2.1: Primers used for genotyping 
Oligonucleotide Sequence Length 
Primer 1: Nrf2-5’ TGGACGGGACTATTGAAGGCTG 22 
Primer 2: LacZ GCGGATTGACCGTAATGGGATAGG 24 
Primer 3: Nrf2 antisense GCCGCCTTTTCAGTAGATGGAGG 23 
 
2.2.4 Liver homogenisation – iTRAQ 
Sections of liver (50-100 mg) from male WT and Nrf2 KO mice (n=4) were homogenised in 
iTRAQ buffer [0.5M triethylammonium bicarbonate (TEAB)/0.1% sodium dodecyl sulphate 
(SDS)] using an eppendorf pestle.  Samples were subjected to a freeze thaw cycle (-80°C; 
overnight), before being sonicated (3 x 10 s at 5 μm amplitude).  The homogenate was 
centrifuged (14 000 g; 10 min), and the supernatant retained. Samples were centrifuged a 
second time (14 000 g; 5 min), and the supernatant was again retained.  Protein 
concentration was determined using the method described by Bradford (Bradford, 1976). 
2.2.5 iTRAQ labelling of liver homogenates 
Liver homogenates (75 μg protein) were prepared in iTRAQ buffer. iTRAQ reagent labelling 
was then carried out according to the ABSciex protocol for an 8plex procedure.  Samples 
were reduced with tris(2-carboxyethyl)phosphine (TCEP) and sulphydryl groups capped 
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with methylmethanethiosulfate (MMTS), before overnight digestion with trypsin. Samples 
were then labelled with isobaric tags. In the first three iTRAQ runs, WT samples were 
labelled with tags 113 to 116 while Nrf2 KO samples received the 117 to 121 tags. In the 
fourth experiment, the sample labelling was reversed such that the WT animals had the 
heavier tags and the KO mice the lighter tags, in order to control for labelling bias. 
Following labelling, samples were pooled and centrifuged (10 000g; 1 minute).  The 
supernatant was removed to a fresh tube and diluted to a volume of 5 mL using 10 mM 
potassium dihyrdrogen phosphate/ 25% acetonitrile (ACN: w/v). The pH was adjusted to <3 
using phosphoric acid and unbound reagent and trypsin were removed by cation exchange 
chromatography.  Cation exchange was performed on a Polysulphoethyl A strong cation-
exchange column (200×4.6 mm, 5 μm, 300 Å; Poly LC, Columbia, MD). A flow rate of 1 
mL/min was applied and peptides were eluted by increasing the concentration of 
potassium chloride (KCl) in the mobile phase to 0.5 M over 60 min. Chromatographic 
fractions of 2 mL were collected and were dried by centrifugation under vacuum 
(Eppendorf concentrator 5301). Samples were stored at 4°C prior to LC-MS/MS analysis. 
2.2.6 Mass spectrometric analysis of iTRAQ samples 
Each cation exchange fraction was resuspended in 120 μL of 5% ACN/0.05% trifluoroacetic 
acid (TFA) and 60 μL were loaded on to the column. Samples were analysed on a QSTAR® 
Pulsar i hybrid mass spectrometer (AB Sciex, Warrington, UK) and were delivered into the 
instrument by automated in-line liquid chromatography (integrated LCPackings System, 
5mm C18 nano-precolumn and 75 μm×15 cm C18 PepMap column; Dionex, California, USA) 
via a nano-electrospray source head and 10 μm inner diameter PicoTip (New Objective, 
Massachusetts, USA). The precolumn was washed for 30 min at 30 μL/min with 5% ACN/ 
0.05% TFA prior to initiation of the solvent gradient in order to reduce the level of salt in 
the sample. A gradient from 5% ACN/ 0.05% TFA (v/v) to 60% ACN/0.05% TFA (v/v) in 70 
min was applied at a flow rate of 300 nL/min. The MS was operated in positive ion mode 
with survey scans of 1 s, and with an MS/MS accumulation time of 1 s for the three most 
intense ions. Collision energies were calculated on the fly based on the m/z of the target 
ion and the formula, collision energy=(slope×m/z)+intercept. The intercepts were increased 
by 3–5 V compared to standard data acquisition in order to improve the reporter ion 
intensities/quantitative reproducibility.  
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2.2.7 iTRAQ data analysis 
Data analysis was performed using ProteinPilot software (Version 3, AB Sciex, Warrington, 
UK). The data were analysed with a fixed modification of MMTS-labelled cysteine, 
biological modifications were allowed and the confidence was set to 10% to enable the 
False Discovery Rate to be calculated from screening the reversed SwissProt database. 
Ratios for each iTRAQ label were obtained, using the “WT mouse 1” sample as the 
denominator. The detected protein threshold (“unused protscore (conf)”) in the software 
was set to 1.3 to achieve 95% confidence. 
2.2.8 iTRAQ statistical analysis 
iTRAQ data for proteins within a 1% false discovery rate and for which full quantification 
data were obtained, were statistically analysed within the R computational environment 
(R_Development_Core_Team, 2009). R is an open source software environment for 
statistical computing and graphics (http://www.r-project.org/). Normality of the data and 
equivalence of variance across the data sets was assessed by Shapiro–Wilk and F-tests, 
respectively, and also by inspection of histogram plots for all proteins identified. Data were 
then analysed by unpaired t-test using the module multtest, a package designed for re-
sampling based multiple hypothesis testing. Benjamini–Hochberg corrections for multiple 
comparisons were performed on all raw p values generated (Katz, 2003). Protein 
expression differences between WT and Nrf2 KO mice giving a p value of <0.05 by t-test 
and a Benjamini–Hochberg value ≤0.2 were accepted for further correlative network 
analysis. The Benjamini–Hochberg cut-off was set at 0.2 to avoid the exclusion of correlated 
Nrf2-regulated proteins through application of too stringent a correction for multiple 
testing in accordance with multivariate modelling approaches to account for potential 
confounders (Katz, 2003). 
2.2.9 Network analysis 
The accession numbers of the 108 proteins identified as significantly different following 
Benjamini–Hochberg adjustment for multiple comparisons (p≤0.2) were converted to 
Entrez gene IDs using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID) (http://david.abcc.ncifcrf.gov/conversion.jsp), and analysed for evidence of 
network wide changes in cellular phenotype using MetaCore from GeneGo Inc., an 
integrated manually curated knowledge database for pathway analysis of gene lists 
(http://www.genego.com/metacore.php). The gene list was analysed using the Pathway 
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Maps tool, which maps the genes listed to defined signalling pathways that have been 
experimentally validated and are widely accepted. The proteins deemed Nrf2-regulated 
according to the criteria defined above were compared against a background file 
containing all of the identified proteins which had similarly been converted to a list of 
Entrez gene IDs using DAVID. The p values generated by the software were used to 
determine the statistical significance of the pathways identified. The p value represents the 
probability that a particular pathway will be represented by chance given the number of 
genes in the experiment and the number of genes in the pathway.  
2.2.10 Liver homogenisation – western immunoblotting 
The remaining liver from male WT and Nrf2 KO mice (n=4) was homogenised in phosphate 
buffered saline (PBS) using 10 passes of a hand held glass-teflon homogeniser.  The 
homogenate was centrifuged (10 000g; 5 min) to pellet unhomogenised tissue and cell 
debris, and the supernatant retained. Whole livers from female WT and Nrf2 KO mice (n=4) 
were homogenised in the same way. Protein concentration was determined using the 
method of Lowry (Lowry et al., 1951). 
2.2.11 Western immunoblotting 
Whole liver homogenate (25 μg of protein) was separated by denaturing electrophoresis on 
a 10% polyacrylamide gel using Tris-Glycine-SDS running buffer and transferred to a 
nitrocellulose membrane.  After transfer, a Ponceau Red stain was used to ensure equal 
loading and the membrane was blocked using 10% milk in TBST [1x tris-buffered saline 
(TBS)/0.1%Tween] for 30 min at room temperature.  After blocking, membranes were 
incubated (4 °C; overnight) with either a rabbit monoclonal antibody to ACL (1:5000) or a 
mouse monoclonal antibody to GST-P1 (1: 10 000) in 2% milk in TBST. The membrane was 
washed with TBST (4x 5 min) and then incubated (1h; room temperature) with the 
secondary antibody [peroxidise-conjugated goat anti-rabbit immunoglobulin G (IgG), 
1:5000 (ACL) or peroxidase-conjugated rabbit anti-mouse IgG 1:10 000 (GST-P1)] in TBST 
containing 2% milk. The membrane was washed as before.  ECL-Plus was used to visualise 
the level of protein-antibody complex. Band volume was measured by densitometry using 
Biorad Quantity One 1D Analysis Software (BioRad). Statistical analysis was performed 
using StatsDirect (version 2.6.8, StatsDirect Ltd, Altrincham, UK).  A Shapiro–Wilk test was 
used to assess the normality of the data.  Normal data were analysed to assess statistical 
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significance using an unpaired t-test, while a Mann Whitney U-test was used for non-
normal data.   
2.2.12 RNA isolation 
RNA isolation was performed using the RNeasy Mini-kit according to the manufacturer’s 
instructions.  Approximately 30 mg of liver tissue was weighed out and the weight 
recorded.  600 μL of buffer RLT was added to the liver sample and tissue was homogenised 
(2 min: 30 s-1) using the MM400 oscillating mill (Retsch, Haan, Germany). Samples were 
centrifuged (18 000 g; 3 min), and the supernatant retained.  600 μL of 70% ethanol was 
added to the homogenate and mixed by pipetting, before the solution was passed through 
an RNeasy spin column by centrifugation (15 s; 10 000g). The RNA, which had bound to the 
spin column, was washed in three subsequent centrifugation steps using the buffers 
provided, before the RNA was eluted in RNase-free dH2O.  The RNA concentration was 
determined using a NanoDrop ND-1000 (Labtech, East Sussex, UK).   
2.2.13 RNA quality determination 
The quality of the RNA was determined using the Agilent RNA 6000 Nano Kit according to 
the manufacturer’s instructions. Gel matrix was filtered by centrifugation (1500 g; 10 min), 
before dye was added (1 μL to 65 μL of gel matrix).  The solution was vortexed and 
centrifuged (13000g; 10 min).  The gel-dye mix was added to the RNA 6000 Nano chip 
before marker (5 μL), ladder (1 μL) and samples (1 μL) were added to the appropriate wells 
of the chip.  The chip was vortexed (2400 rpm; 1 min), before being analysed using the 
Agilent 2100 bioanalyzer (Agilent, Berkshire, UK).   
2.2.14 cDNA synthesis 
cDNA synthesis was carried out using the Promega ImProm-II™ Reverse Transcription 
System according to the manufacturer’s instructions, with some minor modifications: 4μL 
of RNA at a concentration of 0.5 μg/μL was combined with 1 μL of random primer solution, 
and nuclease-free dH2O was added to give a final volume of 15 μL. The solution was 
incubated (70°C; 5 min) and then cooled on ice.  A master-mix containing ImProm-IITM 
reaction buffer, 6mM MgCl2, dNTP mix and ImProm-II
TM reverse transcriptase in a final 
volume of 20 μL was added to the RNA solution.  Strands were annealed (25°C; 5 min) and 
extended (42°C; 1 hour), before the reverse transcriptase was inactivated (70°C; 15 min).  
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160 μL of nuclease-free dH2O was added to each tube and cDNA concentration was 
subsequently determined using the NanoDrop. 
2.2.15 Microfluidic cards 
Microfluidic cards were designed to include well established Nrf2-regulated genes, genes 
encoding proteins identified as Nrf2-regulated in iTRAQ analysis and genes encoding 
proteins that were not identified by iTRAQ but were associated with pathways identified by 
MetaCore analysis. Cards were custom made by Applied Biosystems (Paisley, UK).  18S was 
used as a housekeeping gene. The plate layout and represented genes are detailed in figure 
2.1 and table 2.2. Samples were run in a randomised order, as determined using 
random.org (http://www.random.org/), across 5 TaqMan array cards. A pool of cDNA from 
all samples was run on each card so that data could be compared across plates. 
The cDNA that had previously been synthesised was diluted in nuclease-free dH2O to a 
concentration of 1ng/µL cDNA. 50 µL of this solution was combined with 50 µL of TaqMan® 
Gene Expression Master Mix (Life Technologies, Paisley, UK) to give 50 ng of total cDNA. 
Samples were vortexed and transferred to the appropriate well of the TaqMan array card.  
Pooled cDNA samples were prepared in the same way. Once loaded, cards were 
centrifuged at 331g (2x 1 min) and sealed. The wells were removed, and cards were run on 
the 7900HT Fast Real-Time PCR System (ABSciex) immediately or stored at room 
temperature for up to 24 hours. 
2.2.16 Microfluidic card data analysis  
Data was analysed using the comparative CT method (ΔΔCT).  CT values were determined 
using the RQ manager 1.2 component of the 7900HT Fast System software. The threshold 
was manually set to a value of 0.3 for all plates.  Gene expression was quantified relative to 
the sample pool run on the same plate and normalised to 18S gene expression. Statistical 
analysis was performed to compare relative expression of genes in WT and Nrf2 KO mice 
where CT values were available for ≥4 animals in each group. A Shapiro-Wilk test was used 
to assess the normality of the data with normal data analysed using an unpaired t-test and 
non-normal data analysed using a Mann-Whitney U test.    
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Figure 2.1: Microfluidic TaqMan low density array card layout.  8 samples were run on each plate. Each loading well corresponds to two adjacent rows of the plate; hence 
48 gene targets were amplified per sample.  18S was used as a housekeeping gene. The gene name for each gene code is detailed in table 2.2.
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Table 2.2: Each of the genes represented on the Microfluidic TaqMan low density array card. 
Gene code Gene Name Gene code Gene Name 
Acly ATP citrate lyase Glul Glutamate-ammonia 
ligase/Glutamaine synthetase 
Abcc1 ATP binding cassette subfamily C 
member 1 
Gclc Glutamate-cysteine ligase, modifier 
subunit 
Abcc4 ATP binding cassette subfamily C 
member 4 
Gclm Glutamate-cysteine ligase, catalytic 
subunit 
Elovl 6 Elongation of very long chain fatty 
acids protein 6 
Gsta4 Glutathione S-transferase alpha 4 
Jun Jun oncogene Gstm1 Glutathione S-transferase mu 1 
Nqo1 NAD(P)H dehydrogenase quinone 1 Gstp1 Glutathione S-transferase pi 1 
Ugt1a6a UDP glucuronosyltransferase 1 family 
polypeptide A6 
Gstt3 Glutathione S-transferase theta 3 
Ugt2b5 UDP glucuronosyltransferase 2 family 
polypeptide B5 
Gsr Glutathione reductase 
Acaa1b Acetyl-CoA acyltransferase 1B Glo1 Glyoxalase 1 
Acaca Acetyl-CoA carboxylase alpha Keap1 Kelch-like ECH-associated protein 1 
18S 18S ribosomal subunit Lipg Lipase, endothelial 
Acsl5 Acyl-CoA synthetase long-chain family 
member 5 
Mgst1 Microsomal glutathione S-transferase 
1 
Agxt Alanine-glyoxylate aminotransferase Prdx6 Peroxiredoxin 6 
Aldh8a1 Aldehyde dehydrogenase 8 family 
member A1 
Pklr Pyruvate kinase, liver and RBC 
Bhmt Betaine-homocysteine 
methyltransferase  
Sbp1/2 
(Selenbp1; 
Selenbp2)  
Selenium binding protein 1/Selenium 
binding protein 2 
Ces1g Carboxylesterase 1G Sds Serine dehydratase 
Cyp1a2 Cytochrome P450 family 1 subfamily 
A polypeptide 2 
Slc2a1 Solute carrier family 2 (facilitated 
glucose transporter) member 1 
Cyp2c50 Cytochrome P450 family 2 subfamily 
C polypeptide 50 
Slc22a7 Solute carrier family 22 (organic anion 
transporter) member 7 
Cyp2e1 Cytochrome P450 family 2 subfamily 
E polypeptide 1 
Scd1 Stearoyl-CoA desaturase 1 
Cyp7b1 Cytochrome P450 family 7 subfamily 
B polypeptide 1 
Scp2 Stearoyl carrier protein 2 
Dbi Diazepam binding inhibitor/Acyl CoA 
binding protein 
Srebf1 Sterol regulatory element binding 
transcription factor 1 
Ephx1 Epoxide hydrolase 1 Usp2 Ubiquitin-specific peptidase 2 
Fabp5 Fatty acid binding protein 5, 
epidermal 
Uox Urate oxidase/uricase 
Fasn Fatty acid synthase Nfe2l2 Nuclear factor erythroid derivied 2, 
like 2 
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2.3 Results 
2.3.1 iTRAQ analysis of WT and Nrf2 KO mouse liver proteins 
Proteins from the livers of two independent sets of mice were analysed using iTRAQ stable 
isotope labelling.  iTRAQ analysis 1 involved samples from 4 WT and 4 Nrf2 KO mice, which 
were each analysed on 4 separate occasions using 8-plex iTRAQ reagents.  iTRAQ analysis 2 
used 6 WT and 6 Nrf2 KO mouse livers, which were each analysed once using 3 sets of 4-
plex iTRAQ reagents.  Samples from iTRAQ analysis 2 were used in order to validate the 
reproducibility of the protein changes identified in iTRAQ analysis 1.  The number of 
proteins that were identified and quantified in both iTRAQ analyses is shown in table 2.3.   
2.3.2 iTRAQ analysis 1 
Within the 4 runs of iTRAQ analysis 1, a total of 1109 unique proteins were identified in at 
least 1 run within the FDR of 1% (table 2.3).  769 of these proteins were detected in all 8 
mice in a single run and were selected for full quantitative analysis.  For all samples, protein 
expression was expressed relative to animal WT1. A mean relative expression value was 
calculated for each protein for WT and Nrf2 KO mice and this was used to calculate the 
mean fold change of that protein in Nrf2 KO animals when compared to WTs. When a    
protein was detected in all 8 mice in more than one run, a mean value for protein 
expression in a particular mouse across each complete run was calculated and used in 
subsequent analysis.    
While there was considerable variation in the protein coverage between the 4 runs, with 
run 1 detecting notably fewer proteins than runs 2-4, all runs were used for statistical 
analysis.  This was done in order to maximise the number of proteins included in 
subsequent network analysis.  
Statistical analysis identified 108 proteins that were differentially expressed in the livers of 
WT and Nrf2 KO mice and these are detailed in table 2.4.   45 proteins were expressed at a 
lower level in Nrf2 KO mice and 63 expressed at a higher level.  Of the 769 proteins 
analysed, the number of proteins that were expressed at a higher level in Nrf2 KO when 
compared to WT was approximately equal to the number expressed at a lower level. Figure 
2.2 shows a volcano plot of the 769 proteins analysed, with those identified as significantly 
differentially expressed (t-test – P ≤ 0.05; Benjamini-Hochberg value ≤ 0.2) represented as 
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circles.  Proteins with relative expression values that differed by at least 20% in WT and 
Nrf2 KO mice are shown as filled circles.   
Table 2.3: Total numbers of proteins identified and quantified with a false discovery rate (FDR) 
exclusion of 1% in iTRAQ analyses 1 and 2.  Numbers are given for proteins identified with a 
confidence greater than 90% and for those characterized by at least 2 peptides.  The number of 
proteins quantified relates to those proteins determined in all eight mouse liver samples. 
iTRAQ 
analysis 
LC-MS analysis No. of Proteins 
identified 
No. of proteins 
identified above 
1% global FDR 
No. of proteins 
quantified 
1 Run 1 486 265 162 
 Run 2 1287 911 620 
 Run 3 1003 759 593 
 Run 4 726 563 426 
TOTAL  1654 1109 769 
     
2 Run 1 1068 825 654 
 Run 2 1065 780 661 
 Run 3 1068 711 637 
TOTAL  1717 1070 628 
 
Of the proteins that were expressed at a significantly lower level in Nrf2 KO animals, the 
majority had roles in cytoprotection, for example the conjugative drug metabolism 
enzymes GSTP1 and UGT2B5. This is reflective of the findings of previous oligonucleotide 
assay studies.  However, of the proteins up-regulated in the livers of Nrf2 KO mice, most 
were involved in lipid metabolism.  A list of proteins identified as lipid metabolism or lipid 
transport proteins within the Uniprot database (http://www.uniprot.org/) is given in table 
2.5.  
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Table 2.4: Nrf2-regulated mouse hepatic proteins identified in iTRAQ analysis 1. Relative expression of hepatic proteins in livers of WT and Nrf2 KO mice determined in 
iTRAQ analysis 1. All values are expressed relative to a WT control mouse (WT1). Proteins listed were significantly different in the null mice compared with WT according 
to an unpaired t-test followed by Benjamini-Hochberg (BH) correction for multiple testing at a significance level of p ≤ 0.2. Four replicate iTRAQ analyses were conducted 
on each sample and the number of runs in which each protein appeared is designated by n in column 3. The values for each mouse thus represent the average of n 
replicates. The fold change was calculated from the geometric mean values obtained from the 4 individual mice. Variance of the geometric mean for the four animals in 
each group is expressed as upper and lower 95% confidence intervals (CI). Proteins are listed according to their expression in KO
 
mice relative to WT animals in ascending 
order of the fold-change value. 
  
   
 
 
 Relative expression compared to WT 1 
  
   
 
 
WT  
 
KO 
Fold 
change 
 
SwissProt  
Acc. No. Name n 
Average 
no.  of 
peptides 
Average 
coverage 
(%) 
mouse 
WT1 
mouse 
WT2 
mouse 
WT3 
mouse 
WT4 
Geometric 
mean 
Lower 
95% 
CI 
Upper 
95% CI 
 
mouse 
KO1 
mouse 
KO2 
mouse 
KO3 
mouse 
KO4 
Geometric 
mean 
Lower 
95% CI 
Upper 
95% CI 
KO     
WT
 
BH p 
P02762 Major urinary 
protein 6 
4 19.8 54.9 1.00 1.35 1.29 1.54 1.28 1.07 1.53  0.47 0.28 0.48 0.64 0.45 0.32 0.63 0.35 0.057 
P17427 AP-2 complex 
subunit alpha2 
1 1.0 2.5 1.00 1.25 1.93 1.51 1.38 1.05 1.82  0.46 0.43 0.71 0.66 0.55 0.43 0.71 0.40 0.064 
P10649 Glutathione S-
transferase Mu 1 
4 13.8 39.2 1.00 1.31 1.00 1.11 1.10 0.97 1.24  0.47 0.53 0.44 0.42 0.46 0.42 0.51 0.42 0.009 
Q61656 Probable ATP-
dependent RNA 
helicase DDX5 
1 2.0 5.4 1.00 1.31 1.19 1.35 1.20 1.05 1.38  0.37 0.85 0.51 0.79 0.59 0.40 0.87 0.49 0.148 
Q91WG8 Bifunctional UDP-N-
acetylglucosamine 
2-epimerase 
1 2.0 4.0 1.00 0.98 1.13 1.19 1.07 0.98 1.17  0.49 0.60 0.68 0.59 0.59 0.52 0.67 0.55 0.022 
P19157 Glutathione S-
transferase P 1 
4 43.0 76.3 1.00 1.21 0.94 1.12 1.06 0.95 1.19  0.62 0.56 0.60 0.54 0.58 0.55 0.62 0.55 0.011 
P17717 UDP-glucuronosyl-
transferase 2B5 
4 5.8 15.5 1.00 1.16 0.99 1.08 1.05 0.98 1.13  0.59 0.57 0.56 0.61 0.58 0.56 0.61 0.55 0.004 
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Q63836 Selenium-binding 
protein 2 
4 26.0 47.9 1.00 1.26 0.99 1.48 1.17 0.96 1.41  0.61 0.59 0.67 0.72 0.65 0.59 0.71 0.55 0.051 
Q8VCC2 Liver 
carboxylesterase 1 
3 2.3 4.6 1.00 1.34 1.06 0.94 1.08 0.93 1.25  0.62 0.60 0.58 0.70 0.62 0.58 0.68 0.58 0.042 
Q60991 Cytochrome P450 
7B1 
1 2.0 7.1 1.00 1.43 1.66 1.65 1.40 1.11 1.77  0.85 0.82 0.82 0.79 0.82 0.80 0.84 0.58 0.073 
P46425 Glutathione S-
transferase P2 
1 39.0 71.0 1.00 0.70 0.76 0.61 0.75 0.61 0.93  0.47 0.45 0.43 0.43 0.44 0.43 0.46 0.59 0.063 
P24472 Glutathione S-
transferase A4 
2 2.5 17.6 1.00 1.01 0.99 0.92 0.98 0.94 1.02  0.49 0.62 0.76 0.50 0.58 0.48 0.72 0.60 0.073 
O35660 Glutathione S-
transferase M6 
1 7.0 24.3 1.00 0.68 0.67 0.89 0.80 0.66 0.97  0.50 0.69 0.42 0.40 0.49 0.38 0.62 0.61 0.179 
P00186 Cytochrome P450 
1A2 
3 3.0 10.9 1.00 1.14 1.26 1.21 1.15 1.04 1.27  0.59 0.61 0.91 0.86 0.73 0.58 0.91 0.63 0.186 
Q9EQU5 Protein SET 1 1.0 6.2 1.00 1.22 1.34 0.99 1.13 0.97 1.31  1.05 0.63 0.57 0.71 0.72 0.56 0.94 0.64 0.199 
Q91X77 Cytochrome P450 
2C50 
3 6.0 16.5 1.00 1.30 1.29 1.33 1.22 1.07 1.40  0.67 0.67 1.03 0.87 0.80 0.65 0.98 0.65 0.162 
Q6XVG2 Cytochrome P450 
2C54 
4 3.5 8.5 1.00 1.00 0.96 1.04 1.00 0.97 1.03  0.54 0.70 0.77 0.77 0.69 0.58 0.81 0.69 0.090 
Q91XE8 Transmembrane 
protein 205 
2 1.5 11.4 1.00 0.67 0.70 0.60 0.73 0.58 0.91  0.49 0.47 0.49 0.57 0.50 0.46 0.55 0.69 0.153 
P15105 Glutamine 
synthetase 
4 9.8 25.1 1.00 1.16 1.06 1.29 1.12 1.01 1.25  0.70 0.67 0.99 0.83 0.79 0.66 0.93 0.70 0.182 
O55060 Thiopurine S-
methyltransferase 
2 1.0 5.4 1.00 0.85 0.99 0.75 0.89 0.78 1.02  0.49 0.71 0.71 0.70 0.65 0.54 0.77 0.72 0.194 
O35490 Betaine--
homocysteine S-
methyltransferase 
1 
4 18.3 45.2 1.00 0.81 1.11 1.12 1.00 0.87 1.16  0.76 0.67 0.78 0.80 0.75 0.70 0.81 0.75 0.148 
P24549 Retinal 
dehydrogenase 1 
4 13.8 31.2 1.00 1.07 1.10 1.22 1.10 1.01 1.19  0.80 0.76 0.84 0.92 0.83 0.77 0.90 0.76 0.127 
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P06801 NADP-dependent 
malic enzyme 
3 8.0 20.5 1.00 1.32 1.16 1.22 1.17 1.04 1.31  0.75 0.93 1.06 0.84 0.89 0.77 1.02 0.76 0.201 
P62858 40S ribosomal 
protein S28 
4 1.0 17.4 1.00 1.03 1.08 1.11 1.05 1.01 1.10  0.87 0.76 0.81 0.82 0.82 0.77 0.86 0.77 0.038 
Q91VA0 Acyl-coenzyme A 
synthetase ACSM1, 
mitochondrial 
3 6.3 20.4 1.00 0.95 1.03 0.90 0.97 0.91 1.03  0.80 0.71 0.75 0.75 0.75 0.72 0.79 0.78 0.039 
Q9JIF7 Coatomer subunit 
beta 
2 3.0 3.9 1.00 0.86 0.92 0.94 0.93 0.87 0.99  0.77 0.74 0.65 0.74 0.72 0.67 0.77 0.78 0.044 
O55125 Protein NipSnap 
homolog 1 
3 1.0 4.0 1.00 0.76 0.80 0.93 0.87 0.77 0.98  0.62 0.68 0.68 0.73 0.68 0.64 0.72 0.78 0.201 
Q99JI4 26S proteasome 
non-ATPase 
regulatory subunit 
6 
2 1.0 3.9 1.00 0.76 0.75 0.74 0.81 0.70 0.93  0.65 0.67 0.60 0.61 0.63 0.60 0.67 0.78 0.182 
Q99J99 3-
mercaptopyruvate 
sulfurtransferase 
2 2.0 10.9 1.00 0.99 0.87 0.94 0.95 0.89 1.01  0.72 0.71 0.80 0.79 0.75 0.71 0.80 0.79 0.057 
Q76MZ3 Serine/threonine-
protein 
phosphatase 2A 65 
kDa regulatory 
subunit A alpha 
2 1.0 3.4 1.00 0.76 0.94 0.83 0.88 0.78 0.99  0.65 0.73 0.60 0.82 0.70 0.61 0.80 0.80 0.204 
Q9Z0X1 Apoptosis-inducing 
factor 1, 
mitochondrial 
2 1.0 2.1 1.00 0.99 0.89 0.86 0.93 0.87 1.00  0.67 0.78 0.76 0.80 0.75 0.69 0.81 0.80 0.114 
O70475 UDP-glucose 6-
dehydrogenase 
3 5.7 19.5 1.00 0.94 0.96 1.06 0.99 0.94 1.04  0.77 0.87 0.81 0.75 0.80 0.75 0.85 0.81 0.061 
Q8R1G2 Carboxymethylene-
butenolidase 
homolog 
2 2.5 12.9 1.00 0.85 0.96 1.06 0.96 0.88 1.06  0.71 0.75 0.82 0.86 0.78 0.72 0.85 0.81 0.178 
Q8VCU1 Liver carboxyl-
esterase 31-like 
3 10.0 20.4 1.00 0.95 0.90 0.83 0.92 0.85 0.99  0.74 0.69 0.79 0.78 0.75 0.70 0.79 0.81 0.117 
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Q8VCA8 Secernin-2 1 1.0 4.0 1.00 1.09 1.05 0.92 1.01 0.94 1.09  0.87 0.76 0.93 0.78 0.83 0.76 0.91 0.82 0.156 
Q91VS7 Microsomal 
glutathione S-
transferase 1 
4 5.0 30.2 1.00 0.92 0.95 0.95 0.95 0.92 0.99  0.84 0.71 0.73 0.85 0.78 0.71 0.86 0.82 0.162 
Q9D6Y7 Peptide methionine 
sulfoxide reductase 
3 3.0 16.7 1.00 1.08 1.04 1.06 1.04 1.01 1.08  0.83 0.82 0.93 0.85 0.86 0.81 0.91 0.82 0.044 
P70441 Na(+)/H(+) 
exchange 
regulatory cofactor 
NHE-RF1 
3 1.7 5.7 1.00 0.82 0.84 0.73 0.84 0.74 0.96  0.75 0.68 0.69 0.68 0.70 0.67 0.73 0.83 0.198 
Q8VCW8 Acyl-CoA 
synthetase family 
member 2, 
mitochondrial 
3 6.3 18.5 1.00 0.98 1.00 0.93 0.98 0.94 1.01  0.81 0.77 0.85 0.82 0.81 0.78 0.85 0.83 0.030 
P57776 Elongation factor 1-
delta 
3 3.7 23.5 1.00 0.90 0.87 0.83 0.90 0.83 0.97  0.84 0.76 0.78 0.74 0.78 0.74 0.82 0.87 0.180 
P07759 Serine protease 
inhibitor A3K 
3 9.0 24.5 1.00 1.03 1.16 1.05 1.06 1.00 1.13  0.91 0.91 0.87 0.97 0.92 0.88 0.96 0.87 0.123 
Q91ZJ5 UTP--glucose-1-
phosphate 
uridylyltransferase 
3 3.0 8.0 1.00 0.99 1.08 1.06 1.03 0.99 1.08  0.86 0.89 0.96 0.88 0.90 0.85 0.94 0.87 0.156 
P11352 Glutathione 
peroxidase 1 
4 4.5 26.1 1.00 0.96 1.07 1.12 1.04 0.97 1.11  0.90 0.88 0.95 0.94 0.92 0.89 0.95 0.89 0.193 
P60867 40S ribosomal 
protein S20 
3 2.3 16.2 1.00 0.91 1.01 0.91 0.96 0.90 1.01  0.90 0.81 0.86 0.84 0.85 0.82 0.89 0.89 0.178 
Q9JII6 Alcohol 
dehydrogenase 
[NADP+] 
4 5.5 25.0 1.00 0.95 0.97 0.89 0.95 0.91 1.00  0.85 0.89 0.86 0.84 0.86 0.84 0.88 0.90 0.121 
Q9DBJ1 Phosphoglycerate 
mutase 1 
2 8.0 44.3 1.00 0.98 1.02 1.04 1.01 0.98 1.03  1.09 1.06 1.04 1.10 1.07 1.05 1.10 1.07 0.128 
Q8BVI4 Dihydropteridine 
reductase 
3 3.0 18.4 1.00 1.09 1.05 1.09 1.06 1.02 1.10  1.14 1.12 1.15 1.16 1.14 1.12 1.16 1.08 0.178 
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Q8BH00 Aldehyde 
dehydrogenase 
family 8 memberA1 
3 13.3 31.9 1.00 1.07 1.08 1.14 1.07 1.02 1.13  1.19 1.19 1.14 1.15 1.17 1.14 1.20 1.09 0.206 
Q8BFR5 Elongation factor 
Tu, mitochondrial 
3 2.7 10.4 1.00 0.93 0.97 0.91 0.95 0.91 0.99  1.05 0.99 1.07 1.05 1.04 1.00 1.08 1.09 0.144 
Q3UQ44 Ras GTPase-
activating-like 
protein IQGAP2 
3 3.3 3.4 1.00 1.04 0.99 0.96 1.00 0.97 1.03  1.11 1.15 1.09 1.08 1.10 1.08 1.13 1.11 0.057 
P21107 Tropomyosin alpha-
3 chain 
1 1.0 3.5 1.00 1.00 1.03 1.05 1.02 1.00 1.04  1.12 1.23 1.04 1.16 1.14 1.06 1.22 1.12 0.188 
Q64374 Regucalcin 4 13.8 42.6 1.00 1.07 1.02 1.08 1.04 1.01 1.08  1.12 1.22 1.24 1.09 1.17 1.10 1.24 1.12 0.148 
P45952 Medium-chain 
specific acyl-CoA 
dehydrogenase, 
mitochondrial 
3 4.7 14.2 1.00 1.06 1.11 1.08 1.06 1.02 1.11  1.20 1.20 1.24 1.13 1.19 1.15 1.23 1.12 0.095 
P62991 Ubiquitin 4 4.8 50.3 1.00 1.08 1.03 1.15 1.06 1.00 1.13  1.17 1.27 1.18 1.15 1.19 1.14 1.24 1.12 0.178 
Q8CHT0 Delta-1-pyrroline-5-
carboxylate 
dehydrogenase, 
mitochondrial 
3 7.0 18.0 1.00 1.05 1.09 0.97 1.03 0.98 1.08  1.17 1.20 1.23 1.05 1.16 1.09 1.24 1.13 0.193 
Q99J08 SEC14-like protein 2 3 6.3 25.5 1.00 1.08 1.12 1.21 1.10 1.02 1.19  1.27 1.18 1.32 1.23 1.25 1.19 1.31 1.14 0.186 
Q02053 Ubiquitin-like 
modifier-activating 
enzyme 1 
4 3.5 5.6 1.00 1.05 1.00 1.04 1.02 1.00 1.05  1.10 1.19 1.24 1.14 1.16 1.11 1.22 1.14 0.073 
O88569 Heterogeneous 
nuclear ribo-
nucleoproteins 
A2/B1 
4 4.5 12.5 1.00 0.98 1.03 1.08 1.02 0.98 1.07  1.22 1.17 1.10 1.16 1.16 1.12 1.21 1.14 0.090 
Q9QXD6 Fructose-1,6-
bisphosphatase 
4 16.0 46.5 1.00 0.93 0.98 0.92 0.96 0.92 0.99  1.16 1.14 1.05 1.01 1.09 1.02 1.16 1.14 0.144 
Q99JI6 Ras-related protein 
Rap-1b 
2 1.0 6.5 1.00 1.02 0.99 1.01 1.00 1.00 1.01  1.21 1.20 1.08 1.10 1.14 1.08 1.21 1.14 0.121 
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P50580 Proliferation-
associated protein 
2G4 
2 2.0 6.6 1.00 1.01 1.07 0.98 1.01 0.97 1.05  1.10 1.19 1.25 1.10 1.16 1.09 1.23 1.14 0.127 
Q9R0Q7 Prostaglandin E 
synthase 3 
2 1.5 13.1 1.00 1.05 1.11 1.10 1.06 1.01 1.11  1.17 1.14 1.21 1.36 1.21 1.12 1.31 1.14 0.199 
Q9DCN2 NADH-cytochrome 
b5 reductase 3 
3 6.0 27.9 1.00 1.00 0.98 0.98 0.99 0.98 1.00  1.18 1.05 1.11 1.21 1.13 1.07 1.21 1.15 0.072 
Q99LP6 GrpE protein 
homolog 1, 
mitochondrial 
2 1.0 6.5 1.00 1.18 1.10 1.09 1.09 1.02 1.17  1.31 1.22 1.20 1.31 1.26 1.20 1.32 1.15 0.142 
Q9JI75 Ribosyldihydronicot
inamide 
dehydrogenase 
[quinone] 
2 3.0 19.3 1.00 0.88 0.98 0.91 0.94 0.88 1.00  1.16 1.12 1.02 1.05 1.08 1.02 1.15 1.15 0.144 
P00329 Alcohol 
dehydrogenase 1 
4 13.0 32.8 1.00 1.04 1.10 1.05 1.05 1.01 1.09  1.26 1.20 1.18 1.20 1.21 1.18 1.24 1.16 0.039 
P06151 L-lactate 
dehydrogenase A 
chain 
4 12.5 36.1 1.00 0.92 0.96 0.90 0.94 0.90 0.99  1.22 1.18 1.00 1.06 1.11 1.01 1.22 1.18 0.178 
Q8CHR6 Dihydropyrimidine 
dehydrogenase 
[NADP+] 
2 2.0 2.6 1.00 0.96 1.00 1.01 0.99 0.97 1.01  1.33 1.13 1.16 1.14 1.18 1.10 1.28 1.20 0.072 
P00405 Cytochrome c 
oxidase subunit 2 
2 2.5 15.2 1.00 1.16 0.98 0.99 1.03 0.95 1.11  1.19 1.26 1.18 1.28 1.23 1.18 1.28 1.20 0.105 
Q9QXE0 2-hydroxyacyl-CoA 
lyase 1 
3 2.7 7.5 1.00 1.02 0.89 0.83 0.93 0.84 1.02  1.10 1.17 1.13 1.07 1.12 1.08 1.16 1.20 0.117 
Q60932 Voltage-dependent 
anion-selective 
channel protein 1 
2 1.5 6.6 1.00 1.01 0.95 1.05 1.00 0.96 1.04  1.24 1.22 1.22 1.16 1.21 1.18 1.25 1.21 0.022 
Q61207 Sulfated 
glycoprotein 1 
3 2.0 2.8 1.00 1.08 1.17 1.24 1.12 1.02 1.23  1.35 1.50 1.32 1.30 1.37 1.28 1.46 1.22 0.121 
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Q8VC12 Probable urocanate 
hydratase 
4 8.0 14.9 1.00 1.20 1.12 1.09 1.10 1.02 1.18  1.36 1.39 1.30 1.33 1.35 1.31 1.39 1.23 0.063 
P80316 T-complex protein 1 
subunit epsilon 
1 4.0 14.4 1.00 1.22 1.02 1.03 1.06 0.97 1.16  1.37 1.30 1.23 1.34 1.31 1.25 1.37 1.23 0.103 
P50172 Corticosteroid 11-
beta-
dehydrogenase 
isozyme 1 
4 2.8 10.2 1.00 1.19 0.98 1.09 1.06 0.98 1.16  1.31 1.20 1.41 1.32 1.31 1.23 1.39 1.23 0.103 
Q8VCR7 Abhydrolase 
domain-containing 
protein 14B 
3 3.7 22.1 1.00 1.17 1.01 1.24 1.10 0.99 1.22  1.36 1.36 1.31 1.41 1.36 1.32 1.40 1.24 0.123 
Q9DD20 Methyltransferase-
like protein 7B 
3 3.0 15.2 1.00 0.93 0.90 1.05 0.97 0.90 1.04  1.19 1.23 1.16 1.21 1.20 1.17 1.23 1.24 0.044 
Q61171 Peroxiredoxin-2 3 1.7 10.4 1.00 1.11 0.94 1.21 1.06 0.95 1.18  1.26 1.29 1.38 1.35 1.32 1.27 1.37 1.25 0.142 
P24270 Catalase 4 12.3 25.9 1.00 1.25 1.02 1.14 1.10 0.99 1.21  1.39 1.33 1.41 1.40 1.38 1.35 1.42 1.26 0.096 
P16460 Argininosuccinate 
synthase 
4 26.8 47.6 1.00 0.82 1.02 0.89 0.93 0.84 1.03  1.26 1.31 1.03 1.11 1.17 1.05 1.31 1.26 0.162 
P31786 Acyl-CoA-binding 
protein 
4 4.8 39.1 1.00 0.85 0.92 0.83 0.90 0.83 0.97  1.22 1.20 1.05 1.09 1.14 1.06 1.22 1.26 0.073 
Q61425 Hydroxyacyl-
coenzyme A 
dehydrogenase, 
mitochondrial 
3 3.3 12.1 1.00 1.04 0.98 1.04 1.01 0.99 1.04  1.09 1.25 1.51 1.31 1.28 1.12 1.46 1.26 0.156 
A3KMP2 Tetratricopeptide 
repeat protein 38 
3 2.3 6.4 1.00 0.95 0.96 1.16 1.02 0.93 1.11  1.21 1.41 1.24 1.33 1.29 1.21 1.39 1.27 0.117 
Q99PG0 Arylacetamide 
deacetylase 
3 3.3 12.8 1.00 1.13 1.13 1.12 1.09 1.03 1.16  1.44 1.25 1.36 1.54 1.39 1.28 1.52 1.27 0.072 
P12787 Cytochrome c 
oxidase subunit 5A, 
mitochondrial 
2 3.0 36.6 1.00 1.12 0.85 1.12 1.02 0.89 1.16  1.18 1.27 1.45 1.33 1.31 1.20 1.42 1.29 0.148 
P32020 Non-specific lipid-
transfer protein 
4 11.8 25.1 1.00 1.34 1.09 1.22 1.15 1.02 1.31  1.53 1.41 1.45 1.54 1.48 1.42 1.55 1.29 0.117 
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P55096 ATP-binding 
cassette sub-family 
D member 3 
3 2.3 5.8 1.00 1.29 1.08 1.29 1.16 1.02 1.32  1.46 1.37 1.53 1.64 1.50 1.39 1.61 1.29 0.142 
P05201 Aspartate 
aminotransferase 
cytoplasmic 
3 5.7 19.4 1.00 0.83 1.02 0.90 0.94 0.85 1.03  1.34 1.39 1.04 1.12 1.22 1.06 1.39 1.30 0.178 
P19096 Fatty acid synthase 4 30.3 17.7 1.00 1.10 1.03 1.15 1.07 1.00 1.13  1.35 1.40 1.44 1.36 1.39 1.35 1.43 1.30 0.022 
Q9R0H0 Peroxisomal acyl-
coenzyme A 
oxidase 1 
3 12.0 24.2 1.00 1.06 1.01 0.93 1.00 0.95 1.05  1.31 1.33 1.29 1.31 1.31 1.29 1.33 1.31 0.009 
P17665 Cytochrome c 
oxidase subunit 7C, 
mitochondrial 
1 2.0 47.6 1.00 0.89 0.87 1.07 0.95 0.87 1.05  1.34 1.15 1.34 1.26 1.27 1.18 1.36 1.33 0.072 
Q9QXF8 Glycine N-
methyltransferase 
4 18.0 47.6 1.00 1.27 1.23 1.42 1.22 1.06 1.41  1.63 1.66 1.60 1.61 1.63 1.60 1.66 1.34 0.117 
P35492 Histidine ammonia-
lyase 
3 6.7 13.1 1.00 1.08 1.17 1.12 1.09 1.02 1.17  1.57 1.54 1.33 1.44 1.47 1.36 1.58 1.34 0.044 
P83940 Transcription 
elongation factor B 
polypeptide 1 
1 1.0 8.0 1.00 1.02 0.87 1.11 1.00 0.90 1.10  1.40 1.31 1.33 1.31 1.34 1.30 1.38 1.35 0.050 
P18242 Cathepsin D 2 5.0 17.7 1.00 1.20 1.00 1.42 1.14 0.97 1.35  1.49 1.86 1.47 1.48 1.57 1.40 1.75 1.37 0.178 
P25688 Uricase 4 7.5 27.4 1.00 1.11 0.98 1.04 1.03 0.98 1.09  1.39 1.42 1.43 1.50 1.43 1.39 1.48 1.39 0.009 
Q9QXD1 Peroxisomal acyl-
coenzyme A 
oxidase 2 
1 2.0 3.8 1.00 1.38 1.28 1.32 1.23 1.07 1.42  1.68 1.73 1.57 2.01 1.74 1.57 1.93 1.41 0.117 
P62984 60S ribosomal 
protein L40 
1 1.0 19.2 1.00 0.96 0.93 1.07 0.99 0.93 1.05  1.42 1.52 1.41 1.27 1.40 1.31 1.51 1.42 0.022 
Q99P30 Peroxisomal 
coenzyme A 
diphosphatase 
NUDT7 
4 4.5 30.3 1.00 1.14 0.90 1.14 1.04 0.93 1.16  1.60 1.45 1.40 1.48 1.48 1.40 1.57 1.43 0.044 
Chapter 2 
58 
 
 
 
 
 
 
Q9DBM2 Peroxisomal 
bifunctional 
enzyme 
4 2.3 4.7 1.00 1.35 1.10 1.20 1.16 1.02 1.31  1.52 1.76 1.60 1.73 1.65 1.54 1.76 1.43 0.057 
O35423 Serine--pyruvate 
aminotransferase, 
mitochondrial 
3 1.0 3.1 1.00 0.88 0.86 0.93 0.92 0.86 0.98  1.55 1.67 1.15 1.25 1.39 1.17 1.65 1.51 0.066 
Q8VBT2 L-serine 
dehydratase 
3 4.3 22.3 1.00 0.72 0.97 0.90 0.89 0.77 1.03  1.47 1.58 1.18 1.20 1.35 1.17 1.55 1.51 0.078 
Q8JZR0 Long-chain-fatty-
acid--CoA ligase 5 
2 3.5 7.7 1.00 0.97 0.99 0.88 0.96 0.91 1.02  1.58 1.56 1.20 1.59 1.47 1.29 1.69 1.53 0.044 
Q91V92 ATP-citrate lyase 3 11.3 14.4 1.00 1.13 1.05 1.09 1.07 1.01 1.12  1.97 2.02 1.84 1.79 1.90 1.80 2.01 1.78 0.003 
P62827 GTP-binding 
nuclear protein Ran 
1 1.0 8.8 1.00 1.69 1.44 1.61 1.41 1.12 1.78  2.37 2.79 3.07 2.11 2.56 2.17 3.01 1.82 0.101 
P13516 Stearoyl-CoA 
desaturase 1 
1 2.0 9.0 1.00 1.43 1.09 1.19 1.17 1.00 1.36  4.04 2.12 1.53 2.58 2.41 1.62 3.59 2.07 0.153 
Q8VCH0 3-ketoacyl-CoA 
thiolase B, 
peroxisomal 
3 6.7 25.2 1.00 1.89 1.43 1.44 1.41 1.09 1.82  2.92 3.61 4.04 2.98 3.35 2.88 3.91 2.39 0.044 
Q05816 Fatty acid-binding 
protein, epidermal 
4 1.8 17.0 1.00 1.24 1.01 0.85 1.02 0.87 1.18  3.64 3.17 2.74 2.62 3.02 2.61 3.50 2.97 0.009 
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Table 2.5: Differentially up-regulated proteins listed in the UniProt database as involved in lipid synthesis or metabolism in ITRAQ analysis 1.  The subcellular location for 
each protein is listed: C = cytosol; ER = endoplastic reticulum; Mi = mitochondria; P = peroxisome. 
   
Relative expression compared to WT mouse 1  
  
   
WT  KO  fold change 
 
SwissProt Acc. No. Name 
Subcellular 
location 
Geometric mean 95% CI  Geometric mean 95% CI  
KO            
WT 
P 
Q05816 Fatty acid-binding protein, epidermal C 1.02 (0.87 - 1.18)  3.02 (2.61 - 3.50)  2.97 0.009 
Q8VCH0 3-Ketoacyl-CoA thiolase B, peroxisomal P 1.41 (1.09 - 1.82)  3.35 (2.88 - 3.91)  2.39 0.044 
P13516 Stearoyl-CoA desaturase 1 ER 1.17 (1.00 - 1.36)  2.41 (1.62 - 3.59)  2.07 0.153 
Q91V92 ATP-citrate lyase C 1.07 (1.01 - 1.12)  1.90 (1.80 - 2.01)  1.78 0.003 
Q8JZR0 Long-chain-fatty-acid--CoA ligase 5 ER, Mi 0.96 (0.91 - 1.02)  1.47 (1.29 - 1.69)  1.53 0.044 
Q9DBM2 Peroxisomal bifunctional enzyme P 1.16 (1.02 - 1.31)  1.65 (1.54 - 1.76)  1.43 0.057 
Q99P30 Peroxisomal coenzyme A diphosphatase NUDT7 P 1.04 (0.93 - 1.16)  1.48 (1.40 - 1.57)  1.43 0.044 
Q9QXD1 Peroxisomal acyl-coenzyme A oxidase 2 P 1.23 (1.07 - 1.42)  1.74 (1.57 - 1.93)  1.41 0.117 
Q9R0H0 Peroxisomal acyl-coenzyme A oxidase 1 P 1.00 (0.95 - 1.05)  1.31 (1.29 - 1.33)  1.31 0.009 
P19096 Fatty acid synthase C 1.07 (1.00 - 1.13)  1.39 (1.35 - 1.43)  1.30 0.022 
P32020 Non-specific lipid-transfer protein C 1.15 (1.02 - 1.31)  1.48 (1.42 - 1.55)  1.29 0.117 
Q61425 
Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial 
Mi 1.01 (0.99 - 1.04)  1.28 (1.12 - 1.46)  1.26 0.156 
P31786 Acyl-CoA-binding protein Mi 0.90 (0.83 - 0.97)  1.14 (1.06 - 1.22)  1.26 0.073 
P50172 Corticosteroid 11-beta-dehydrogenase isozyme 1 ER 1.06 (0.98 - 1.16)  1.31 (1.23 - 1.39)  1.23 0.103 
Q9QXE0 2-Hydroxyacyl-CoA lyase 1 P 0.93 (0.84 - 1.02)  1.12 (1.08 - 1.16)  1.20 0.117 
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Figure 2.2: Volcano plot of the entire set of proteins quantified during iTRAQ analysis 1. Each point 
represents the difference in expression (fold-change) between WT and Nrf2 KO mice plotted against 
the level of statistical significance. Solid filled shapes represent differential expression differences of 
±20% and a significance level of P<0.05 (unpaired t-test), with green squares representing proteins 
with a Benjamini–Hochberg significance value ≤0.2. Proteins represented by diamonds were not 
differentially expressed.  
2.3.3 iTRAQ analysis 2 
1070 proteins with a FDR below 1% were identified in iTRAQ run 2, and of these, 628 were 
identified in all 12 mice (table 2.3). The number of proteins identified in each of the three 
runs was largely consistent; however the total number of unique proteins that were 
quantified was slightly lower than in iTRAQ analysis 1. 38 proteins were identified as 
statistically significantly differentially expressed (t-test - P<0.05; Benjamini-Hochberg value 
≤ 0.2) in the livers of WT and Nrf2 KO mice and are shown in table 2.6. 
A summary of the overlap between iTRAQ analyses 1 and 2 is given in the Venn diagram in 
figure 2.3 and in table 2.7.  
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Table 2.6: Nrf2-regulated mouse hepatic proteins determined in iTRAQ analysis 2 (test set).  All values are expressed relative to a WT control mouse (WT1). Proteins listed 
were significantly different in the Nrf2 KO mice compared with WT controls (Benjamini Hochberg; p ≤ 0.2).  
  
Relative expression compared to WT mouse 1   
  
WT  KO 
fold 
change  
SwissProt 
Acc. No. 
Name 
Geometric 
mean Lower 
95% CI 
Upper 
95% CI 
 
Geometric 
mean Lower 
95% CI 
Upper 
95% CI 
KO
 
WT 
P 
P10649  Glutathione S-transferase Mu 1  1.00 0.91 1.10  0.44 0.40 0.47 0.44 0.001 
P17717  UDP-glucuronosyltransferase 2B5  0.99 0.93 1.06  0.55 0.52 0.57 0.55 0.001 
Q8VCC2  Liver carboxylesterase 1  1.06 0.96 1.17  0.59 0.54 0.64 0.56 0.001 
Q91X77  Cytochrome P450 2C50  0.97 0.87 1.08  0.56 0.46 0.69 0.58 0.001 
P19157  Glutathione S-transferase P 1  0.95 0.89 1.01  0.58 0.54 0.63 0.62 0.001 
Q9D379  Epoxide hydrolase 1  0.97 0.90 1.05  0.63 0.59 0.68 0.65 0.001 
Q64458  Cytochrome P450 2C29  1.08 0.90 1.29  0.75 0.62 0.90 0.69 0.001 
P30115  Glutathione S-transferase A3  1.03 0.98 1.08  0.72 0.66 0.78 0.70 0.001 
P24549  Retinal dehydrogenase 1  0.94 0.86 1.04  0.68 0.58 0.80 0.72 0.021 
O70475  UDP-glucose 6-dehydrogenase  1.09 0.97 1.23  0.79 0.63 0.99 0.73 0.183 
Q62452  UDP-glucuronosyltransferase 1-9  0.99 0.93 1.06  0.73 0.58 0.92 0.74 0.183 
Q91VA0  Acyl-coenzyme A synthetase ACSM1, mitochondrial  0.97 0.91 1.04  0.79 0.74 0.84 0.81 0.001 
Q64442  Sorbitol dehydrogenase  1.02 0.92 1.13  0.84 0.78 0.91 0.83 0.081 
P97494  Glutamate--cysteine ligase catalytic subunit  1.15 1.06 1.25  0.95 0.89 1.02 0.83 0.021 
Q8CG76  Aflatoxin B1 aldehyde reductase member 2  1.06 1.01 1.11  0.88 0.81 0.96 0.83 0.013 
Q9CQX2  Cytochrome b5 type B  1.01 0.91 1.13  0.85 0.76 0.94 0.83 0.197 
Q9JII6  Alcohol dehydrogenase [NADP+]  1.01 0.98 1.04  0.86 0.80 0.92 0.85 0.003 
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Q8VCW8  Acyl-CoA synthetase family member 2, mitochondrial  1.00 0.93 1.08  0.86 0.79 0.93 0.86 0.132 
O55022  
Membrane-associated progesterone receptor 
component 1  1.03 0.96 1.11  0.89 0.81 0.98 0.86 0.207 
P47738  Aldehyde dehydrogenase, mitochondrial  1.02 0.99 1.06  0.88 0.85 0.92 0.86 0.000 
Q8QZS1  3-hydroxyisobutyryl-CoA hydrolase, mitochondrial  1.07 1.00 1.13  0.94 0.89 1.00 0.89 0.084 
Q9ET01  Glycogen phosphorylase, liver form  0.98 0.96 1.00  0.87 0.80 0.94 0.89 0.081 
O35945  Aldehyde dehydrogenase, cytosolic 1  0.97 0.93 1.01  0.86 0.83 0.89 0.89 0.024 
Q8VDJ3  Vigilin  1.10 1.05 1.15  0.99 0.94 1.04 0.90 0.069 
Q9EQ20  
Methylmalonate-semialdehyde dehydrogenase 
[acylating], mitochondrial  1.00 0.98 1.03  0.92 0.87 0.98 0.92 0.140 
Q9Z2I8  
Succinyl-CoA ligase [GDP-forming] subunit beta, 
mitochondrial  1.02 0.99 1.06  0.96 0.92 0.99 0.93 0.121 
Q99P30  Peroxisomal coenzyme A diphosphatase NUDT7  0.98 0.93 1.03  1.10 1.05 1.17 1.13 0.039 
Q9CW42  MOSC domain-containing protein 1, mitochondrial  0.95 0.90 1.00  1.09 1.04 1.15 1.15 0.095 
Q9QXD6  Fructose-1,6-bisphosphatase 1  1.02 0.96 1.09  1.21 1.10 1.33 1.18 0.117 
P31786  Acyl-CoA-binding protein  1.01 0.94 1.07  1.19 1.06 1.34 1.18 0.207 
P24369  Peptidyl-prolyl cis-trans isomerase B  0.95 0.89 1.01  1.12 1.05 1.20 1.18 0.017 
Q8VDM4  26S proteasome non-ATPase regulatory subunit 2  0.90 0.80 1.02  1.08 1.00 1.17 1.20 0.183 
P06151  L-lactate dehydrogenase A chain  0.97 0.89 1.05  1.16 1.06 1.28 1.20 0.086 
Q61207  Sulfated glycoprotein 1  0.94 0.84 1.05  1.14 1.07 1.21 1.21 0.057 
P16460  Argininosuccinate synthase  1.02 0.93 1.13  1.27 1.16 1.40 1.25 0.038 
Q3THE2  Myosin regulatory light chain MRLC2  1.13 1.03 1.24  1.46 1.25 1.70 1.29 0.117 
Q8VBT2  L-serine dehydratase  1.02 0.91 1.15  1.37 1.13 1.67 1.34 0.183 
Q05816  Fatty acid-binding protein, epidermal  1.17 0.96 1.43  2.10 1.69 2.60 1.79 0.005 
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Table 2.7: Proteins identified as Nrf2 dependent in two analyses.   Each protein was significantly (p < 0.05, unpaired t-test) over- or under-expressed in Nrf2 KO
 
mice 
compared with the WT controls in both of the independent iTRAQ analyses. Fold changes are the ratios of the mean expression changes from 4-6 mice. 
   
 
iTRAQ Analysis 1  iTRAQ Analysis 2  
SwissProt 
Acc. No. Protein name Fold-change p 
 
Fold-change p 
 
Q8VCW8  Acyl-CoA synthetase family member 2, mitochondrial   0.83 0.030  0.86 0.132  
P31786  Acyl-CoA-binding protein   1.26 0.073  1.18 0.207  
Q91VA0  Acyl-coenzyme A synthetase ACSM1, mitochondrial   0.78 0.039  0.81 0.001  
Q9JII6  Alcohol dehydrogenase [NADP+]   0.90 0.121  0.85 0.003  
P24549 Aldehyde dehydrogenase family 1, subfamily A1 0.76 0.127  0.72 0.021  
P16460  Argininosuccinate synthase   1.26 0.162  1.25 0.038  
Q91X77  Cytochrome P450 2C50   0.65 0.162  0.58 0.001  
Q05816  Fatty acid-binding protein, epidermal   2.97 0.009  1.79 0.005  
Q9QXD6  Fructose-1,6-bisphosphatase 1   1.14 0.144  1.18 0.117  
P10649 Glutathione S-transferase, mu 1 0.42 0.009  0.44 0.001  
P19157 Glutathione S-transferase, pi 1 0.55 0.011  0.62 0.001  
Q8VCC2  Liver carboxylesterase 1   0.58 0.042  0.56 0.001  
P06151  L-lactate dehydrogenase A chain   1.18 0.178  1.20 0.086  
Q8VBT2  L-serine dehydratase   1.51 0.078  1.34 0.183  
Q99P30  Peroxisomal coenzyme A diphosphatase NUDT7   1.43 0.044  1.13 0.039  
Q61207  Sulfated glycoprotein 1   1.22 0.121  1.21 0.057  
O70475  UDP-glucose 6-dehydrogenase   0.81 0.061  0.73 0.183  
P17717  UDP-glucuronosyltransferase 2B5   0.55 0.004  0.55 0.001  
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Figure 2.3: Venn diagram indicating the overlap between the proteins identified as Nrf2-regulated 
across both iTRAQ analyses. 
2.3.4 Cellular defence and lipid metabolism are the primary biochemical functions 
regulated by Nrf2 
The functional pathways that were represented by proteins identified as Nrf2-regulated in 
iTRAQ run 1 were investigated using 2 methods of correlative network analysis: the 
PANTHER database and MetaCore.  Analysis using PANTHER generated a pie chart    
indicating the specific cellular pathways to which the proteins submitted belonged (figure 
2.4). The largest class of proteins were those related to lipid, fatty acid and steroid 
metabolism (18%).  Other metabolism (9.6%), electron transport (9%), carbohydrate 
metabolism (9%) and immunity and defence (9%) were the pathways that accounted for 
the next most significant portions of the chart. 
The MetaCore software allows the identification of canonical pathways that are over 
represented by proteins in a data set as compared to a background group of proteins.  The 
769 proteins used for full quantitative analysis of iTRAQ run 1 were selected as the 
background file. 752 of the proteins were recognised by the software and 504 had been 
mapped to pathways.  Of the 108 proteins identified as Nrf2-regulated following statistical 
analysis, 104 were recognised by MetaCore and 68 had been mapped to pathways.  
Comparison of the Nrf2-regulated pathways against the background data set identified ten 
pathways that were differentially regulated in the livers of WT and Nrf2 KO mice at a 
statistically significant level (P < 0.05), and these are detailed in table 2.8.  The pathway 
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Figure 2.4: Panther functional classification of proteins shown to be differentially regulated in the 
Nrf2 KO mouse. 
diagrams of 4 of the pathways are shown in figure 2.5. 7/10 pathways were linked to fatty 
acid metabolism or lipid regulation.  Only 1, glutathione metabolism, was directly linked to 
the cytoprotective response, however, 5 of the proteins in this pathway were identified as 
expressed at a lower level in Nrf2 KO mice in the iTRAQ analysis.  Thus both Panther and 
MetaCore analysis identified lipid metabolism and cytoprotection as key cellular processes 
regulated by the transcription factor Nrf2. 
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Table 2.8: MetaCore network analysis of data from iTRAQ analysis 1.  Proteins identified in iTRAQ analysis 1 as being differentially expressed (Benjamini-Hochberg p ≤ 0.2) 
were interrogated for pathway perturbation using the pathway analysis software MetaCore. The total list of all quantified proteins was applied as a background for the 
analysis. 
 
 
 
 
Pathway Name 
Negative log p 
value  
Number of  pathway 
objects 
1  n-6 Polyunsaturated fatty acid biosynthesis 2.52  5 
2  n-3 Polyunsaturated fatty acid biosynthesis 2.52  5 
3  Regulation of lipid metabolism_Regulation of lipid metabolism via LXR, NF-Y and SREBP 2.44  3 
4  Vitamin E (alfa-tocopherol) metabolism 1.98  5 
5  Regulation of metabolism_Bile acids regulation of glucose and lipid metabolism via FXR 1.89  4 
6  Fatty Acid Omega Oxidation 1.64  4 
7  Peroxisomal straight-chain fatty acid beta-oxidation 1.64  4 
8  CFTR-dependent regulation of ion channels in Airway Epithelium (norm and CF) 1.62  2 
9  Cell cycle_Role of SCF complex in cell cycle regulation 1.62  2 
10  Glutathione metabolism / Rodent version 1.3  5 
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Figure 2.5: Four of the pathways identified as differentially regulated in WT and Nrf2 KO mouse 
livers by MetaCore analysis.  
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2.3.5 Western blotting confirmed the changes identified in ACL and GST-pi expression 
by iTRAQ analysis 
In order to validate some of the changes identified in protein expression by iTRAQ analysis, 
the expression of 2 proteins identified as Nrf2-regulated were selected for western blot 
analysis.  GST-P1 was expressed at a statistically significantly lower level in Nrf2 KO mice in 
both iTRAQ analysis 1 (0.55-fold change) and iTRAQ analysis 2 (0.62-fold change) and has 
been confirmed as Nrf2-regulated in previous studies studies (Chanas et al., 2002; Satoh et 
al., 2002). Conversely, ACL was expressed at a higher level in Nrf2 KO mice in both iTRAQ 
analysis 1 (1.75-fold change) and iTRAQ analysis 2 (1.2-fold change), however this 
difference did not reach statistical significance in analysis 2.  An increase in ACL at the 
mRNA level in Nrf2 KO mice has previously been noted (Yates et al., 2009), but a difference 
in expression at the protein level has not been investigated.   
In each case, a Ponceau red stain to show total protein on the membrane was used as a 
loading control. 
Densitometric analysis of the GST-P1 western blot (figure 2.6) showed a 0.63-fold change in 
the livers of Nrf2 KO mice when compared to WT (P = 0.01; unpaired t-test).  While 
densitometry performed on the ACL western blot (figure 2.7) indicated a 3.2-fold change in 
the protein in the livers of Nrf2 KO mice when compared to WT (P = 0.0005; unpaired t-
test).  
The differences in the magnitude of the fold-change in ACL protein expression as detected 
by iTRAQ and western blot analyses may reflect a difference in linearity between the 2 
methods. However, both techniques provide useful methods for the relative comparison of 
protein expression and together give confidence that ACL expression is higher in livers of 
Nrf2 KO animals at a statistically significant level.   
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Figure 2.6: Western immunoblot of GST-P1 in liver homogenate from WT and Nrf2 KO mice. (a) 
Immunoblot for GST-P1. The molecular mass of GST-P1 is approximately 23 kDa.  (b) Ponceau 
protein stain of the transfer membrane shown in (a) indicating approximately equal loading across 
the gel. (c) Densitometric analysis of immunoblot showing a statistically significant difference in 
expression of GST-P1 in WT and Nrf2 KO mouse livers (*P<0.05; unpaired t-test).  
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Figure 2.7: Western immunoblot of ATP-citrate lyase (ACL) in liver homogenate from WT and Nrf2 
KO mice. (a) Immunoblot for ACL.  The molecular mass of ACL is approximately 120 kDa. (b) Ponceau 
protein stain of the transfer membrane shown in (a) indicating approximately equal loading across 
the gel. Lane KO1 shows slightly decreased loading which is consistent with the lower level of ACL in 
the blot above.  (c) Densitometric analysis of immunoblot showing a statistically significant 
difference in expression of ACL in WT and Nrf2 KO mouse livers (***P<0.001; unpaired t-test). 
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2.3.6 Analysis of livers from female mice confirmed that the increase in ACL protein 
expression in Nrf2 KO mice was not sex-specific 
A potential role for Nrf2 in the negative regulation of lipid metabolism in the liver has only 
recently been identified.  Consequently, in order to confirm whether the differences seen 
in ACL protein expression were sex-specific, livers from female WT and Nrf2 KO mice were 
also analysed (n=4; figure 2.8).  A 1.8-fold change in ACL expression was also identified by 
densitometric analysis of western blots from Nrf2 KO female mouse livers (P = 0.0032; 
unpaired t-test), indicating that the effect was not sex-specific.   
2.3.7 Identification of putative antioxidant response elements (ARE) and ARE-related 
motifs in the promoters of genes encoding the proteins identified as Nrf2-regulated 
Nrf2 is known to bind to the ARE in the promoter region of cytoprotective genes, thus 
initiating their transcription.  Consequently, 2000 bp promoter regions of genes encoding 
each of the proteins that were identified as Nrf2-regulated in iTRAQ analysis 1 were 
interrogated for ARE or ARE-like enhancer elements.  The consensus sequence derived by 
Nioi et al (Nioi et al., 2003), RTGABNNNTCA, was used as the input term for a string-based 
search algorithm.   
The number of consensus sequences identified in the promoter regions of genes encoding 
the 9 proteins that were most differentially expressed in WT and Nrf2 KO mice (>0.4-fold 
difference) are listed in table 2.9.  There was little correlation between the fold change in 
protein expression in WT and Nrf2 KO mice and the number of perfect ARE motifs 
identified in the genes encoding the proteins.  In fact, the mean number of ARE consensus 
sequences identified in all genes interrogated was 1.21, while in those identified as Nrf2-
regulated it was 1.25. 
Matrix analysis was also performed, in which the patser algorithm assigns a score for each 
region within the promoter that matches the position-specific probability matrix. This is 
based on the degree of similarity to the most frequently observed sequence within a series 
of known Nrf2 target genes.  A reference score was determined by way of searching the 
promoter regions of all 769 proteins quantified for ARE sequences. For the Nrf2-regulated 
genes, the mean patser score was 2.03, while for the reference protein set it was 2.50.   
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Figure 2.8: Western immunoblot of ATP-citrate lyase (ACL) in liver homogenate from female WT 
and Nrf2 KO mice. (a) Immunoblot for ACL.  The molecular mass of ACL is approximately 120 kDa. (b) 
Ponceau protein stain of the transfer membrane shown in (a) indicating approximately equal loading 
across the gel. (c) Densitometric analysis of immunoblot showing a statistically significant difference 
in expression of ACL in female WT and Nrf2 KO mouse livers (**P<0.01; unpaired t-test). 
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Table 2.9: Promoter analysis for the mouse genes encoding Nrf2-regulated proteins.   Sequences of the genes of Nrf2-regulated proteins were obtained from the ENSMBL 
mouse genome database and interrogated for ARE and ARE-like consensus sequences using the RSAT analysis software (http://rsat.ulb.ac.be/rsat/). Both string-based (dna-
pattern) and matrix-based (patser) pattern searching strategies were adopted. For the dna-pattern analysis, returned sequences were rated against the ‘perfect’ consensus 
sequence RTGABNNNGCA. For the patser analysis, the number of sequences matching the position specific scoring matrix with a score >1 are given, along with the highest 
score attained.  For comparison, equivalent data from the entire set of identified proteins is included at the foot of the table. 
   
String search 
(dna-pattern)  Matrix analysis (patser)  Highest scoring ARE 
SwissProt 
Acc. No. Protein name 
Fold-
change 
Number of consensus 
sequences 
(RTGABNNNGCA)  
Number of 
matching 
sequences 
Highest 
score 
Mean 
score SD 
Location  
  from to Sequence 
P02762 Major urinary protein 6  0.35 0  14 4.89 2.03 1.07 -1935 -1923 ttccCTGTCACTAAGCAtgtt 
P10649 Glutathione S-transferase Mu 1 0.41 4  15 4.40 2.42 1.09 -56 -44 gtggGCAGGACAAAACAgcgg 
P19157 Glutathione S-transferase P 1 0.54 0  13 4.02 2.11 0.98 -68 -56 aacgTGTTGAGTCAGCAtccg 
Q91WG8 Bifunctional UDP-N-acetylglucosamine 2-
epimerase/N-acetylmannosamine kinase 
0.55 0  12 5.95 2.50 1.70 -387 -375 gcagGGGTGGCAAAGCTtaaa 
            
P17717 UDP-glucuronosyltransferase 2B5 0.55 1  13 5.59 2.40 1.23 -398 -386 cagtCCATGACTGAGTTtgaa 
Q99P30 Peroxisomal coenzyme A diphosphatase NUDT7 1.41 1  8 4.68 2.49 1.14 -848 -836 caagGCATTACACAGCCcagg 
Q8JZR0 Long-chain-fatty-acid--CoA ligase 5 1.57 1  10 7.66 2.56 1.90 -1234 -1222 cttaGAATGACCCAGCCcttg 
Q91V92 ATP-citrate lyase 1.75 1  9 10.02 3.26 2.58 -1899 -1887 agaaAAATGACTAAGCAggta 
Q8VCH0 3-ketoacyl-CoA thiolase B, peroxisomal 2.21 2  15 5.84 2.55 1.44 -137 -125 tgggGGAAGACTCAGGAagag 
Q05816 Fatty acid-binding protein, epidermal 2.81 0  15 4.37 2.59 0.86 -1728 -1716 agtgGGATGTCGCAGCTcagg 
Mean values for all Nrf2-regulated proteins 1.26 1.25  13.69 5.62 2.50 1.33    
Mean values for all down-regulated Nrf2-dependent 
proteins 0.57 1.00  15.40 5.20 2.54 1.23    
Mean values for all  up-regulated Nrf2-dependent proteins 1.57 1.36  12.91 5.81 2.49 1.37    
Mean values for all proteins identified 
 
1.21  13.20 6.48 2.03 1.62    
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2.3.8 Microfludic TaqMan low density array (TLDA) cards 
Following analysis of the iTRAQ data, microfluidic TLDA cards were designed. Each card 
allows the simultaneous amplification of 48 gene targets in 8 samples.  Targets included 
genes established as Nrf2-regulated, genes encoding a selection of the proteins that were 
found to be differentially expressed in livers of WT and Nrf2 KO mice by iTRAQ, and genes 
encoding proteins that were not detected in iTRAQ analysis but were associated with the 
pathways highlighted by MetaCore analysis.  18S was used as a housekeeping gene.  
cDNA reverse transcribed from RNA extracted from the livers of untreated WT and Nrf2 KO 
mice (n=8) was amplified using real-time PCR, with data analysed using the ΔΔCT method. 
As 5 separate plates were required to run the samples, a pool of cDNA from all samples 
was run in lane 1 on each plate, and expression of all other samples on the plate was 
expressed relative to the pool and normalised to expression of the house-keeping gene, 
18S.      
The mean relative expression of each gene was calculated for WT and Nrf2 KO animals and 
standard error of the mean (SEM) was determined (figure 2.9).  Four of the genes, Abcc1, 
Abcc4, Bhmt and Fabp5, were excluded from the analysis because data sets were 
incomplete for more than 4/8 samples. Of the remaining 43 genes, expression of 9 was 
statistically significantly higher in WT animals when compared to Nrf2 KO.  None of the 
genes were expressed at a significantly higher level in Nrf2 KO animals.  Of the genes 
differentially expressed, Ces1 expression differed most between the two groups (KO/WT = 
0.11; P<0.001).   
Expression of the Nrf2 gene was not statistically different in WT and Nrf2 KO animals.  
However, genotyping of the mice confirmed that exon 5 of the Nrf2 gene was indeed 
absent in the livers of the KO animals and hence the Nrf2 gene expressed was not 
functional. Such results have also been noted in previous studies (Lu et al., 2011). 
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Figure 2.9: Relative level of mRNA expression in livers of WT and Nrf2 KO male mice as detected by Microfluidic TaqMan low density array analysis. Levels of mRNA for 
NQO1, UGT1a6a, UGT2b5, CES1, CYP2C50, EPHX, GCLC, GSTa4 and GSTm1 were statistically significantly higher in WT animals when compared to Nrf2 KO as determined by 
unpaired t-test (normal data) or Mann Whitney U-test (non-normal data). 
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2.4 Discussion  
The aim of the work described in this chapter was to identify the protein networks that are 
constitutively perturbed in the livers of Nrf2 KO mice when compared to WT animals and to 
construct a list of proteins that are indicative of Nrf2 activity.  Such proteins could serve as 
a pool of biomarkers with applications in preclinical drug safety assessment and have 
potential translational utility as markers of Nrf2 activity in man.   
Results from iTRAQ analysis 1 identified 108 proteins that were differentially expressed in 
the livers of WT and Nrf2 KO animals. Many were expressed at a higher level in WT mice, 
although somewhat surprisingly, there was also a group of proteins with hepatic expression 
that was higher in Nrf2 KO mice.  This would suggest that Nrf2 negatively regulates their 
expression, although it is also possible that the up-regulation of some genes is an 
adaptation resulting from the permanent disruption of the Nrf2 pathway.  The majority of 
the proteins up-regulated in KO animals were primarily associated with lipid metabolism, 
and MetaCore analysis was used in order to identify the biochemical pathways that were 
represented by these proteins.  Of the ten pathways that were identified as statistically 
significantly different in WT and Nrf2 KO animals, seven were related to the biochemistry of 
lipids, with lipid synthesis being the most prominent functional category.  Studies 
investigating the importance of Nrf2 have largely focussed on the role of the transcription 
factor in the cytoprotective response, and usually investigate genes that are down-
regulated in Nrf2 KO animals. These factors may explain why a role for Nrf2 in the 
regulation of lipid metabolism has only recently come to light.  
 A small number of recent studies have noted a relationship between Nrf2 activity and the 
expression of genes in lipid metabolism pathways.  Following the feeding of a high fat diet 
(HFD) for 4 weeks, expression of genes encoding fatty acid synthesis enzymes and proteins 
important for cholesterol synthesis and transport were shown to be increased in the livers 
of Nrf2 KO animals when compared to WT (Tanaka et al., 2008). Treatment with the Nrf2 
inducer CDDO-Im dosed for a 3 month period has also been shown to reduce the mRNA 
levels of fatty acid synthase (FAS) and acetyl CoA carboxylase-1 (ACC1) in WT mice fed a 
HFD, with no similar reduction in Nrf2 KO animals (Shin et al., 2009). Additionally, lipid 
metabolism was identified as the functional category that was most significantly altered in 
the livers of mice treated with CDDO-Im in a study in which mRNA levels of the fatty acid 
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biosynthesis enzymes including sterol regulatory element-binding protein-1c (SREBP1c), 
FAS, ACC1, and ACL were also down-regulated on  Nrf2 activation (Yates et al., 2009).  
Together, these studies support the emerging role for Nrf2 in the regulation of lipid 
metabolism, most notably fatty acid synthesis but also in the storage and transport of lipids 
and the synthesis of cholesterol.  However, further work is required in order to understand 
the mechanisms by which the transcription factor regulates lipid pathways.   
Western immunoblots for ACL were performed on liver homogenate from both male and 
female WT and Nrf2 KO mice in order to validate the differences in levels of fatty acid 
synthesis enzymes that had been identified by iTRAQ analysis. Western blotting confirmed 
that hepatic ACL protein expression was higher in both Nrf2 KO male and female mice 
when compared to their WT counterparts.  ACL plays an important role in providing the 
cytosolic acetyl CoA required for fatty acid synthesis in hepatocytes as well as other cells.  
The enzyme has also recently been shown to have a key role in histone acetylation, and 
thus function to modulate gene transcription (Cousins et al., 2010; Wellen et al., 2009).   
Given that the loss of Nrf2 results in a significant up-regulation in the levels of ACL, a 
relatively high-abundance enzyme, regulation of ACL by Nrf2 may have important 
implications for a range of cellular functions, and this is the subject of further investigation 
in the department. 
A number of proteins, including GSTs and UGTs, that are well characterised as Nrf2-
regulated were identified by iTRAQ analysis as having significantly higher expression in WT 
animals. However, there was little concordance between the proteins identified in the 
study described in this chapter and the gene expression profiles presented in previous 
microarray studies.  In fact, the number of cytoprotective proteins was surprisingly small, 
with only one out of ten pathways identified by MetaCore analysis as Nrf2-modulated 
relating to cellular defence (glutathione metabolism).  While iTRAQ is a valuable tool 
because it enables the simultaneous identification of over one thousand proteins, it is 
associated with the same limitations as other global proteomic methods in that high 
abundance species are preferentially detected.   
Following analysis of the iTRAQ data, microfluidic TLDA cards were designed to include 
genes encoding proteins that were identified as Nrf2-regulated in the iTRAQ analysis, genes 
encoding proteins in associated pathways that were not detected by iTRAQ as well as a 
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number of well-defined Nrf2 target genes from the literature.  Such cards have the 
potential to be employed as a screen for Nrf2 activity or oxidative stress in preclinical drug 
safety assessment models.  However, in the context of this study they are also a means of 
investigating the relationship between protein and gene expression changes and can 
provide preliminary information on the mechanisms of Nrf2 regulation. 
While the expression of cytoprotective genes encoding nine enzymes including CES1, NQO1 
and a number of GSTs and UGTs were expressed at a statistically significantly higher level in 
livers of WT mice when compared to Nrf2 KOs, there was no significant difference in 
expression of any of the lipid metabolism enzymes at the mRNA level.   Although no 
previous study has directly investigated the expression of lipid metabolism genes in basal 
WT and Nrf2 KO mice, studies exploring the effects of a HFD and diabetes in Nrf2 KO 
animals have compared the expression of lipid metabolism genes in control animals 
(Tanaka et al., 2008; Wu et al., 2011).   In accordance with our TLDA data, no difference 
was identified in the basal expression of FAS or ACC1 in livers of WT and Nrf2 KO animals at 
the mRNA level. However, expression of stearoyl-CoA desaturase-1 (SCD1) was found to be 
2-fold higher in Nrf2 KO mice when compared to WT, a differences that was not replicated 
in our analysis.  These data suggest that in the context of Nrf2 regulation at the constitutive 
level, post translational regulation of fatty acid synthesis enzymes may be more significant 
than transcriptional regulation.  
In summary, the work in this chapter has identified a panel of hepatic proteins with 
expression that is regulated by Nrf2.  In iTRAQ analysis 1, robust statistical analysis showed 
that 108 proteins were significantly differentially expressed in WT and Nrf2 KO animals, 
with some of the proteins expressed at a lower level in the Nrf2 KO animals and expression 
of others enhanced in the absence of the transcription factor. A second independent iTRAQ 
analysis identified eighteen proteins in common with iTRAQ analysis 1, providing further 
confidence that these proteins are Nrf2-regulated and have potential utility as candidate 
biomarkers in preclinical and translational studies.  The fact that the majority of proteins 
that were expressed at a higher level in the livers of Nrf2 KO animals were related to lipid 
metabolism was an unexpected finding of this study and will be the subject of further 
investigation. 
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3.1 Introduction 
Glutathione is an important antioxidant that functions to protect the cell from oxidative 
stress.  It is involved in the detoxification of reactive species through the scavenging of free 
radicals and the conjugation of electrophiles.  Glutathione is synthesised from glutamate, 
cysteine and glycine by the action of two enzymes, GCL and GS, with GCL catalysing the 
rate limiting step in the production of the tripeptide.   
Glutathione depletion and the ratio of reduced to oxidised glutathione (GSH/GSSG) are 
common indicators of oxidative stress. Under physiological conditions, more than 90% of 
glutathione is in the reduced form; however when the intracellular redox balance is 
perturbed, levels of the disulphide rise. The administration of a number of drugs that are 
associated with cases of DILI have also been shown to result in hepatic oxidative stress and 
glutathione depletion (Xu et al., 2008); Consequently a reliable method for the 
quantification of GSH and GSSG that can be used in order to identify perturbations in 
glutathione homeostasis is an important component of any preclinical model used to 
investigate the role of oxidative stress in drug toxicity.  
The results described in chapter 2 of this thesis highlighted the importance of Nrf2 in the 
regulation of glutathione homeostasis.  Pathway analysis identified glutathione metabolism 
as one of the most significantly differentially regulated pathways between WT and Nrf2 KO 
mice and proteins including glutathione peroxidase 1, GCLC and a number of GSTs were 
identified as being expressed at a lower level in Nrf2 KO animals. 
Nrf2-mediated regulation of the glutathione pathway is well established, with genes 
including those encoding the GSTs, GCL and GS all identified as Nrf2 regulated in a range of 
studies (Chan et al., 2001; Li et al., 2009; Moinova et al., 1999; Thimmulappa et al., 2002). 
Furthermore, the importance of the transcription factor in glutathione repletion after toxic 
insult is also widely documented (Chan et al., 2001; Gao et al., 2010; Reisman et al., 2009). 
While this means that the pathways important in glutathione metabolism have the 
potential to provide novel candidate biomarkers of Nrf2 activity, it also highlights the 
importance of the quantification of glutathione levels in gaining a comprehensive insight 
into the mechanisms by which oxidative stress and Nrf2 activation occur.   
A wide variety of methods exist for the quantification of glutathione.  Some methods 
measure total glutathione while others discriminate between GSH and GSSG.  The majority 
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of methods are either spectrophotometric or HPLC-based, although NMR and capillary 
electrophoresis methods have also been developed (D'Agostino et al., 2011; Reglinski et al., 
1992). As the technology associated with LC-MS/MS has advanced, the use of such 
methods has become increasingly popular as they offer high levels of specificity and 
sensitivity.  
There are a number of important factors to consider when developing a reliable method 
for the quantification of GSH and GSSG: the thiol group of GSH is particularly susceptible to 
auto-oxidation resulting in disulphide formation, and this can result in inaccuracy when 
determining the relative levels of GSH and GSSG.  Thiol capping reagents are employed in 
order to prevent this oxidation, with N-ethylmaleimide (NEM) and iodoacetic acid (IAA) 
being among the most common. Derivatisation of the thiol group can also improve 
retention of the highly polar GSH, with HPLC conditions and column selection also having 
implications for retention time.  The choice of protein precipitation reagent and internal 
standard are also important factors in the development of a sensitive, accurate and 
reproducible method.   The details of a range of validated methods for the measurement of 
GSH and GSSG are given in table 3.1. 
The aim of the work described in this chapter was to explore existing methods for the 
quantification of glutathione and to adapt these methods in order to produce a robust LC-
MS/MS assay that would allow the quantification of GSH and GSSG in mouse liver samples.  
Appropriate aspects of the FDA guidelines for the validation of bioanalytical methods were 
employed in order to assess the reproducibility of the method (FDA, 2001).  The method 
developed was subsequently employed to compare the GSH and GSSG levels in livers of WT 
and Nrf2 KO mice in order to investigate whether the differences in glutathione 
metabolism previously identified by iTRAQ analysis translate to a statistical difference in 
levels of reduced and/or oxidised glutathione. 
     
Chapter 3 
83 
 
Table 3.1: Validated methods for the quantification of GSH and GSSG in biological samples.   
Sample type LC column type LC conditions Detection Internal 
Std 
Linear range Thiol trapping/ 
protein 
precipitation (PPT) 
Reference 
 
PBMCs Nucleosil 100-7 OH 
250x2mm 
Acetonitrile (ACN): 
1% acetic acid (25:75) 
LC-MS  Thiosalicylic 
acid (TSA) 
0.01-20uM GSH, 0.05-
20uM GSSG 
NEM (100:1 molar 
ratio);  
AcN PPT 
(Camera et al., 
2001) 
Hepatocytes Hamilton PRP-X110S 
anion exchange 
100x2.1mm 
0.1% formic acid (FA)/ACN (1:1) 
and 2% FA/ACN 1/1 
Gradient 
LC-MS glutamyl-
glutamic acid 
(Glu-Glu)
0.16-16uM GSH 0.08-
81.6uM  GSSG 
IAA; 
AcN PPT 
(Loughlin et al., 
2001) 
Blood Bio-Rad Biosil NH2 
column 250x4.6mm, 
0-10 min 70 % 80:20 MeOH:H2O, 
30% 0.5M acetate buffer pH4.6, 
linear grad 30-95%B for 35 min 
UV NA 50-1500 uM GSH 
2-500uM for GSSG 
NEM;  
TCA PPT 
(Giustarini et 
al., 2003) 
Brain, lung, liver, 
heart, kidneys, 
erythrocytes and 
plasma 
Adsorbosil C18 
250x3.2mm 
0-2 min 100% 0.1% 
Trifluoroacetic acid; 2-13 min 
linear increase to 60% ACN, held 
from 13-15 min 
LC-MS Glutathione-
ethylester 
(GSHee)
LOD 0.16 µM for GSH-
Ellman and GSSG 
Ellman’s reagent; SSA 
PPT 
(Guan et al., 
2003) 
Blood Stability BSC 17 
150mm ×2mm 
 
7.5mM ammonium acetate (pH 
2.4): MeOH (50:50) 
LC-MS Glu-Glu 0.01–20 µM GSH 
0.05–20 µM GSSG 
NEM; SSA PPT (Steghens et al., 
2003) 
Liver Uptisphere C18 
100x2mm 
0.1%FA and ACN:0.1%FA (20:80) 
0-2 min 100% A; 2-4 min linear 
increase to 100% B; 4-7 min 
100% B; 7-15 min 100% A.    
LC-MS GSHee 0.1ug/mL-100ug/mL IAA; SSA PPT (Bouligand et 
al., 2006) 
Saliva Atlantis HILIC 
150x2.1mm 
0.5mM Ammonium formate 
(pH4) and ACN 
 0-20 min 90-70%B 
LC-MS Glu-Glu 0.1-100uM GSH-NEM NEM (100:1); solid 
phase extraction 
(Iwasaki et al., 
2006) 
Monocyte/ 
macrophage 
 cell line 
Jupiter 5u 
150mmx2mm 
0.1% FA and ACN:0.1% FA (80:20) 
0-2.5 min 2% B; 2.5-4.5 min 8% B; 
4.5-11 min 70-100% B; 11-15 min 
100% B; 15.5-24 min 2% B. 
LC-MS 
13
C2
15
N1-GSH 

5-400 nmol/mL GSH 
0.5-40 nmol/mL GSSG 
4-fluoro-7-
sulfamoylbenzofurazan;
SSA PPT 
(Zhu et al., 
2008) 
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3.2 Materials and methods 
3.2.1 Materials 
LC-MS grade dH2O and methanol, ethylene diamine-tetracetic acid (EDTA), ammonium 
bicarbonate and potassium chloride were from Fisher Scientific (Loughborough, UK). 
Amber eppendorfs for use with light sensitive samples were from Eppendorf UK Ltd 
(Stevenage, UK).  All other reagents were from Sigma (Poole, UK), unless otherwise 
specified. 
3.2.2 Animal Studies  
Mice were housed as described previously in this thesis. Livers used for method 
development were from WT (C57BL/6) animals. For the determination of glutathione levels 
in WT and Nrf2 KO mice, 8-12 week old males were culled between 10 am and 12 pm.  All 
animals were killed by exposure to a rising concentration of CO2 followed by cervical 
dislocation. Livers were removed, snap frozen in liquid nitrogen and stored at -80°C.   
The samples used for comparison of the LC-MS/MS and spectrophotometric glutathione 
methods were from livers of CD1 mice treated with 750mg/Kg paracetamol or vehicle 
control (0.5% methyl cellulose in 0.1% tween 80; i.p.) once daily for up to 4 days (0h, 24h, 
48h, 72h) and culled at various time-points after the first dose (2h, 4h, 6h, 24h, 48h, 72h, 
96h).   
3.2.3 Liver homogenisation 
Livers were homogenised using the method of Bouligand et al (Bouligand et al., 2006) with 
minor modifications.  50-100 mg of liver tissue was weighed and homogenised in acidic 
(pH2) homogenisation buffer (1.15% w/v potassium chloride, 1 mM EDTA and 2 mM batho-
phenanthroline disulphonate (BPDS) in 0.1% v/v formic acid) using the Retsch oscillating 
mill (30/s; 3 min).  Samples were centrifuged (16 000g; 15 min; 4°C) and the supernatant 
retained.  The pellets were reserved for protein concentration determination by the 
method of Lowry (Lowry et al., 1951). 
3.2.4 Preparation of standard solutions  
1mM stock solutions of GSH and GSSG were prepared in dH2O and aliquots stored at -20°C.  
As required, a single working solution of 200 µM GSH/GSSG was prepared and serial diluted 
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in order to achieve solutions of 20x the final desired standard concentration (final 
concentrations: 10, 7.5, 5, 4, 3, 2, 1, 0.5, 0.1 µM).  
During assay optimisation, the use of two different internal standards was explored, 
glutathione ethyl ester (GSHee) and stable isotope labelled GSH [GSH-Gly(13C2
15N)].  Both 
were prepared as solutions of 100 µM and stored at -20 °C.  
3.2.5 Matrix effects 
Given that the biological matrix can impact the quantification of an analyte, matrix effects 
must be taken into account when producing a standard curve.  Consequently, a pooled 
matrix sample was prepared from livers of six mice homogenised as described above and 
diluted to give a protein concentration of 5mg/mL. The matrix was used in order to spike 
standards used for quantification and was stored in aliquots at -80 °C. 
3.2.6 Thiol derivatisation 
50 µL of internal standard was added to 50 µL of homogenised samples or standards.  50 µL 
of matrix was also spiked into standards.  100 µL of IAA derivatisation solution [10 mM IAA 
in 10 mM ammonium bicarbonate with NH3OH 0.5% (v/v); pH 9.5] was added and the 
solutions were incubated (1.5 hours; room temperature).  Reactions were performed in 
amber eppendorfs for light sensitive samples. 
In order to stop the reaction and precipitate proteins, 50 µL of ice cold sulphosalicylic acid 
(SSA) solution (10% w/v) was added.  Samples and standards were vortexed and 
centrifuged (16 000g; 15 min; 4 °C) before being filtered (1500 g; 20 min) using a 96 well 
MultiScreen filter plate (Millipore Ltd, Watford, UK). All solutions were made up to a final 
volume of 1 mL with 0.1% (v/v) formic acid, and 100 µL transferred to a glass vial for LC-
MS/MS analysis.   
During assay optimisation, derivatisation with NEM was also tested. The NEM protocol was 
based on the method of Iwasaki et al (Iwasaki et al., 2006). Glutathione standards were 
incubated with 5mM NEM for 30 minutes at room temperature and centrifuged (10 000g; 3 
minutes), before addition of ice cold ACN.  Incubation of NEM treated standards for 20 
minutes on ice was also tested as described in a paper by Camera et al (Camera et al., 
2001). All samples were evaporated to dryness, before re-suspension in 0.1% formic acid.   
Chapter 3 
 
86 
 
3.2.7 LC-MS/MS  
The Dionex UltiMate 3000 HPLC system with autosampler, bianary pump and column 
compartment (Thermo Fisher, UK Ltd, Surrey, UK) was used in combination with a Kinetex 
2.6μm C18 100 Å 100 x 2.1 mm column (Phenomenex, Macclesfield, UK), in order to 
achieve separation of analytes. The column oven was held at a temperature of 30 °C. The 
injection volume was 10 µL, with the syringe washed with 5% methanol prior to each 
injection.  The flow rate was 100 µL/min with mobile phases 0.1% (v/v) formic acid in dH2O 
(solvent A) and 0.1% (v/v) formic acid in methanol (solvent B).  The elution gradient was as 
follows, with a total run time of 15 minutes: 
 0 minutes: 0% B 
 0-5 minutes: 0-20% B 
 5-10 minutes: 20% B 
 10.01-15 minutes: 0% B  
An ABSciex Q Trap mass spectrometer (ABSciex UK Ltd, Warrington, UK) was used for 
analyte detection using a multiple reaction monitoring (MRM) method.  The parameters 
used for each analyte are detailed in table 3.2.   
Table 3.2: Parameters used for MS/MS analyte detection. DP = declustering potential; CE = collision 
energy; CXP = collision cell exit potential. 
Analyte Q1 mass Q3 mass DP (volts) CE (volts) CXP (volts) 
CM-GSH 366.3 237.0 65.0 16.0 10.0 
GSSG 613.4 355.2 83.0 32.0 10.0 
CM-GSH-IS 369.1 84.0 71.0 53.0 2.0 
 
3.2.8 Assay validation 
Appropriate aspects of the FDA industry guidelines for bioanalytical method validation 
(FDA, 2001) were employed in order to validate the assay.  Accuracy and precision were 
determined using matrix-spiked solutions of known GSH and GSSG concentration (n=6) at a 
high (7.5 µM), medium (4 µM) and low (0.5 µM) concentration. The same solutions were 
used to determine percentage recovery, with recovery calculations based on comparison to 
unspiked standards.     
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3.2.9 Spectrophotometric enzymatic recycling method for determination of total 
glutathione levels 
Approximately 50 mg of liver tissue was homogenised in 800 μL sodium phosphate buffer 
(0.1M NaH2PO4 with 0.5M EDTA; pH 7.4) with 200 μL 6.5% (w/v) SSA using the Retsch 
oscillating mill (30/s; 3 min).  Samples were centrifuged (16 000g; 5 min) and the 
supernatant removed to a fresh tube and stored at -80°C.  The pellets were reserved for 
protein concentration determination by the method of Lowry (Lowry et al., 1951). 
A 1 mM GSH stock solution was prepared in sodium phosphate buffer and used in order to 
prepare standards (0 – 80 nmol/mL).  Samples were diluted in sodium phosphate buffer 
and 20 µL of samples and standards were added to wells of a 96 well plate. A further 20 µL 
of sodium phosphate buffer was added to each well before 200 µL of daily assay reagent (1 
mM 5,5-dithiobis-1,2-nitrobenzoic acid (DTNB) with 0.28 mg/mL NADPH in sodium 
phosphate buffer) was added and the plate incubated (room temperature; 5 min).  50 µL of 
GSH reductase (6.96 units/mL) was added to each well and the plate read immediately at 
405 nm using the MREe plate reader (Dynex Technologies Limited, Worthing, West Sussex) 
in order to determine total glutathione levels.   
3.3 Results 
3.3.1 Assay development  
In order to develop a robust LC-MS/MS method for the quantification of GSH and GSSG in 
liver tissue, previously validated methods were identified in the literature (table 3.1).  
These methods had been optimised for a range of different tissues and biofluids and 
employed different methods of sample preparation, thiol capping, protein precipitation, 
internal standard normalisation and analyte detection.   
3.3.2 Liver Homogenisation 
Given that the method of Bouligand et al had been optimised for the quantification of GSH 
and GSSG in liver samples, the protocol described in the paper was used for sample 
homogenisation (Bouligand et al., 2006).  The acidity of the homogenisation buffer (pH2) 
inhibits the oxidation of GSH to the disulphide, while EDTA and BPDS function as metal ion 
chelators.   
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3.3.3 Thiol derivatisation 
The most commonly employed reagents for thiol derivatisation in methods identified were 
IAA and NEM.  NEM has been shown to react with thiols at a faster rate, but its use is 
associated with the presence of artifacts in the spectra (Gilbert, 1995; Giustarini et al., 
2003; Santori et al., 1997). Treatment of GSH with NEM results in a GSH-NEM derivative, 
while treatment with IAA results in a carboxymethyl-GSH (CM-GSH) derivative (figure 3.1). 
Incubation of liver homogenates with NEM at room temperature and on ice both resulted 
in the presence of a double peak in the chromatogram generated by MS analysis (figure 
3.2). IAA gave a single peak that was also more intense and was therefore selected as the 
derivatisation agent for use in the assay. 
An IAA concentration of 10 mM was selected for thiol derivatisation as this concentration 
had been employed in a number of the methods identified (Bouligand et al., 2006; Loughlin 
et al., 2001). A relatively long incubation time of 1.5 hours was required in order to achieve 
complete derivatisation of the GSH, with underivatised GSH detected after incubation 
times of 1 and 1.25 hours. The reaction was carried out in amber eppendorfs designed for 
light sensitive samples as it has been suggested that exposure to light can facilitate GSH 
oxidation (Rahman et al., 2006). 
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Figure 3.1: The derivatisation of GSH with N-ethylmaleimide (NEM) and iodoacetic acid (IAA). (a) 
Thiol capping of GSH with NEM results in formation of the GSH-NEM derivative.  (b) Thiol capping of 
GSH with IAA results in the formation of S-carboxymethyl-glutathione (CM-GSH).  
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NEM 
GSH-NEM 
IAA 
GSH 
+ 
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Figure 3.2: Chromatograms for derivatised GSH.  GSH was derivatised using (a) N-ethylmaleimide 
(NEM) at room temperature, (b) NEM on ice and (c) iodoacetic acid (IAA) at room temperature. 
Samples were analysed by LC-MS/MS.   
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3.3.4 Internal standard selection 
The suitability of GSHee and glutathione-(glycine-13C2,
15N) were investigated for use as an 
internal standard. The structure of both molecules is given in figure 3.3.  GSHee was 
employed as an internal standard in two of the methods identified in the literature 
[Bouligand and also Guan].  However, when a solution of GSHee was treated with the IAA 
derivatisation solution and analysed by LC-MS/MS, CM-GSH was also identified (figure 3.4).  
This suggests that a degree of GSHee hydrolysis had occurred, something that has also 
been noted in the literature (Iwasaki et al., 2006).  Consequently glutathione-(glycine-
13C2,
15N) was selected for use as the internal standard (GSH-IS). The optimised spectra for 
CM-GSH, GSSG and CM-GSH-IS are given in figure 3.5.  
Figure 3.3: Structure of (a) glutathione ethyl ester (GSHee) and (b) Glutathione-(glycine-
13
C2,
15
N) 
(GSH-IS).  
(a) 
GSH-IS 
  13 
13 
17 
GSHee 
(b) 
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Figure 3.4: GSHee can be hydrolysed to GSH (a) A solution of 0.5 µM GSHee was treated with IAA to 
yield CM-GSHee.  (b) CM-GSH was also detected when the sample was analysed by LC-MS/MS.  
(a) 
(b) 
 
In
te
n
si
ty
 (
C
P
S)
 
Time (min) 
In
te
n
si
ty
 (
C
P
S)
 
Time (min) 
0.0 
 
    1.0   2.0 3.0   4.0 5.0  6.0   7.0   8.0  9.0    10.0   11.0 
0.0 
5.0e4 
1.0e 
1.5e5 
500 
1000 
1500 
  12.0  13.0   14.0 
    1.0    2.0 3.0   4.0 5.0  6.0    7.0  8.0   9.0    10.0      11.0     12.0  13.0   14.0 
CM-GSHee 
 CM-GSH 
Chapter 3 
 
93 
 
 
Figure 3.5: Representative chromatograms for CM-GSH (a), GSSG (b) and CM-GSH-IS (c). The 
concentration of all analytes is 5 μM.  
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3.3.5 Matrix effects 
The biological matrix can have a significant impact on the quantification of an analyte 
within a sample. Consequently, it is necessary to take the matrix effect into account when 
generating a standard curve.  Example standard curves constructed from standards that 
have been spiked with matrix are compared to curves from unspiked standards in figure 
3.6. The addition of the matrix to GSSG standards was found to have a notable effect on 
the gradient of the standard curve.  
3.3.6 Method validation 
Assay validation was performed using three different concentrations of matrix-spiked 
standards (n=6). The three selected values were all within the range of the standard curve, 
with low (0.5 µM), medium (4 µM) and high (7.5µM) concentrations used. The accuracy 
and precision of the assay were determined, as well as the percentage recovery of analytes.  
Recovery values were calculated by comparing values obtained from matrix-spiked and un-
spiked standards, with unspiked standard values designated as 100% recovery. 
FDA guidelines for assay validation state that in order to be considered accurate, mean 
concentration values as determined by a given method should be within 15% of actual 
values, except at the lower limit of quantification (LLOQ) where a deviation of 20% is 
acceptable.  In terms of precision, the range of values for a given concentration should not 
exceed 15% of the coefficient of variation (CV), or 20% at the LLOQ (FDA, 2001). Accuracy 
for CM-GSH determination was ≥90% for the medium and high values, and so fell within 
the FDA guidelines, while accuracy at the lowest concentration was 80%, and thus 
represents the LLOQ (table 3.3).  The values calculated for all three concentrations of CM-
GSH were found to be precise. 
Precision for GSSG in standards that were treated with IAA was also within the acceptable 
range, however accuracy was low and recovery values showed that levels of GSSG were 
being underestimated by 70-80%.  There is evidence to suggest that when thiol 
derivatisation reagents are used, the equilibrium of the system is affected such that 
derivatisation of GSH promotes the reduction of GSSG, thus resulting in GSSG levels being 
underestimated (Rossi et al., 2002). 
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Figure 3.6: The effect of liver homogenate matrix on glutathione quantification.  Standard curves 
were produced for (a) S-carboxymethyl-glutathione (CM-GSH) and (b) oxidised glutathione (GSSG) 
standards in the presence and absence of mouse liver homogenate (matrix).  
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Table 3.3: Accuracy, precision and recovery values for the determination of CM-GSH and GSSG 
levels by LC-MS/MS. Matrix-spiked standards at three concentrations (low: 0.5µM; medium: 4 µM 
and high: 7.5 µM) were used in order to validate the assay (n=6). GSSG validation was performed in 
the presence and absence of iodoacetic acid (IAA). CV = coefficient of variation.  
 Accuracy 
 (%) 
Precision 
(%CV) 
Recovery 
(%) 
CM-GSH 
Low 80.0 10.3 115.2 
Medium 91.7 4.9 103.8 
High 90.0 3.9 86.3 
GSSG + IAA 
Low 44.0 8.0 21.3 
Medium 53.0 6.4 25.9 
High 53.7 10.0 26.2 
GSSG - IAA 
Low 58.0 14.8 73.5 
Medium 68.7 12.0 76.4 
High 60.7 12.1 66.8 
 
In order to investigate the effect of IAA derivatisation on the recovery and accurate 
quantification of analytes, standards were also prepared without the addition of IAA.  
Precision was reduced when compared to IAA treated GSSG standards, but values were still 
within FDA guidelines.  Accuracy did improve, but was still below 85%.  Recovery levels 
were approximately 3-fold higher in the absence of IAA at 65-80%, thus suggesting that 
treatment of samples with IAA did impact the GSH/GSSG equilibrium.   
3.3.7 LC-MS/MS and spectrophotometric method comparison 
The spectrophotometric enzymatic recycling assay is commonly used in order to determine 
the concentration of glutathione in tissues, biofluids and cell extracts (Rahman et al., 2006; 
Tietze, 1969). Consequently the spectrophotometric assay and the LC-MS/MS assay were 
both used to analyse the same samples in order to investigate whether the two methods 
were comparable. Homogenates of livers from mice treated with a 750mg/kg dose of 
paracetamol daily for up to 4 days and culled at different time points after the first dose 
were analysed for total glutathione content (figure 3.7). The concentrations of glutathione 
detected by LC-MS/MS in the samples were slightly higher at 6/8 time points but the values 
were not statistically different between the two methods.  SEM values were also 
comparable.   
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Figure 3.7: Comparison of LC-MS/MS and plate reader methods for the determination of 
glutathione concentration.  Samples are from livers of mice treated with repeat doses of 
paracetamol and culled at various time-points after the initial dose (750 mg/kg; n=4).  Total 
glutathione was determined using the plate reader assay, while GSH and GSSG were determined 
independently by LC-MS/MS and the values combined to give total glutathione. Values are 
normalised to protein concentration (mg/mL). Error bars represent SEM.   
3.3.8 Determination of GSH and GSSG levels in livers of WT and Nrf2 KO mice by LC-
MS/MS 
Following validation, the LC-MS/MS assay was used in order to determine the level of GSH 
and GSSG in the livers of WT and Nrf2 KO animals, with GSSG levels corrected for recovery 
values as determined during the validation process.  Hepatic GSH levels in Nrf2 KO animals 
were 78.5% of those in WT animals (P<0.001; figure 3.8). GSSG levels were not statistically 
different between the genotypes.  The GSH/GSSG ratio was also calculated and did not 
differ in WT and Nrf2 KO livers, yielding values of 13.5 and 13.4 respectively.   
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Figure 3.8: Concentrations of reduced (GSH) and oxidised (GSSG) glutathione in homogenates from 
the livers of WT and Nrf2 KO mice as determined by LC-MS/MS. Values are normalised to protein 
concentration (mg/mL).  Error bars represent SEM (n=8). Statistical significance was determined 
using an unpaired t=test (***P<0.001). There was no difference in the GSSG levels detected in WT 
and Nrf2 KO animals.  
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3.4 Discussion 
The aim of the work described in this chapter was to investigate validated LC-MS/MS 
methods for the determination of GSH and GSSG in biological samples and to develop a 
robust assay that would allow quantification of the two analytes in mouse liver 
homogenates.  
GSH can undergo auto-oxidation to the disulphide and so one of the major challenges in 
accurately quantifying GSH and GSSG is to minimise the oxidation of GSH during sample 
preparation.  Given that the oxidation of GSH has been shown to occur rapidly in solutions 
of pH>7 (Anderson, 1985; Camera et al., 2002; Rossi et al., 2002) this was achieved by use 
of an acidic buffer for sample homogenisation, and subsequent treatment of homogenised 
samples with the thiol derivatising agent, IAA.  
Experiments designed to validate the method showed that GSH could be accurately and 
precisely quantified within the range of the standard curve (0.5-10µM). However, while 
GSSG could be precisely measured, the accuracy was well below the value recommended 
by the FDA for assay validation (FDA, 2001) and recovery of the analyte was determined to 
be only 20-30%.  Evidence suggests that while GSH oxidation can occur during sample 
preparation, conversely, derivatisation of the GSH thiol can result in perturbation of the 
GSH/GSSG equilibrium, with the system acting to restore GSH levels by reduction of GSSG 
(Rossi et al., 2002). 
In order to investigate whether IAA treatment was contributing to the underestimation of 
GSSG levels, samples were prepared for LC-MS/MS analysis without IAA treatment.  The 
percentage recovery of GSSG in these samples was increased to values of 65-80%.  This 
suggests that the method employed for derivatisation of GSH did have a significant impact 
on the concentration of the disulphide, although accuracy was still below 85% and so other 
factors may also have a role to play. 
One strategy that could be investigated for improving GSSG quantification is the inhibition 
of glutathione reductase (GR), the enzyme that catalyses the reduction of GSSG to GSH.  
For example, the use of the GR inhibitor, 1,3-bis(2-chloroethyl)-1-nitrosourea, has been 
shown to significantly reduce the loss of GSSG in blood samples treated with IAA (Rossi et 
al., 2002).  It should also be noted however, that the incubation time of 1.5 hours for IAA 
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derivatisation is relatively long, for example, in the paper of Bouligand et al the incubation 
time was only 15 minutes (Bouligand et al., 2006). During the process of method 
development, shorter IAA incubation times were investigated but were found to be 
insufficient for complete derivatisation of GSH.  The concentration of IAA in the 
derivatisation solution could be increased to facilitate a shorter incubation time, for 
example other methods have employed concentrations up to 100 mM IAA (Santori et al., 
1997). 
The method described in this chapter is largely based on that of Bouligand et al (Bouligand 
et al., 2006). However the notable difference between the two methods is the use of the 
stable isotope labelled glutathione-(glycine-13C2
15N) internal standard as opposed to GSHee. 
Hydrolysis of GSHee to yield GSH was detected during validation, and while the levels of 
GSH detected as a result of hydrolysis were low compared to GSH levels in liver 
homogenates, further investigation found that levels of hydrolysis was variable across 
samples and so difficult to control for.  Furthermore, if the assay were to be adapted for 
use in cell extracts or other samples in which levels of glutathione were considerably lower 
than those in mouse liver, the relative contribution of GSH from GSHee hydrolysis would be 
greater. 
The LC-MS/MS method described in this chapter was compared to the spectrophotometric 
enzymatic recycling method (Rahman et al., 2006; Tietze, 1969), which is an assay widely 
used in the department and elsewhere for the determination of total glutathione levels in 
biological samples.  There was no significant difference between glutathione levels as 
determined by the two assays, suggesting that both are valuable for the determination of 
total glutathione concentrations in liver homogenates.   
However, there are advantages to the LC-MS/MS assay: While the determination of GSSG 
levels is possible if a second assay employing GSH-derivatising agents such as 2-vinylpridine 
is used alongside the enzymatic recycling method (Griffith, 1980), the LC-MS/MS method 
can quantifying GSH and GSSG in a single assay.  Furthermore, the LC-MS/MS method could 
also be adapted to investigate levels of protein-bound GSH and may be optimised to 
include other thiols and disulphides which are important in the synthesis of glutathione 
(Bouligand et al., 2006).  Such methods could be used to provide valuable insight into the 
impact of oxidative stress on the wider glutathione metabolism pathway. 
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While there were limitations associated with the quantification of GSSG, the LC-MS/MS 
method was used in order to determine the levels of the analytes in the livers of WT and 
Nrf2 KO mice, with GSSG levels corrected according to the calculated recovery values 
determined during method validation. Work described in chapter 2 of this thesis 
highlighted the important role that Nrf2 plays in regulating glutathione metabolism.  
Previous investigations suggest that genetic modulation of the Keap1:Nrf2 pathway has 
implications for hepatic glutathione concentration, with lower levels reported in Nrf2 KO 
mice when compared to WT animals and an increase in hepatic glutathione levels in a 
Keap1 heaptocyte specific model (Wu et al., 2011).  However, it is important to establish 
the baseline glutathione levels in mice from the Nrf2 colony at the University of Liverpool 
as basal glutathione status may have important implications for future studies. 
Nrf2-regulation of glutathione metabolism was shown to have functional implications in 
terms of basal levels of hepatic glutathione, as levels of GSH in livers of Nrf2 KO animals 
were 78.5% of those in WT animals (P<0.001).  This result is comparable to the differences 
in total glutathione levels identified in previous studies (Wu et al., 2011).  Furthermore, the 
absolute concentrations of both GSH and GSSG in livers of WT mice in the study were 
within the range of those previously determined in livers of C57BL/6 mice (Bouligand et al., 
2006), thus giving confidence in the calculation correcting for GSSG levels based on 
percentage recovery values.   
In summary, the LC-MS/MS method described in this chapter allows precise and accurate 
determination of GSH levels in mouse liver homogenates.  While improvements are 
necessary in order to allow the accurate quantification of GSSG, a preliminary calculation of 
GSSG levels in livers of WT and Nrf2 KO mice was possible based on the percentage 
recovery values determined during method validation.  
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4.1 Introduction 
Nrf2 is a transcription factor that plays a vital and well documented role in the 
cytoprotective response to chemical stress. Work described in chapter 2 of this thesis 
characterising the constitutive hepatic proteomic profile of WT and Nrf2 KO mice, 
highlighted the importance of Nrf2 in the regulation of the expression of proteins important 
for cytoprotection.  However, the study also identified lipid metabolism as a process that 
was significantly differentially regulated in the WT and Nrf2 KO animals. A number of 
proteins involved in lipid metabolism were expressed at a higher level in the absence of a 
functional Nrf2 gene, thus suggesting that the transcription factor negatively regulates 
hepatic lipid metabolism.  
There is a growing body of evidence pointing to a functionally significant role for Nrf2 in the 
regulation of lipid synthesis.  When mice are fed a HFD, the expression of genes encoding 
enzymes key for fatty acid synthesis has been shown to be increased at a significantly 
higher level in Nrf2 KO mice when compared with WT animals (Tanaka et al., 2008). While 
administration of the Nrf2-inducer CDDO-Im prevented the weight gain and increase in 
serum triglycerides associated with a HFD in an Nrf2-dependent manner (Shin et al., 2009).  
Furthermore, Yates et al identified lipid metabolism as the functional category most 
significantly modulated at the mRNA level following both genetic and pharmacological 
activation of Nrf2 (Yates et al., 2009).   
Although the relationship between the roles of cytoprotection and lipid regulation is not 
currently well defined, Nrf2 is emerging as a multifunctional transcription factor with a 
pivotal role in two processes that are both vital for the maintenance of homeostasis in the 
liver.  While a wealth of studies have been carried out on the role of Nrf2 in cell defence, 
the emerging role for Nrf2 in the regulation of hepatic lipid metabolism has yet to be fully 
elucidated. 
Of the fifteen lipid metabolism-related proteins that were significantly up-regulated in Nrf2 
KO animals in the iTRAQ study, SCD1, ACL and FAS, are key enzymes in the cytosolic fatty 
acid synthesis pathway.  In the pathway, fatty acids are synthesised from the precursors, 
acetyl-CoA and malonyl-CoA, with the primary product of the FAS enzyme being the 
saturated fatty acid, palmitic acid.  Longer chain and desaturated fatty acids are 
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subsequently synthesised by the action of elongases and desaturases respectively. These 
fatty acids go on to be incorporated into triglycerides, cholesterols and phospholipids. 
Consequently, the modulation of fatty acid synthesis by Nrf2 could have important 
implications for the homeostasis of the hepatic lipid profile. The fatty acid synthesis 
pathway is summarised in figure 4.1.   
While there is evidence pointing to a role for Nrf2 in the regulation of a number of enzymes 
in this pathway at the mRNA level following Nrf2 induction (Shin et al., 2009; Yates et al., 
2009), the iTRAQ data in this thesis was the first showing how basal Nrf2 expression affects 
protein levels of the enzymes.  Furthermore, although lipid profile changes have been 
identified following the modulation of Nrf2 expression in mouse models (Shin et al., 2009; 
Tanaka et al., 2008), the effect of Nrf2 deletion on levels of hepatic fatty acids has not been 
investigated. Consequently, the functional outcome of changes in fatty acid synthesis 
enzymes at the mRNA and protein level has yet to be elucidated.   
Dietary modulation provides a method by which the effects of perturbations in lipid 
metabolism pathways can be investigated. A number of the studies noted above have 
explored the effects of a HFD on Nrf2 expression and lipid profiles (Shin et al., 2009; Tanaka 
et al., 2008). However, no study has investigated the effects of altering dietary 
carbohydrate content in the context of Nrf2 signalling and lipid metabolism. Carbohydrate 
restriction has been shown to result in perturbations in hepatic fatty acid levels in the 
triglyceride, sphingomyelin and phosphatidylcholine lipid classes, as well as altering the 
ratio of unsaturated to saturated fatty acids in the liver (Bruss et al., 2010; Forsythe et al., 
2008; Rojas et al., 1993). 
Given the pivotal role that the hepatic fatty acid pathway plays in lipid homeostasis, and 
the emerging role for Nrf2 in the regulation of lipid metabolism, the aim of the work 
described in this chapter was to characterise and compare the fatty acid profile of livers of 
WT and Nrf2 KO mice, both basally and following feeding of a carbohydrate-restricted 
(CHO-R) diet. Carbohydrate restriction was employed as a tool to explore how WT and Nrf2 
KO animals respond to perturbations in hepatic fatty acid metabolism. Preliminary 
investigations characterised the effects of the CHO-R diet on the Nrf2 pathway, before work 
was carried out in order to determine whether hepatic lipid profiles of WT and Nrf2 KO 
animals were altered by carbohydrate restriction.  The characterisation of the hepatic lipid 
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profile of mice in which Nrf2 expression has been modulated may provide valuable insight 
into the role of Nrf2 in the regulation of lipid metabolism as well as identifying potential 
preclinical biomarkers of Nrf2 activity. 
  
Figure 4.1: The synthesis of fatty acids. Fatty acid synthesis occurs in the cytosol, however the 
precursor acetyl CoA is synthesised in the mitochondria from pyruvate.  It must be converted into 
citrate in order to be transported to the cytosol where ATP citrate lyase (ACL) converts it back to 
acetyl CoA.  Acetyl CoA carboxylase (ACC1) catalyses the synthesis of malonyl CoA from 2 molecules 
of acetyl CoA.  Malonyl CoA is used in order to synthesise the 16 carbon chain fatty acid, palmitic 
acid, in a reaction catalysed by fatty acid synthase (FAS). Subsequent elongation and desaturation 
reactions are catalysed by enzymes including fatty acid elongase 6 (ELOVL6) and stearoyl CoA 
desaturase (SCD), producing monounsaturated and very long chain fatty acids, which are used in the 
synthesis of phospholipids, triglycerides and cholesterol esters.    
 
 
Acetyl CoA 
Mitochondrion 
Citrate 
Acetyl CoA 
ACL  
FAS 
SCD 
Oxaloacetate 
Citrate  
Pyruvate 
Pyruvate 
Malate 
Malate 
 
Malonyl CoA  
TCA 
cycle 
Palmitic acid 
ACC  
Stearic acid  
Oleic acid  
SCD 
Palmitoleic acid 
Phospholipids, triglycerides, 
cholesterol esters 
ELOVL6 
Chapter 4 
 
107 
 
4.2 Materials and Methods 
4.2.1 Materials 
NQO1 goat monoclonal antibody, GCLC rabbit monoclonal antibody and glycogen assay kit 
were from Abcam, (Cambridge, UK). Peroxidise-conjugated rabbit anti-goat 
Immunoglobulins was from Dako, (Denmark). All other reagents were from Sigma (Poole, 
UK), unless otherwise specified.  
4.2.2 Animal Studies  
All mice were housed as described previously in this thesis.  For the work investigating the 
effects of carbohydrate-restriction, a preliminary study (study 1; n=3) and a follow-up study 
(study 2; n=4) were carried out.  Animals in study 1 were 8-10 weeks old at the outset, 
while animals in study 2 were 12-14 weeks old.   
All mice had their body weight recorded before being fed a control diet for 1 week and 
were subsequently fed either a control or a CHO-R diet for 4 weeks, with their body weight 
and weight of food consumed recorded each day. Food for both diets was from Special Diet 
Services (Essex, UK). For the CHO-R diet, carbohydrate was reduced by 40% but all other 
dietary components were comparable to the control diet.  At the end of the 4 week period, 
animals were culled between 10 am and 12 pm by exposure to a rising concentration of CO2 
followed by cardiac puncture. Livers were removed, and in study 2 were also weighed, 
before being snap frozen in liquid nitrogen and stored at -80°C.   
4.2.3 Glutathione concentration determination 
GSH and GSSG concentration in the livers of all mice was determined using the LC-MS/MS 
method that is detailed in chapter 3 of this thesis. 
4.2.4 Liver homogenisation for western immunoblotting 
Sections from livers (≈ 100 mg) were homogenised in 1 mL of PBS (30 s-1; 2 min) using a 
Retsch oscillating mill. Samples were centrifuged (10 000 g; 5 min) and the supernatant 
retained. Protein concentration was determined using the method described by Lowry 
(Lowry et al., 1951).  
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4.2.5 Western immunoblotting 
Western immunoblotting for the ACL protein and subsequent analysis was performed on 
mouse liver homogenate as described in chapter 2. Western blots for NQO1 and GCLC were 
performed using the same protocol with the primary antibody for NQO1 a goat polyclonal 
antibody (1:5000) and for GCLC a rabbit polyclonal antibody (1:10000).  The secondary 
antibodies were a peroxidase-conjugated rabbit anti-goat immunoglobulins/HRP (1:5000; 
NQO1) and a peroxidase-conjugated goat anti-rabbit IgG (1:10000; GCLC).  
Actin was tested as a potential loading control.  Actin western blots were performed using 
the same protocol with minor modifications, in that membranes were blocked overnight in 
10% milk and primary antibody incubation was for 20 minutes (mouse monoclonal 
antibody; 1:20000).  The secondary antibody was a peroxidase-conjugated rabbit anti-
mouse IgG (1:20000).   
4.2.6 Methanol-chloroform-water metabolite extraction 
Liver samples from all mice were extracted using a method adapted from Le Belle et al (Le 
Belle et al., 2002).  Approximately 50 mg of tissue were pulverised in 600 μL 
methanol:chloroform (2:1 v/v) for 10 min at a frequency of 1/17 s-1 using the Qiagen 
TissueLyser (Qiagen, Crawley, UK).  Samples were sonicated for 15 minutes and 200 μL of 
chloroform and 200 μL dH2O added to form an emulsion.  The samples were centrifuged (18 
000 g; 5 min) in order to generate distinct aqueous and organic fractions, which were 
subsequently separated.  The organic layer was dried overnight in a fume hood, while the 
aqueous layer was dried overnight in an evacuated centrifuge. 
4.2.7 GC-FID 
Once dried, the organic layer was resuspended in 600 μL of chloroform:methanol (1:1 v/v). 
150 μL were transferred to a glass vial, before again being evaporated to dryness in the 
fume hood. The samples were resuspended in 750 μL of chloroform:methanol (1:1 v/v), and 
250 μL of D-25 tridecanoic acid (200 μM in chloroform) was added as an internal standard. 
125 μL 10% boron trifluoride (BF3) in methanol was added as a derivatisation agent and the 
solution incubated (80°C; 90 minutes).  Vials were cooled, before the addition of 500 μL of 
dH2O and 1 mL of hexane.  After vortexing, the solution separated into two distinct layers, 
the majority of the upper organic layer was transferred to a glass vial and evaporated to 
dryness in the fume hood overnight, before being reconstituted in 200 μL of hexane prior to 
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gas chromatography/flame-ionisation detector  (GC/FID) analysis.  A fatty acid methyl ester 
(FAME) standard (Supelco 37 component FAME mix 10 000 μg/mL in CH2Cl2) was also 
prepared using the same method.     
Samples were separated by GC using a ZB-WAX column (Phenomenex, Macclesfield, UK; 30 
m × 0.25 mm ID × 0.25 μm; 100% polyethylene glycol).  The temperature was held at 60 °C 
for 2 minutes and was then increased by 15 °C/minute to 150 °C. It was subsequently 
increased by 3 °C/minute to reach a temperature of 230 °C. The column was held at this 
temperature for 10 minutes.  The eluent was passed to a FID (Thermo Electron Corporation, 
Herts, UK).  Chromatograms obtained were analysed using Xcalibur (Version 2.0; Thermo 
Fisher) and peak area normalised to that of D-25 tridecanoic acid in the corresponding 
sample.   
4.2.8 LC-MS/MS lipidomic analysis 
The lipid fraction of samples from study 1 that had previously been dried and stored at -
80°C were reconstituted in 300 μL methanol:chloroform (2:1 v/v). 10 μL of sample were 
added to a glass vial together with 190 μL of the methanol:chloroform mixture.  A pooled 
sample constituting 10 μL of each individual sample was also made.  
Samples were run in duplicate and in a randomised order using an ACQUITY UPLC® system 
(Waters Ltd, Hertfordshire) equipped with an ACQUITY UPLC 1.7 µm bridged ethyl hybrid 
C8 column (2.1×100 mm) which was kept at 65 °C and coupled to a Micromass QToF-
Ultima™ API with a Z-spray™ electrospray source (Waters Ltd, Hertfordshire), with the 
electrospray used in positive ion mode.   
Solvent A was 10 mM ammonium acetate with 0.1% FA, while solvent B was 10 mM 
ammonium acetate in ACN:ICN (5:2) with 0.1% FA.  The flow rate was set to 0.6 mL/min and 
the gradient used was as follows:  
 0 minutes :  60% B 
 0.5 minutes: 60% B 
 8 minutes: 100% B 
 10.10 minutes: 60% B 
 12 minutes: 60% B 
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Reserpine (0.5 μM in 0.2% FA) was used as a lock spray reference compound to 
compensate for any drift.   Data were processed using Micromass MarkerLynx Applications 
Manager (Waters Ltd, Hertfordshire). 
4.2.9 Multivariate analysis  
Principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) 
were performed in order to analyse the LC-MS/MS data using SIMCA-P 11.0 (Umetrics, 
Umea, Sweden).  
4.2.10 Glycogen assay 
A glycogen assay kit was used in order to determine relative glycogen levels in the livers of 
WT and Nrf2 KO animals from study 2 according to the manufacturer’s instructions.  Briefly, 
10 mg of liver tissue was homogenised in dH2O and heated at 100 °C for 5 minutes.  
Samples were centrifuged (13000 rpm; 5 min) and the supernatant retained.  Samples and 
glycogen standards were diluted as desired with hydrolysis buffer and samples were 
incubated at room temperature for 30 minutes. Reaction mix containing development 
buffer, development enzyme mix and OxiRed probe was added to each sample before they 
were incubated in the dark for 30 minutes at room temperature.  Intensity was measured 
at 570 nm using the MREe plate reader (Dynex Technologies Limited, Worthing, West 
Sussex). 
4.3 Results 
4.3.1 The effect of CHO-R on body weight and liver weight 
Body weight was recorded on each of the 28 days during both study 1 and 2 (figure 4.2).  
The weight of the control diet mice rose by a mean value of 1.4 g during study 1, while the 
weight increased by a mean value of only 0.2g in study 2. This reflects the fact that the 
animals used in study 2 were approximately 4 weeks older than those in study 1.  Although 
the mean weight of the Nrf2 KO animals was slightly lower than the WT animals in both 
studies, the difference was not statistically significant.   The CHO-R animals of both 
genotypes steadily lost weight for the first 7 days in both studies and then the weight 
remained constant until the end of the study.  Weight was not statistically different 
between the WT and Nrf2 KO mice in the CHO-R groups.   
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At the end of study 2, liver weight was also recorded (figure 4.3). Liver weight and liver 
weight as a percentage of body weight was statistically significantly lower in the CHO-R 
Nrf2 KO animals when compared to control. Both were also lower in CHO-R WT animals 
when compared to control, however this did not reach significance.  The weight of the liver 
of one of the WT control animals (WT ctrl 3) was only 64% of that of the other livers in the 
same group (0.73 g when compared to 1.21 ± 0.04 g).  The spleen of this animal was noted 
to be enlarged, so an underlying condition may have contributed to the lower liver weight 
in this animal.   
4.3.2 Histopathology 
A summary of the histological analysis of livers from WT and Nrf2 KO fed a control or CHO-R 
diet in study 2 is detailed in tables 4.1 and 4.2 respectively.  There were no consistent signs 
of liver injury in all animals within any one group, although some individual animals did 
show signs of liver damage.  WT ctrl 3, the animal that was noted to have a reduced liver 
weight, was identified as having the most severe liver damage of all the mice thus providing 
further evidence of underlying disease. KO CHO-R 4 also showed signs of liver damage that 
was more severe than other animals within the group.     
Glycogen was present in the livers of control diet mice but was largely absent from livers of 
mice fed a CHO-R diet. Within the control diet animal groups, two KO mice showed signs of 
glycogen depletion, while the three healthy WT control animals did not. The Oil-Red Orange 
stain did not provide any evidence of significant differences in hepatocellular fat content 
between mice based on diet or genotype.  
Other organs including the lung, pancreas, kidney, adrenal gland and a cross section of the 
heart were also examined, with none of the organs exhibiting any significant histological 
differences.    
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Figure 4.2: Mean body weights of WT and Nrf2 mice fed a control or CHO-R diet for 4 weeks (a) 
represents the weight of mice in study 1, while (b) represents the weight of mice in study 2.  Error 
bars represent standard error of the mean. 
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Figure 4.3: (a) Liver weight and (b) liver weight expressed as a percentage of body weight of WT 
and Nrf2 KO mice fed a control or carbohydrate restricted (CHO-R) diet for 4 weeks in study 2. An 
unpaired t-test was performed to determine statistical significance (*P < 0.05; **P < 0.01). 
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Table 4.1: A summary of the results from histopathological analysis of liver samples from WT and Nrf2 KO mice fed a control diet in study 2. 
Mouse Findings PAS reaction Fat stain Comments 
WT ctrl 1 Diffuse glycogen; no histological abnormality is 
recognised (NHAIR) 
 
Diffuse glycogen One to a few small fat droplets 
within hepatocytes (approx 30%). 
 
WT ctrl 2 Diffuse glycogen; NHAIR 
 
Diffuse glycogen Negative  
WT ctrl 3 Marked anisokaryosis; centrolobular hydropic swelling 
and most intense megalocytosis, bile duct hyperplasia; 
individual hepatocyte necrosis, small NL aggregates, 
dilated central veins (CV) with activated endothelial cells 
(EC) and focal adjacent LC aggregates 
 
Patchy glycogen (mainly 
centrolobular); mitotic 
hepatocytes neg. 
 
[RVG: No fibrosis]  
Negative Cause for liver 
changes cannot be 
identified 
WT ctrl 4 Diffuse glycogen; multiple small leukocyte aggregates 
(extramedullary haematopoiesis (EMH)?) 
Diffuse glycogen Hepatocytes negative, Ito (stellate) 
cells positive 
 
     
KO ctrl 1 Diffuse glycogen; moderate random mixed cellular (with 
EMH?) focal aggregates with occasional dying 
hepatocytes 
 
Diffuse glycogen Hepatocytes negative, scattered Ito 
(stellate) cells positive. 
 
KO ctrl 2 Diffuse glycogen; scattered leukocyte aggregates with 
necrotic hepatocytes 
 
 
Diffuse glycogen (but in 
wide areas relatively low 
amount) 
Negative  
KO ctrl 3 No glycogen; random small mixed cellular aggregates 
(EMH?) 
 
 
Patchy glycogen, mainly 
individual cells 
Most hepatocytes negative, 
scattered with several small 
cytoplasmic fat droplets 
 
KO ctrl 4 Diffuse glycogen; NHAIR Diffuse glycogen Some hepatocytes with small fat 
droplets, Ito (stellate) cells often 
positive 
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Table 4.2: A summary of the results from histopathological analysis of liver samples from WT and Nrf2 KO mice fed a CHO-R diet in study 2. 
Mouse Findings PAS reaction Fat stain Comments 
WT CHO-R 1 No glycogen; hepatocytes reduced in size?; bile duct 
hyperplasia (+)? 
 
No glycogen Negative [small tissue fragment]  
WT CHO-R 2 No glycogen; hepatocytes reduced in size?; bile duct 
hyperplasia (+)? 
 
 
Very low level of 
glycogen, mainly in zone 
2 hepatocytes 
Negative  
WT CHO-R 3 No glycogen; hepatocytes reduced in size?; multiple small 
leukocyte aggregates (EMH) 
 
No glycogen Negative  
WT CHO-R 4 No glycogen; hepatocytes reduced in size?; bile duct 
hyperplasia (+)? 
Very low level of 
glycogen, mainly in zone 
2 hepatocytes 
Hepatocytes negative, Ito (stellate) 
cells positive 
 
     
KO CHO-R 1 No glycogen; hepatocytes reduced in size?; multiple small 
leukocyte aggregates (EMH?) 
 
No glycogen Negative  
KO CHO-R 2 No glycogen; hepatocytes reduced in size?; moderate 
multifocal random, relatively small aggregates of mixed 
cellular (LC, NL, macrophages) infiltration; bile duct 
hyperplasia (+)? 
 
No glycogen Hepatocytes negative, Ito (stellate) 
cells positive 
 
KO CHO-R 3 No glycogen; random small mixed cellular aggregates 
(EMH?) 
 
Patchy areas of cells with 
glycogen, majority 
negative 
Hepatocytes negative, some Ito 
(stellate) cells positive? 
 
KO CHO-R 4 No glycogen; NL between hepatic cords; small aggregates, 
disseminated, moderate; individual hepatocyte death 
(apoptosis?), also (predominantly) centrolobular (?); bile 
duct hyperplasia (+)?; increased anisokaryosis  
No glycogen (some 
positive macrophages) 
 
[RVG: No fibrosis] 
Most hepatocytes with variable 
amounts of small fat droplets 
Cause for liver 
changes cannot be 
identified 
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4.3.3 The effect of CHO-R on hepatic glutathione levels in WT and Nrf2 KO mice 
In order to investigate the hepatic glutathione status of animals fed a CHO-R diet, GSH and 
GSSG levels were measured by LC-MS/MS in the livers of mice from both study 1 and 2.  
CHO-R resulted in GSH-depletion in both genotypes at a statistically significant level (P < 
0.001) with 30% depletion in WT and 50% depletion in Nrf2 KO animals (figure 4.4).   Mean 
GSH levels in the livers of Nrf2 KO mice were 14% lower than that in WT animals, but this 
difference was not statistically significant. There were no differences in GSSG levels 
between any of the groups, and the mean GSH/GSSG was >10 for all treatment groups.  
 
Figure 4.4: The effect of carbohydrate restriction (CHO-R) on levels of reduced (GSH) and oxidised 
(GSSG) glutathione in livers of WT and Nrf2 KO male mice (n=7). Glutathione levels were 
determined by LC-MS/MS and normalised to protein concentration. Statistical analysis was 
performed with normal data analysed by an unpaired t-test and non-normal data analysed by a 
Mann Whitney U-test (***P < 0.001). 
4.3.4 Relative actin expression in mice fed a control or CHO-R diet  
Actin was tested as a protein loading control for immunoblotting, however relative actin 
expression was statistically significantly lower in WT animals fed a CHO-R diet when 
compared to those fed a control diet. A Ponceau stain showed that total protein loading 
was equal across the samples (figure 4.5). Consequently the Ponceau total protein stain 
was used in subsequent experiments in the study to show consistent protein loading. 
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4.3.5 CHO-R results in Nrf2 activation 
Given that a CHO-R diet resulted in glutathione depletion in the livers of mice, the effect of 
CHO-R on Nrf2 activation was also investigated., Western immunoblotting for NQO1 was 
performed on liver homogenates from mice in both study 1 (figure 4.6) and 2 (figure 4.7).  
WT control mouse 3 in study 2 showed high expression of NQO1 when compared to all 
other WT control animals. This is likely to be reflective of the underlying disease identified 
by histological analysis, and consequently the animal was excluded from statistical analysis 
performed on the combined data from both studies. NQO1 protein expression was found to 
be induced 2.6-fold in CHO-R animals when compared to those fed a control diet (P < 0.01; 
figure 4.8) indicating that CHO-R induces Nrf2 expression in the livers of mice.  NQO1 
expression was not induced in the livers of Nrf2 KO mice fed a CHO-R diet.  
4.3.6 GCLC protein expression is not statistically altered by CHO-R 
GCLC is the catalytic subunit of the enzyme that catalyses the rate limiting step in 
glutathione synthesis. Expression of the GCLC is also known to be regulated, in part, by 
Nrf2. Consequently, the expression levels of GCLC was also investigated in samples from 
study 1 (figure 4.6) and study 2 (figure 4.7).  Statistical analysis of GCLC protein levels in 
livers of mice from both studies combined showed that while CHO-R reduced the mean 
level of GCLC expression in both WT and Nrf2 KO animals, the difference was not significant 
(figure 4.8).   
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Figure 4.5: Western immunoblot of actin in livers from WT mice fed a control or carbohydrate 
restricted (CHO-R) diet. (a) Immunoblot for actin (n=6).  The molecular mass of actin is 
approximately 42 kDa. (b) Ponceau protein stain of the transfer membrane. (c) Densitometric 
analysis of the immunoblots. An unpaired t-test was performed in order to determine statistical 
significance (***P < 0.001).  
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Figure 4.6: Western immunoblots of NQO1 and GCLC in livers from WT and Nrf2 KO mice fed a 
control or carbohydrate restricted (CHO-R) diet in study 1. (a) Immunoblots for NQO1 and GCLC in 
livers of the mice (n=3).  The molecular mass of NQO1 is approximately 31 kDa, while the molecular 
mass of GCLC is approximately 73 kDa. (b) Ponceau protein stain of the transfer membrane, both 
proteins were run on the same membrane. (c) Densitometric analysis of the immunoblots.  
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Figure 4.7: Western immunoblots of NQO1 and GCLC in livers from WT and Nrf2 KO mice fed a 
control or carbohydrate restricted (CHO-R) diet in study 2. (a) Immunoblots for NQO1 and GCLC in 
livers of the mice (n=4).  The molecular mass of NQO1 is approximately 31 kDa, while the molecular 
mass of GCLC is approximately 73 kDa. (b) Ponceau protein stains of the transfer membranes, both 
proteins were run on the same membrane. (c) Densitometric analysis of the immunoblots 
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 Figure 4.8: Combined statistical analysis of densitometric data from western immunoblots of 
NQO1 and GCLC in livers from WT and Nrf2 KO mice fed a control or carbohydrate restricted (CHO-
R) diet in study 1 and 2 (n=7). WT control 3 from study 2 was excluded from the analysis because of 
an underlying liver condition as identified by histopathology, therefore n=6 for the WT control group.  
Normal data were analysed by an unpaired t-test, while non-normal data were analysed by a Mann 
Whitney U-test (**P < 0.01). 
4.3.7 ACL protein expression in CHO-R mice 
The effect of CHO-R restriction on hepatic ACL expression was determined by western 
immunoblotting in order to investigate the impact of the diet on protein expression of 
enzymes in the fatty acid synthesis pathway.  Immunoblotting was performed on samples 
from livers of WT and Nrf2 KO mice fed a control or CHO-R diet in study 1 (figure 4.9) and 
study 2 (figure 4.10).  Analysis of the combined data (figure 4.11) showed that carbohydrate 
restriction reduced ACL expression in Nrf2 KO animals by 36.4% at a statistically significant 
level (P < 0.001).  Levels of ACL were also reduced by 17.8% in livers of WT animals but the 
difference was not statistically significant.  In line with data from chapter 2 of this thesis, 
ACL was also found to be expressed at a level that was 49.0% higher in Nrf2 KO animals 
when compared to WT (P < 0.001).  
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Figure 4.9: Western immunoblot of ACL in livers from WT and Nrf2 KO mice fed a control or 
carbohydrate restricted (CHO-R) diet in study 1. (a) Immunoblot for ACL in livers of the mice (n=3).  
The molecular mass of ACL is approximately 120 kDa. (b) Ponceau protein stain of the transfer 
membrane. (c) Densitometric analysis of the immunoblot.  
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Figure 4.10: Western immunoblot of ACL in livers from WT and Nrf2 KO mice fed a control or 
carbohydrate restricted (CHO-R) diet in study 2. (a) Immunoblot for ACL in livers of the mice (n=4).  
The molecular mass of ACL is approximately 120 kDa. (b) Ponceau protein stains of the transfer 
membranes. (c) Densitometric analysis of the immunoblot.  
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Figure 4.11: Combined statistical analysis of densitometric data from western immunoblots of ACL 
in livers from WT and Nrf2 KO mice fed a control or carbohydrate restricted (CHO-R) diet in study 1 
and 2 (n=7). WT control 3 from study 2 was excluded from the analysis because of an underlying 
liver condition as identified by histopathology, therefore n=6 for the WT control group.  Normal data 
were analysed by an unpaired t-test, while non-normal data were analysed by a Mann Whitney U-
test (***P < 0.001). 
4.3.8  GC-FID analysis of fatty acids 
GC-FID analysis was performed in order to determine the relative levels of fatty acids in WT 
and Nrf2 KO mice fed a control or CHO-R diet.  Prior to being run on the GC-FID, fatty acids 
were derivatised to yield fatty acid methyl esters (FAMEs). The peaks generated from the 
analysis were integrated and normalised to an internal standard, D-25 tridecanoic acid, and 
levels of each fatty acid detected were expressed as a percentage of total fatty acids within 
that sample. Peaks were assigned based on retention time and relative concentration using 
a FAME standard spectra, an example of which is given in figure 4.12.   
A list of the 20 (study 1) and 19 (study 2) most abundant fatty acids that were detected are 
summarised in table 4.3. 16 fatty acids were assigned based on the FAME standard spectra, 
however 7 peaks could not be identified.  3 cholesterol esters were also detected in study 
1.  Figures 4.13 and 4.14 show the relative levels of fatty acids detected in livers of mice in 
study 1 and study 2 respectively.   
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Figure 4.12: A typical FAME standard spectra. Each peak represents a different fatty acid.  The 
retention time of known peaks in the FAME standard spectra was used to identify fatty acids within 
the samples.    
14 of the fatty acids were detected in both study 1 and 2 and differences in these fatty 
acids were analysed for statistical significance. In the control diet group (figure 4.15), 8/14 
fatty acids had mean levels that were higher in Nrf2 KO animals when compared to their 
WT counterparts, however levels of only one of the fatty acids, pentadecanoic acid (C15:1), 
was statistically significantly different (P<0.05).  5/14 fatty acids were detected at lower 
levels in Nrf2 KO animals and this difference was significant (P<0.05) for stearic acid (C18:0) 
and lignoceric acid (C24:0).  It should be noted that the statistical analysis for C18:0 is based 
on results of study 2 as it was not detected in Nrf2 KO livers of either diet group in study 1. 
In CHO-R animals, mean levels of 8/14 fatty acids were also detected as being higher in Nrf2 
KO animals (figure 4.16), with oleic acid (C18:1; P<0.05), linoleic acid (C18:2; P<0.05) and α-
linoleic acid (C18:3; P<0.01) significantly different.  6/14 fatty acids had levels that were, on 
average, lower in Nrf2 KO animals, but only C18:0 was statistically significant (P<0.01).   
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Table 4.3: Fatty acids detected by GC-FID analysis.  Peaks were assigned based on retention time 
and comparison to previously assigned FAME standard peaks.  
Peak number 
(run 1) 
Peak number 
(run 2) 
Fatty acid Name 
1  C11:0 Undecylic acid 
2 1  Internal standard 
 2  not identified 
3  C14:0 Myristic acid 
 3  not identified 
4  C15:1 Pentadecenoic acid 
5 4 C16:0 Palmitic acid 
6 5 C17:0 Margaric acid 
7 6 C18:0 Stearic acid 
8 7 C18:1 Oleic acid 
 8  not identified 
9 9 C18:2 Linoleic acid 
 10  not identified 
10 11 C18:3 α-linoleic acid 
11 12 C20:0 Arachidic acid 
 13  not identified 
12 14 C20:2 Eicosadienoic acid 
13 15 C20:3 Eicosatrienoic acid 
14 16 C20:4 Arachidonic acid 
15 17 C23:0 Tricosylic acid 
 18  not identified 
16 19 C24:0 Lignoceric acid 
17 20 C24:1 Nervonic acid 
18   not identified 
19   Cholesterol ester 
20   Cholesterol ester 
21   Cholesterol ester 
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Figure 4.13: Relative levels of fatty acids detected by GC-FID analysis of livers from WT and Nrf2 
KO mice fed a control or carbohydrate-restricted (CHO-R) diet in study 1. The relative peak areas 
were normalised to an internal standard (D-25 tridecanoic acid) and expressed as a % of total fatty 
acids. (a) shows the 6 fatty acids that each make up more than 5% of the total fatty acids detected 
while (b) shows the 14 less abundant fatty acids.  Error bars show standard error of the mean (n=3).   
U.I. = unidentified; CE = cholesterol ester.  
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 Figure 4.14: Relative levels of fatty acids detected  by GC-FID analysis of livers from WT and Nrf2 
KO mice fed a control or carbohydrate-restricted (CHO-R) diet in study 2.The relative peak areas 
were normalised to an internal standard (D-25 tridecanoic acid) and expressed as a % of total fatty 
acids. (a) shows the 6 fatty acids that each make up more than 5% of the total fatty acids detected 
while (b) shows the 13 less abundant fatty acids. Error bars show standard error of the mean (n=3). 
U.I. = unidentified.  
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Figure 4.15: Relative levels of fatty acids in livers of WT and Nrf2 KO mice fed a control diet 
detected in both study 1 and 2. The relative peak areas were normalised to an internal standard (D-
25 tridecanoic acid) and expressed as a % of total fatty acids.  (a) Shows the six most abundant fatty 
acids detected, while (b) shows the eight less abundant fatty acids.  Error bars show standard error 
of the mean (n=7).  Statistical analysis was performed with normal data analysed by an unpaired t-
test and non-normal data analysed by a Mann Whitney U test. *P<0.05.  
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Figure 4.16: Relative levels of fatty acids in livers of WT and Nrf2 KO mice fed a CHO-R diet 
detected in both study 1 and 2. The relative peak areas were normalised to an internal standard (D-
25 tridecanoic acid) and expressed as a % of total fatty acids.  (a) Shows the six most abundant fatty 
acids detected, while (b) shows the eight less abundant fatty acids.  Error bars show standard error 
of the mean (n=7).  Statistical analysis was performed with normal data analysed by an unpaired t-
test and non-normal data analysed by a Mann Whitney U test (*P<0.05; **P<0.01).  
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4.3.9 LC-MS/MS lipidomic analysis 
LC-MS/MS analysis was also performed on extracts from livers of mice in study 1 in order to 
give a more comprehensive picture of the hepatic lipid profile of the animals. PCA was used 
to analyse the data.  PLS-DA is a method by which components from PCA can be rotated in 
order to achieve maximum separation between classes, and to identify the components 
that account for the separation.  Q2 and R2 are used in order to assess the validity of the 
model. A high Q2 value indicates a good predictive model, while a low R2 value is indicative 
of high noise.  In general for analysis of biological samples, Umetrics guidelines state that a 
good model would have R2 ≥ 0.5 and Q2 ≥ 0.4 (http://www.umetrics.com/simca).  
PLS-DA of all data showed separation between animals fed a control and CHO-R diet in 
study 1 (Q2: 0.461; R2: 0.803) suggesting that the components of the model accounting for 
the most variation differ as a result of diet.  Within the CHO-R group there was separation 
between WT and Nrf2 KO mice, while the genotypes were not separated in the control diet 
group (figure 4.17).   
 
Figure 4.17: Partial least square discriminant analysis (PLS-DA) scores plots following LC-MS/MS 
analysis of livers from WT and Nrf2 KO mice fed a control or CHO-R diet for 4 weeks in study 1 (Q2: 
0.461; R2: 0.803). All samples were run in duplicate (n=3).   
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PLS-DA focussing on selected groups of data (figure 4.18) showed separation between 
control diet WT and Nrf2 KO animals (Q2: 0.629; R2: 0.273), WT and Nrf2 KO animals fed a 
CHO-R diet (Q2: 0.791; R2: 0.341), WT animals fed a control or CHO-R diet (Q2: 0.89; R2: 
0.319) and Nrf2 KO animals fed a control or CHO-R diet (Q2: 0.8741; R2: 0.342) in study 1. 
The Q2 and R2 values in each case suggest that while the analysis is valid as a predictive 
model, the data contains a high level of irrelevant information that does not contribute to 
the model.   
Multivariate analysis of LC-MS/MS data suggests that there are differences in the lipid 
profiles of WT and Nrf2 KO animals both in control and CHO-R diet groups.  However, the 
lipids that are responsible for the separation have yet to be identified as while PLS-DA lists 
the peaks that account for the variation between groups in a given model these peaks have 
not been assigned thus far.   
4.3.10 Glycogen 
Although histopathology results showed no consistent differences in WT and Nrf2 KO 
animals with respect to hepatic glycogen levels, there was some evidence of glycogen 
depletion in 2/4 Nrf2 KO control animals.  Glucose can be stored intracellularly as glycogen 
or converted to pyruvate via glycolysis.  Pyruvate is a precursor to acetyl CoA and is 
therefore important for the synthesis of fatty acids, as well as energy production via the 
tricarboxylic acid cycle. Consequently, there may be a link between the increase in fatty 
acid synthesis in Nrf2 KO animals and glycogen depletion.   
A quantitative glycogen assay was used in order to determine whether there were any 
difference in glycogen levels in WT and Nrf2 KO mouse livers. The assay employs the 
enzyme glucoamylase, which hydrolyses the glycogen yielding glucose.  Oxidation of the 
glucose and subsequent reaction with the OxiRed probe results in a proportional change in 
colour.  A measurement of background glucose allows the relative concentration of 
glycogen across the samples to be determined.   
Hepatic glycogen was depleted to levels that were not detectable in CHO-R animals 
regardless of genotype (data not shown).  In animals fed a control diet, mean glycogen 
levels were lower in Nrf2 KO animals when compared to their WT counterparts; however 
this difference was not statistically significant (figure 4.19).  
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Figure 4.18: Partial least square discriminant analysis (PLS-DA) scores plots following LC-MS/MS 
analysis of livers from WT and Nrf2 KO mice fed a control or CHO-R diet for 4 weeks.  (a) Plots WT v 
KO mice on the control diet (Q2: 0.629; R2: 0.273).  (b) Plots WT v KO mice on the carbohydrate-
restricted diet (Q2: 0.791; R2: 0.341).  (c) Plots control diet v carbohydrate-restricted diet WT mice 
(Q2: 0.89; R2: 0.319). (d) Plots control diet v carbohydrate-restricted diet KO mice (Q2: 0.8741; R2: 
0.342).  All samples were run in duplicate (n=3).   
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Figure 4.19: Glycogen levels in livers from WT and Nrf2 KO mice fed a control diet in study 2 (n=4). 
Values were determined by a colorimetric assay. Statistical analysis was performed using an 
unpaired t-test, with no statistical difference identified.  
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4.4 Discussion  
Work described in chapter 2 of this thesis identified lipid metabolism as a process that is 
regulated by Nrf2.  A number of proteins associated with lipid pathways, including enzymes 
important for fatty acid biosynthesis, were expressed at a higher level in the livers of Nrf2 
KO mice when compared to WT animals suggesting that Nrf2 negatively regulates their 
expression.  The function of Nrf2 in the regulation of lipid metabolism has only recently 
emerged and has yet to be comprehensively defined.  The aim of this chapter was to 
contribute to the understanding of the role of Nrf2 in lipid homeostasis by characterising 
the hepatic lipid profile of WT and Nrf2 KO mice. 
A CHO-R diet was also used as a tool in order to investigate how mice with differing Nrf2 
genotypes responded to perturbations in lipid metabolism. Carbohydrate restriction has 
previously been shown to have an impact on the hepatic fatty acid profile (Bruss et al., 
2010; Forsythe et al., 2008; Rojas et al., 1993).  Levels of ACL, an important enzyme for 
cytosolic fatty acid synthesis, were determined by western immunoblotting performed on 
samples from livers of WT and NRF2 KO mice. Analysis of the blots showed that CHO-R 
resulted in a decrease in the expression of the protein, thus confirming that carbohydrate 
restriction resulted in perturbations in fatty acid metabolism.   
Preliminary results from experiments characterising the carbohydrate restricted mice 
showed that body weight and liver weight was reduced when compared to their control 
diet counterparts.  The diet also resulted in hepatic glutathione depletion in both WT and 
Nrf2 KO animals. Nrf2 did offer protection against glutathione depletion as levels were 
depleted by 50% in Nrf2 KO animals but by only 30% in WT animals.  However, the 
transcription factor could not completely prevent perturbations in glutathione 
homeostasis.  NQO1 western blotting demonstrated that Nrf2 was activated by a CHO-R 
diet as NQO1 was induced in the livers of WT animals.   
Given that iTRAQ analysis identified a significant role for Nrf2 in the regulation of the 
expression of fatty acid synthesis enzymes, fatty acid levels were the primary focus of the 
investigations into the hepatic lipid profiles of WT and Nrf2 KO mice. GC-FID served as a 
powerful tool for the targeted analysis of fatty acids by way of a method optimised for the 
detection of fatty acid methyl esters. Extracts from livers from WT and Nrf2 KO animals fed 
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a control or CHO-R diet were analysed by GC-FID, with 14 fatty acids detected in samples 
from both study 1 and study 2. 
While there were small differences in levels of fatty acids in the livers of WT and Nrf2 KO 
mice, with a majority of fatty acids increased in Nrf2 KO animals, in most cases the 
differences were not statistically significant. The biological significance of small changes in 
relative fatty acid levels however, remains unclear.  Interestingly, a number of the fatty 
acids that were differentially expressed were those with chains of 18 carbon atoms. C18:0 
was expressed at a statistically higher level in WT animals fed either a control or CHO-R diet 
when compared to their Nrf2 KO counterparts, and was not detected at all in livers of Nrf2 
KO animals in study 1 regardless of diet group.  Conversely, in CHO-R Nrf2 KO mouse livers, 
C18:1, C18:2 and C18:3 were all detected at a statistically higher level when compared to 
those in WT animals.   
C18:1 is synthesised from C18:0 in a reaction catalysed by the Δ9 desaturase enzyme, SCD, 
an enzyme that was shown by iTRAQ analysis to be up-regulated in the livers of Nrf2 KO 
mice.  However, while C18:2 (linoleic acid) and C18:3 (linolenic acid) are also fatty acids 
with chains of 18 carbon atoms, they are essential fatty acids that cannot be synthesised by 
mammals, so levels of fatty acid synthesis enzymes cannot account for differences in levels 
of C18:2 or C18:3.   Both fatty acids are precursors for the synthesis of longer chain fatty 
acids, including C20:4 (arachidonic acid) which is formed by the action of Δ5 and Δ6 
desaturases as well as elongase enzymes.  It may be that the synthesis of one of the 
desaturases required for modification of C18:2 and C18:3 is reduced as levels of SCD are 
increased, thus resulting in an increase in levels of the two fatty acids, however further 
work is required in order to investigate this hypothesis.   
In order to give a more comprehensive view of lipid profiles of the livers of WT and Nrf2 KO 
mice, samples from study 1 were also analysed by LC-MS/MS. Although the small number 
of samples analysed was a limiting factor, PLS-DA revealed that while diet accounted for 
the most significant differences between mice in the study, there was also separation 
based on genotype. To date, the peaks that were identified as contributing most to the 
model have yet to be assigned and consequently the lipids with expression levels that differ 
in WT and Nrf2 KO have not been determined.  However, the data do provide further 
evidence of a role for Nrf2 in the regulation of lipid metabolism and the lipids represented 
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by these peaks have the potential to provide further insight into the nature of this 
emerging relationship. 
The work in this chapter has shown that there are differences in the hepatic lipid profiles of 
WT and Nrf2 KO mice, although the link between the up-regulation of fatty acid synthesis 
enzymes in Nrf2 KO animals and differences in fatty acid levels has yet to be defined. When 
animals are fed a CHO-R diet, a number of the differences in fatty acid levels between WT 
and Nrf2 KO mice are exacerbated.  These results suggest that Nrf2 plays a role in 
regulating the response to the changes in lipid metabolism imposed by CHO-R, thus 
providing further evidence of a role for Nrf2 in the regulation of lipid homeostasis.  
Together, the studies emphasise the potential that lipids and other metabolites associated 
with lipid synthesis may have to serve as preclinical biomarkers of Nrf2 activity and suggest 
that a comprehensive lipidomic analysis of WT and Nrf2 KO mice could provide valuable 
insight.   
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Chapter 5 Investigating the proteomic profile of Nrf2 induction 
using the synthetic triterpenoid CDDO-Me 
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5.1 Introduction 
The role of Nrf2 in the cytoprotective response is widely documented and has been 
highlighted by work previously described in this thesis.  The identification of Nrf2 as a 
‘master regulator’ of cell defence has generated considerable interest in its potential as a 
therapeutic target, with inducers undergoing clinical evaluation for cancer and chronic 
kidney disease (Pergola et al., 2011; Speranza et al., 2012; Tsao et al., 2010).  Pre-clinically, 
Nrf2 induction has also been investigated as a means of protection in in vivo models of 
inflammatory liver injury (Osburn et al., 2008) and paracetamol-induced hepatotoxicity 
(Reisman et al., 2009), and has shown promise as a chemopreventive strategy (Kwak et al., 
2010; Liby et al., 2007).  
The synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its 
derivatives have been shown to be particularly potent inducers of Nrf2, resulting in vitro 
Nrf2 activation at nanomolar concentrations  (Liby et al., 2005).  CDDO was originally 
synthesised for its anti-inflammatory properties through the modification of the A and C 
rings of oleanolic acid and was found to potently inhibit nitric oxide production (Honda et 
al., 1998). Analogues including the methyl ester (CDDO-Me) and imidazole (CDDO-Im) 
derivatives were subsequently synthesised with the aim of further optimising potency and 
bioavailability (Honda et al., 1999; Place et al., 2003).  
A link between Nrf2 induction and CDDO treatment was first identified in a study in which 
the compound was shown to potently induce the phase II response in mouse embryonic 
fibroblasts (Dinkova-Kostova et al., 2005), a response that was abolished in Nrf2-null cells.  
Further in vitro work showed that CDDO and its derivatives induced Nrf2 protein levels as 
well as mRNA levels of the Nrf2 target gene haem oxygenase 1 (HO-1) (Liby et al., 2005).  
Evidence of in vivo  Nrf2 induction came from a study showing that the Nrf2-regulated 
gene, NQO1 was transcriptionally activated in the liver, lung and small intestine of CDDO-
Im and CDDO-Me-treated mice after a single oral dose (Yates et al., 2007).  
As well as activation of the Nrf2 pathway, CDDO and its derivatives have been shown to 
modulate signalling associated with the PPAR-γ receptor (Wang et al., 2000) and JAK-STAT 
pathway (Ahmad et al., 2008; Liby et al., 2006) and to inhibit both the constitutive and 
inducible activation of  NF-κB (Ahmad et al., 2006; Shishodia et al., 2006; Yore et al., 2006), 
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with some of these effects noted in vitro following triterpenoid treatment in the nanomolar 
range.   
CDDO-Me, which is also known as bardoxolone methyl, is currently in Phase III clinical trials 
as an Nrf2 inducer for the treatment of chronic kidney disease (CKD) in patients with type II 
diabetes.  However, the precise mechanism of action of CDDO-Me in CKD and the 
beneficial effects of Nrf2 inducers in other conditions remains to be defined.  Given that 
activation of alternative pathways has also been postulated to account for the therapeutic 
properties of compounds known to activate Nrf2, it is important to define the precise 
effects of Nrf2 inducers at the protein level and to ascribe these effects as Nrf2 dependent 
or independent actions. Furthermore, in order to directly assess the efficacy of drugs such 
as CDDO-Me, biomarkers that specifically reflect Nrf2 activity at both the constitutive and 
induced level would be invaluable to define the level of human Nrf2 variability and its 
activation in response to chronic drug exposure.   
There is consequently a clear imperative to generate a definitive list of Nrf2-regulated 
genes, since this may yield proteins or protein products that are potential biomarkers for 
such translational research. The Nrf2 KO mouse model provides a useful tool to define 
which of the changes in protein expression following CDDO-Me administration are Nrf2-
dependent.  
Differences in the basal hepatic profiles of WT and Nrf2 KO mice have been compared in 
chapter 2 of this thesis using iTRAQ-based proteomic analysis. Other studies have 
employed gene microarrays and targeted protein analysis in order to investigate 
constitutive differences and the effects of compounds identified as inducers of Nrf2, such 
as the isothiocynates, in the small intestine and liver (Hu et al., 2006a; Hu et al., 2006b; 
Thimmulappa et al., 2002).  However, to date no comprehensive comparative proteomic 
characterisation of liver tissue from WT and Nrf2 KO mice following administration of an 
Nrf2 inducer has been conducted.  
The aim of the work described in this chapter was to treat WT and Nrf2 KO mice with the 
potent Nrf2 activator, CDDO-Me, in order to define the Nrf2-inducible hepatic proteome. 
The two methods employed alongside each other allows the full range of Nrf2 activity to be 
defined, from zero in the Nrf2 KO mouse model through to the maximum activation 
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following an acute dose of CDDO-Me. By the characterisation of protein profiles resulting 
from Nrf2 activation, it is hoped that biomarkers will be identified that have translational 
potential as tools to assess the importance of Nrf2 variability and activation in the human 
population. 
5.2 Materials and Methods  
5.2.1 Materials 
The ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5) antibody was from 
Abcam (Cambridge, UK).  The CYP2A5 antibody was kindly provided by Risto Juvonen 
(University of Eastern Finland, Kuopio, Finland). CDDO-Me was synthesised by Michael 
Wong (Department of Chemistry, University of Liverpool, UK). All other reagents were of 
analytical grade and quality and purchased from Sigma (Poole, Dorset, UK).  
5.2.2 Animal studies 
All mice were housed as described previously in this thesis.   Male mice of 10-12 weeks of 
age were used for both the pilot study and subsequent proteomic study. 
In order to determine a dose of CDDO-Me that would result in Nrf2 activation and 
subsequent protein expression after 24 hours, WT mice were given a single i.p. injection of 
CDDO-Me (0, 0.1, 0.3, 1, 3, or 10 mg/kg; n=2) in DMSO vehicle control (total volume 100 uL) 
at 10 am.  At 24 h after dosing, the animals were culled by exposure to a rising 
concentration of CO2 followed by cardiac puncture.  Livers were removed, snap-frozen in 
liquid nitrogen and stored at -80°C.   
For the proteomic study, livers were harvested from WT and Nrf2 KO mice dosed with 
3mg/kg CDDO-Me or DMSO vehicle control (n=6), using the same protocol as described for 
the pilot study.    
5.2.3 iTRAQ labelling and mass spectrometric analysis of liver homogenates 
Liver samples (≈100 mg wet weight) were homogenised, labelled with iTRAQ isobaric tags 
and subjected to cation exchange as described in chapter 2 of this thesis.  Fractions were 
desalted using a macroporous C18 column (Agilent, Santa Clara, California) on a Vision 
workstation and dried by centrifugation under vacuum (SpeedVac, Eppendorf). Samples 
were analysed on a Triple TOF 5600 mass spectrometer (AB Sciex) and were delivered into 
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the instrument by automated in-line liquid chromatography Eksigent NanoUltra cHiPLC 
System mounted with microfluidic trap and analytical column (15 cm × 75 μm) packed with 
ChromXP C18-CL 3μm via a nano-electrospray source head and 10 μm inner diameter 
PicoTip (New Objective, Massachusetts, USA). The precolumn was washed for 10 min at 2 
μL/min with 2%ACN/0.1% FA. A gradient from 2%ACN/0.1% FA (v/v) to 50% ACN/0.1% FA 
(v/v) in 90 min was applied at a flow rate of 300 nL/min.  
The MS was operated in positive ion mode with survey scans of 250 ms, and with an 
MS/MS accumulation time of 100 ms for the 25 most intense ions (total cycle time 2.5 s). A 
threshold for triggering of MS/MS of 100 counts per second was used, together with 
dynamic exclusion for 12 seconds and rolling collision energy, adjusted for the use of iTRAQ 
reagent in the Analyst method. Information-dependent acquisition was powered by Analyst 
TF 1.5.1. software, using mass ranges of 400-1600 atomic mass units (amu) in MS and 100-
1400 amu in MS/MS . The instrument was automatically calibrated after every fifth sample 
using a beta-galactosidase digest. 
5.2.4 iTRAQ Protein Identification and Statistical Analyses 
Liver samples from WT and Nrf2 KO mice treated with CDDO-Me or DMSO vehicle control 
(n=6), were analysed across four iTRAQ runs with a comparator pooled sample 
incorporated in each run for normalisation between iTRAQ experiments. Samples were 
randomised across the four runs to minimise label bias. Ratios for each iTRAQ label were 
obtained, using the common pool as the denominator (iTRAQ label 113). Data analysis was 
performed using ProteinPilot software (Version 3, Applied Biosystems, Warrington, UK). 
The data were analysed with MMTS as a fixed modification of cysteine and biological 
modifications.  The SwissProt database was searched with a confidence interval of 95% and 
also screened in reverse to facilitate false discovery rate (FDR) analysis.  Proteins identified 
from peptides with more than 95% confidence and a global FDR of less than 1% were 
included in the statistical analysis.   
The limma package within the R programming environment (Team, 2005) allowed 
simultaneous comparisons between multiple treatments using design and contrast 
matrices.  This open source software generates a linear regression model (lm) to facilitate 
the analysis of differential protein expression.  Mean fold changes were calculated and 
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analysis conducted on the logged fold-change values. Unadjusted (raw) P values and P 
values following Benjamini-Hochberg (BH) correction for multiple testing were determined. 
Nrf2- and CDDO-Me-dependent protein expression was defined by comparing Nrf2 KO 
control  with WT control (group A), WT control with WT CDDO-Me (group B) and Nrf2 KO 
control with Nrf2 KO CDDO-Me mice (group C).  The resulting protein lists for genetic 
disruption and pharmacological pathway activation were compared to identify changes 
that were both common and unique to Nrf2 and CDDO in a similar manner to the gene 
expression studies performed in Keap1 hepatocyte-specific KO and  triterpenoid-treated 
mice reported by Yates et al. (2009). 
5.2.5 Network analysis 
Pathway analysis was performed as in chapter 2 of this thesis using MetaCore from GeneGo 
Inc. The software was used in order to identify the pathways most significantly 
differentially regulated in livers of WT and Nrf2 KO mice as well as in WT vehicle control 
and WT CDDO-Me-treated animals.    
5.2.6 Immunoblotting for Nrf2 target proteins 
Western immunoblotting for NQO1 and ACL was performed as described in chapter 4. In 
order to validate the iTRAQ-identified expression changes in key Nrf2- and CDDO-driven 
gene targets, immunoblotting was also undertaken for CYP2A5 and ENTPD5.  The same 
protocol was employed with minor modifications, in that membranes were blocked 
overnight in 10% milk and primary antibody incubation was for 1 hour (monoclonal chicken 
anti-CYP2A5 antibody: 1:10000; monoclonal rabbit anti-ENTPD5 antibody: 1:10000).  The 
secondary antibodies used were a peroxidase-conjugated rabbit anti-chicken IgG (CYP2A5; 
1:10000) and a peroxidase-conjugated goat anti-rabbit IgG (ENTPD5; 1:10000).  
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5.3 Results 
5.3.1 CDDO-Me pilot study for dose determination 
A pilot study was performed in order to determine a suitable dose of CDDO-Me that would 
result in Nrf2 induction and downstream protein expression 24 hours after a single dose.  
The dose range used in the study was based on data from an investigation in which CDDO-
Me was dosed to ICR mice resulting in an increase in NQO1 activity 24h after 
administration of the compound (Yates et al., 2007). Nrf2 induction was determined by 
NQO1 western immunoblotting (figure 5.1). A dose of 3mg/kg CDDO-Me was found to 
produce the highest NQO1 signal, with the response appearing to diminish at higher doses. 
Consequently 3mg/kg was selected for use in the subsequent proteomic study.   
5.3.2 Induction of Nrf2 by CDDO-Me in the proteomic study 
WT and Nrf2 KO mice were administered a dose of 3mg/kg CDDO-Me (i.p) and culled 24 
hours later. In order to confirm that a dose of 3mg/kg had indeed resulted in hepatic Nrf2 
induction in WT mice, the expression of NQO1 was assessed by immunoblotting.  Figure 
5.1c shows a representative blot of NQO1 levels in each treatment group (n=3), while 
figure 5.1d shows densitometric analysis of expression of NQO1 in all animals in the study 
(n=6).  Administration of CDDO-Me resulted in a two-fold increase in NQO1 in WT animals 
at 24h but no statistically significant change in the Nrf2 KO mice.  NQO1 was expressed at a 
level that was 8-fold lower in Nrf2 KO control animals when compared to their WT 
counterparts.   
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Figure 5.1: Immunoblots of liver homogenates from mice treated with CDDO-Me in DMSO (i.p) 
and culled 24 hours later.  Immunoblots for NQO1 and actin from (a) the pilot study to determine 
the dose of CDDO-Me that results in maximum NQO1 induction and (c) the iTRAQ study employing a 
dose of 3mg/kg CDDO-Me. (b) and (d) show densitometric analysis of the immunoblots in (a) and (c) 
respectively with NQO1 expressed relative to actin.  Error bars represent SEM (n=2, pilot study; n=6, 
iTRAQ study). Statistical analysis was performed using an unpaired t-test (**P< 0.01).  
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5.3.3 Characterization of the constitutive Nrf2-responsive hepatic proteome 
A comparative iTRAQ-based proteomic analysis of livers from WT and Nrf2 KO mice was 
conducted. In order to define Nrf2-dependent expression of proteins at both the basal and 
inducible (24h post dosing) levels, proteins were extracted from both DMSO vehicle treated 
mouse livers and those treated with CDDO-Me (3 mg/kg). Proteome profiling of all mouse 
liver samples yielded 3655 unique identifications at a FDR of <1%. From this total, 1521 
were shown to be quantifiable in at least four mice belonging to each of the four treatment 
groups, and these proteins were incorporated in the full statistical analysis.  
Table 5.1 shows the list of proteins that were up- or down-regulated by at least 30% 
(unpaired t-test, P<0.05) in Nrf2 KO mice when compared to WT animals  at the basal level. 
By applying a relatively non-stringent statistical analysis (without correction for multiple 
testing), a total of 165 liver proteins were deemed statistically different between WT and 
Nrf2-null mice. Whilst this level of statistical analysis is insufficient for unequivocal 
designation of Nrf2-driven proteins, it provides a sufficient number of nominally Nrf2-
regulated proteins to provide candidates for biomarker assessment and to allow 
meaningful ontology and pathway analysis. As noted by Subramanian et al. (Subramanian 
et al., 2005), the application of stringent multiple testing correction algorithms (such as 
Bonferroni or Benjamini Hochberg analyses) to large scale global analysis data can preclude 
the identification of modest expression changes that can collectively modulate a specific 
pathway.  
Of the 165 Nrf2-regulated proteins identified, 99 were expressed at a lower level in the null 
mice and 66 were up-regulated. This is in line with work in chapter 2 of this thesis, and with 
genomic studies, which show both positive and negative regulation through the Nrf2 
transcription pathway. Protein expression differences between WT and Nrf2 KO animals 
were evaluated to identify the primary biological functions and pathways associated with 
these genes. Analysis using MetaCore identified 48 pathways that were significantly 
differentially regulated in the livers of WT and Nrf2 KO mice (table 5.2; P<0.05). The 
network diagrams for the four most significantly different pathways are shown in figure 
5.2.   
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Table 5.1: Constitutively regulated Nrf2-dependent proteins. iTRAQ-based proteomic comparison 
of liver proteins in WT and Nrf2 KO mice. Proteins with expression that was down- or up-regulated 
by at least 30% (unpaired t-test P < 0.05) in Nrf2 KO relative to WT mice are listed.  Mean expression 
values relative to a common pool are given for n = 4-6 animals. Proteins are ordered according to 
the ratio between WT and Nrf2-null mice (WT/Nrf2 KO; highest to lowest) such that proteins with 
expression that is most markedly reduced in Nrf2 deficient animals appear at the top of the list.  
Protein 
Accession  
Name  WT/ Nrf2 KO 
ratio 
P-value 
Proteins down-regulated in Nrf2
(-/-)
 mouse liver    
P17717 UDP-glucuronosyltransferase 2B17  4.28 0.001 
P10649 Glutathione S-transferase Mu 1  4.11 0.001 
P19639 Glutathione S-transferase Mu 3  4.04 0.001 
P02762 Major urinary protein 6  3.62 0.005 
Q8VCC2 Liver carboxylesterase 1  2.64 0.010 
O70475 UDP-glucose 6-dehydrogenase  2.64 0.003 
P97493 Thioredoxin, mitochondrial  2.52 0.033 
P30115 Glutathione S-transferase A3  2.42 0.005 
Q9WUZ9 Ectonucleoside triphosphate diphosphohydrolase 5  2.22 0.001 
P24549 Retinal dehydrogenase 1  2.17 0.001 
O08709 Peroxiredoxin-6  2.16 0.003 
P20852 Cytochrome P450 2A5  2.12 0.045 
P19157 Glutathione S-transferase P 1  2.12 0.025 
Q60991 25-hydroxycholesterol 7-alpha-hydroxylase  2.09 0.027 
P15626 Glutathione S-transferase Mu 2  2.09 0.001 
P22907 Porphobilinogen deaminase  2.04 0.001 
Q9D379 Epoxide hydrolase 1  2.00 0.001 
P06801 NADP-dependent malic enzyme  1.91 0.001 
Q6XVG2 Cytochrome P450 2C54  1.88 0.006 
Q91X77 Cytochrome P450 2C50  1.79 0.002 
Q8R0Y6 Cytosolic 10-formyltetrahydrofolate 
dehydrogenase 
 1.70 0.003 
Q9CXN7 Phenazine biosynthesis-like domain-containing 
protein 2 
 1.70 0.008 
Q9D1L0 Coiled-coil-helix-coiled-coil-helix domain-
containing protein 2 
 1.69 0.020 
Q9DCY0 Glycine N-acyltransferase-like protein Keg1  1.65 0.002 
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Q91VA0 Acyl-coenzyme A synthetase ACSM1, mitochondrial  1.64 0.001 
Q9QZX7 Serine racemase  1.62 0.029 
Q64442 Sorbitol dehydrogenase  1.58 0.002 
P24472 Glutathione S-transferase A4  1.58 0.003 
Q64458 Cytochrome P450 2C29  1.56 0.042 
Q9EQK5 Major vault protein  1.55 0.001 
O70570 Polymeric immunoglobulin receptor  1.55 0.003 
P52760 Ribonuclease UK114  1.55 0.001 
Q922Q8 Leucine-rich repeat-containing protein 59  1.52 0.023 
Q8CG76 Aflatoxin B1 aldehyde reductase member 2  1.51 0.001 
O55022 Membrane-associated progesterone receptor 
component 1 
 1.50 0.002 
Q80W22 Threonine synthase-like 2  1.49 0.007 
Q7TNG8 Probable D-lactate dehydrogenase, mitochondrial  1.49 0.028 
Q91V76 Ester hydrolase C11orf54 homolog  1.48 0.003 
Q9DCM0 Protein ETHE1, mitochondrial  1.48 0.013 
O88844 Isocitrate dehydrogenase [NADP] cytoplasmic  1.46 0.004 
P15105 Glutamine synthetase  1.46 0.034 
Q9R0P3 S-formylglutathione hydrolase  1.45 0.003 
Q6ZWV3 60S ribosomal protein L10  1.43 0.015 
O08966 Solute carrier family 22 member 1  1.42 0.035 
P11589 Major urinary protein 2  1.39 0.032 
Q8K1N1 Calcium-independent phospholipase A2-gamma  1.39 0.016 
Q9JII6 Alcohol dehydrogenase [NADP+]  1.39 0.018 
P47738 Aldehyde dehydrogenase, mitochondrial  1.38 0.040 
Q64514 Tripeptidyl-peptidase 2  1.37 0.028 
P97494 Glutamate--cysteine ligase catalytic subunit  1.37 0.014 
Q9DBG5 Perilipin-3  1.37 0.050 
Q9Z1Z2 Serine-threonine kinase receptor-associated 
protein 
 1.37 0.015 
Q61425 Hydroxyacyl-coenzyme A dehydrogenase, 
mitochondrial 
 1.36 0.022 
Q3UJU9 Regulator of microtubule dynamics protein 3  1.35 0.001 
P28474 Alcohol dehydrogenase class-3  1.35 0.011 
Q8K157 Aldose 1-epimerase  1.33 0.024 
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O35945 Aldehyde dehydrogenase, cytosolic 1  1.32 0.011 
Q9Z2W0 Aspartyl aminopeptidase  1.32 0.015 
Q99KQ4 Nicotinamide phosphoribosyltransferase  1.31 0.013 
Q9JMH6 Thioredoxin reductase 1, cytoplasmic  1.30 0.033 
Q9DCQ2 Putative L-aspartate dehydrogenase  1.30 0.049 
Q9ET01 Glycogen phosphorylase, liver form  1.30 0.027 
Proteins up-regulated in Nrf2
(-/-)
 mouse liver    
Q91V92 ATP-citrate lyase  0.69 0.023 
P48678 Prelamin-A/C  0.68 0.005 
P21981 Protein-glutamine gamma-glutamyltransferase 2  0.66 0.008 
P08032 Spectrin alpha chain, erythrocyte  0.66 0.021 
Q9WU19 Hydroxyacid oxidase 1  0.65 0.001 
O08917 Flotillin-1  0.63 0.015 
Q99P30 Peroxisomal coenzyme A diphosphatase NUDT7  0.62 0.044 
P32020 Non-specific lipid-transfer protein  0.62 0.014 
Q9CQC9 GTP-binding protein SAR1b  0.60 0.035 
P11714 Cytochrome P450 2D9  0.58 0.004 
P42225 Signal transducer and activator of transcription 1  0.51 0.043 
Q8BVA5 UPF0554 protein C2orf43 homolog  0.46 0.032 
Q05816 Fatty acid-binding protein, epidermal  0.40 0.009 
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Table 5.2: Pathway analysis of Nrf2-regulated gene products at the basal level. GeneGo MetaCore 
was used to identify pathways enriched in the WT animals compared with the Nrf2 KO mice. All 
significant (P < 0.05) pathways are listed along with the number of objects within the protein set 
associated with that pathway. The total number of objects in the entire pathway is shown in 
parentheses.  
 Pathway P Value Objects 
1 Pyruvate metabolism/ Rodent version 0.0000040 7 (66) 
2 NRF2 regulation of oxidative stress response 0.000016 6 (54) 
3 Naphthalene metabolism 0.000032 6 (61) 
4 Glutathione metabolism / Rodent version 0.000075 6 (71) 
5 Glutathione metabolism 0.00048 5 (65) 
6 Glutathione metabolism / Human version 0.00051 5 (66) 
7 Tryptophan metabolism/ Rodent version 0.00055 6 (102) 
8 CAR-mediated direct regulation of xenobiotic metabolizing enzymes 
/ Rodent version 
0.00074 4 (41) 
9 CAR-mediated direct regulation of xenobiotic metabolizing enzymes 
/ Human version 
0.00074 4 (41) 
10 Pyruvate metabolism 0.0015 4 (49) 
11 Lysine metabolism/ Rodent version 0.0018 5 (87) 
12 Transcription_Transcription regulation of aminoacid metabolism 0.0019 3 (25) 
13 Folic acid metabolism 0.0019 4 (53) 
14 Triacylglycerol metabolism p.1 0.0031 4 (60) 
15 Tryptophan metabolism 0.0035 5 (101) 
16 Ascorbate metabolism / Rodent version 0.0036 3 (31) 
17 Butanoate metabolism 0.0037 4 (63) 
18 Development_EPO-induced Jak-STAT pathway 0.0051 3 (35) 
19 Retinol metabolism / Rodent version 0.0053 4 (70) 
20 Transcription_Role of AP-1 in regulation of cellular metabolism 0.0065 3 (38) 
21 Retinol metabolism 0.0065 4 (74) 
22 Propionate metabolism p.1 0.0070 3 (39) 
23 Histidine-glutamate-glutamine and proline metabolism/ Rodent 
version 
0.0072 5 (120) 
24 Leucine, isoleucine and valine metabolism/ Rodent version 0.0085 4 (80) 
25 Benzo[a]pyrene metabolism 0.0086 3 (42) 
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26 Immune response_IL-7 signaling in B lymphocytes 0.0092 3 (43) 
27 Immune response_IL-5 signalling 0.0098 3 (44) 
28 Lysine metabolism 0.011 4 (85) 
29 Mechanisms of CFTR activation by S-nitrosoglutathione (normal and 
CF) 
0.011 3 (46) 
30 Androstenedione and testosterone biosynthesis and metabolism p.1 0.016 3 (53) 
31 Immune response_Fc epsilon RI pathway 0.018 3 (55) 
32 Androstenedione and testosterone biosynthesis and metabolism 
p.1/ Rodent version 
0.020 3 (57) 
33 Immune response_CCR5 signaling in macrophages and T 
lymphocytes 
0.021 3 (58) 
34 Propionate metabolism p.2 0.029 3 (66) 
35 Polyamine metabolism 0.031 3 (68) 
36 Acetaminophen metabolism 0.034 2 (29) 
37 Histamine metabolism 0.034 2 (29) 
38 Immune response_Signaling pathway mediated by IL-6 and IL-1 0.036 2 (30) 
39 Cholesterol and Sphingolipids transport / Distribution to the 
intracellular membrane compartments (normal and CF) 
0.039 2 (31) 
40 Beta-alanine metabolism/ Rodent version 0.041 2 (32) 
41 Signal transduction_ERK1/2 signaling pathway 0.041 2 (32) 
42 (L)-Arginine metabolism 0.041 3 (76) 
43 Leucine, isoleucine and valine metabolism.p.2 0.044 3 (78) 
44 Development_CNTF receptor signalling 0.046 2 (34) 
45 Fatty Acid Omega Oxidation 0.046 2 (34) 
46 Immune response_Role of the Membrane attack complex in cell 
survival 
0.046 2 (34) 
47 Immune response_Oncostatin M signaling via MAPK in mouse cells 0.048 2 (35) 
48 Estrone metabolism 0.048 2 (35) 
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Figure 5.2: Pathway analysis of Nrf2-regulated gene products at the basal level. GeneGo MetaCore 
was used to identify pathways enriched in the WT animals compared with the Nrf2 KO mice. (a) 
Shows the 10 most significant pathways along with the –log(P value). (b) Shows the pathway 
diagrams for the 4 most significant pathways as detailed by the software.  
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5.3.4 Characterization of the CDDO-Me inducible Nrf2-dependent hepatic proteome 
Following administration of CDDO-Me, 59 proteins were either up- or down-regulated in 
WT mice. Of these, only 2 were similarly altered in Nrf2 KO mice.  These data are displayed 
graphically in Figure 5.3, which presents the fold difference for each individual protein 
identified in at least 4 mice (1521 in total) plotted against the unpaired t-test derived P 
value; figure 5.3a represents the comparison between WT and Nrf2 KO mice at the basal 
level, whilst the effect of CDDO-Me treatment in WT animals is shown in figure 5.3b.   
Inspection of these plots suggests that the influence of Nrf2 upon the basal proteome may 
be generally more profound than the effect of induction. Overall, more proteins lie above 
the statistical cut-off of P<0.05 with the comparison at the basal level than are statistically 
induced by CDDO-Me. Moreover, with the exception of CYP2A5 (labelled in fig 5.3b), the 
fold differences between WT and Nrf2 KO mice at the constitutive level comprised a far 
greater range than those following CDDO-Me treatment.  
It is also notable that a sizable proportion of proteins were expressed at a lower level in WT 
animals than in Nrf2 KO animals, indicating a level of negative regulation by Nrf2. In 
contrast, the majority of the changes observed following CDDO-Me treatment were up-
regulations. A summary of proteins uniquely up- or down-regulated by at least 30% in WT 
mice, but not in Nrf2-deficient animals, is given in Table 5.3. Sixteen proteins were induced 
compared with just four with expression that was decreased after CDDO-Me.   
As with the constitutively regulated proteins (table 5.1), proteins induced by CDDO-Me 
were heavily dominated by drug metabolizing enzymes and proteins involved in lipid 
synthesis/metabolism. However, there was no indication that CDDO-Me resulted in a 
reduced expression of proteins involved in fatty acid synthesis.  A negative regulation of 
such proteins, including ACL, FAS and SCD, at the constitutive level was observed both in 
the current iTRAQ analysis and in the work described in chapter 2 of this thesis. Several of 
the key lipid metabolic enzymes showed a numerically reduced expression following CDDO-
Me administration, with ACL for example reduced by 25% following induction.  However, 
these values were not statistically significant. 
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Figure 5.3: Volcano plots of the proteins quantified during iTRAQ analysis comparing (a) WT ctrl 
and Nrf2 KO ctrl and (b) WT CDDO and WT ctrl mice. Each point represents the difference in 
expression (fold-change) between the two groups of mice compared plotted against the level of 
statistical significance. Dotted vertical lines represent differential expression differences of ±30%, 
while the dotted horizontal line represents a significance level of p<0.05 (unpaired t-test). Proteins 
represented by a filled square are those with expression that differs by at least 30% at a statistically 
significant level.  
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Table 5.3: CDDO-Me inducible Nrf2-dependent proteins. iTRAQ-based proteomic comparison of 
liver proteins in DMSO vehicle control treated and CDDO-Me treated WT mice. Proteins with 
expression that was up- or down-regulated in WT mice (but not in Nrf2 KO mice) by at least 30% 
(unpaired t-test P < 0.05) following CDDO-Me administration are listed.  Mean expression values 
relative to a common pool are given for n = 4-6 animals. Proteins are ordered according to the ratio 
between CDDO-Me treated WT mice and vehicle control treated WT mice (WT CDDO/WT ctrl) 
highest to lowest such that proteins with expression that is most markedly induced by CDDO-Me 
appear at the top of the list.
 
 
Uniprot 
Accession  
Name  WT CDDO/ 
WT ctrl 
P-value 
Proteins up-regulated by CDDO-Me    
P20852 Cytochrome P450 2A5  8.12 0.001 
Q9WUZ9 Ectonucleoside triphosphate diphosphohydrolase 5  2.04 0.002 
P48758 Carbonyl reductase [NADPH] 1  1.63 0.003 
P19639 Glutathione S-transferase Mu 3  1.58 0.007 
O70475 UDP-glucose 6-dehydrogenase  1.57 0.007 
O35386 Phytanoyl-CoA dioxygenase, peroxisomal  1.51 0.036 
P24456 Cytochrome P450 2D10  1.51 0.038 
Q9D379 Epoxide hydrolase 1  1.48 0.034 
O88455 7-dehydrocholesterol reductase  1.46 0.041 
P50285 Dimethylaniline monooxygenase [N-oxide-forming] 1  1.45 0.005 
Q07076 Annexin A7  1.42 0.006 
Q9R1J0 Sterol-4-alpha-carboxylate 3-dehydrogenase, 
decarboxylating 
 1.42 0.023 
Q923D2 Flavin reductase (NADPH)  1.33 0.008 
Q9DD20 Methyltransferase-like protein 7B  1.33 0.019 
P29341 Polyadenylate-binding protein 1  1.32 0.003 
P37040 NADPH--cytochrome P450 reductase  1.31 0.022 
Proteins down-regulated by CDDO-Me    
Q91Y97 Fructose-bisphosphate aldolase B  0.69 0.036 
Q9QXD6 Fructose-1,6-bisphosphatase 1  0.68 0.025 
P70398 Probable ubiquitin carboxyl-terminal hydrolase FAF-X  0.64 0.014 
P70255 Nuclear factor 1 C-type  0.61 0.032 
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Analysis using MetaCore identified 8 pathways that were significantly altered in the livers 
of WT mice treated with CDDO-Me, when compared to vehicle control-treated mice (table 
5.4; P<0.05). The network diagrams for four of the pathways are shown in figure 5.4.   
Table 5.4: Pathway analysis of Nrf2-regulated gene products induced by CDDO-Me.  GeneGo 
MetaCore was used to identify pathways enriched in the WT animals treated with CDDO-Me (3 
mg/kg) for 24h compared with the vehicle control-treated WT mice. All significant (P < 0.05) 
pathways are listed along with the number of objects within the protein set associated with that 
pathway. The total number of objects in the entire pathway is shown in parentheses.  
 Pathway P Value Objects 
1 Glycolysis and gluconeogenesis (short map) 0.0015 3 (66) 
2 Cholesterol Biosynthesis 0.0034 3 (88) 
3 Glycogen metabolism 0.0076 2 (38) 
4 SCAP/SREBP Transcriptional Control of Cholesterol and FA Biosynthesis 0.0084 2 (40) 
5 Galactose metabolism 0.018 2 (59) 
6 Fructose metabolism 0.027 2 (74) 
7 Peroxisomal branched chain fatty acid oxidation 0.033 2 (83) 
8 Fructose metabolism/ Rodent version 0.034 2 (84) 
 
5.3.5 Characterisation of proteins regulated by Nrf2 at both basal and CDDO-Me-
inducible level 
Five proteins were basally expressed at a significantly lower level in Nrf2 KO when 
compared to WT and were also significantly up-regulated following CDDO-Me treatment in 
WT mice, with expression differences in each case of >30%.  A summary of the function of 
the proteins is given in table 5.5. Of the proteins identified as most significantly regulated 
by Nrf2, Glutathione S-transferase Mu 3 and Epoxide hydrolase 1 are well characterised as 
an Nrf2-regulated proteins. The regulation of CYP2A5 and UDP-glucose 6-dehydrogenase 
by Nrf2 has also been noted previously (Abu-Bakar et al., 2007; Thimmulappa et al., 2002).  
However, as far as I am aware, Nrf2-regulation of ENTPD5 is a novel finding of this study.  
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Figure 5.4: Pathway analysis of Nrf2-regulated gene products induced by CDDO-Me.  GeneGo 
MetaCore was used to identify pathways enriched in the WT animals treated with CDDO-Me (3 
mg/kg) for 24h compared with the vehicle treated WT mice. (a) Shows the 8 most significant 
pathways along with the –log(P value). (b) Shows the pathway diagrams for 4 of the most significant 
pathways that have not previously been represented in figure 5.2. 
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Table 5.5: Proteins regulated by Nrf2 at both basal and CDDO-Me-inducible level. iTRAQ-based proteomic comparison of liver proteins in DMSO vehicle control treated 
WT and Nrf2 KO mice and CDDO-Me treated WT mice. Proteins with expression that was up-regulated by at least 30% in both WT/KO and WT-CDDO/WT comparisons are 
listed.  Mean expression values relative to a common pool are given for n = 4-6 animals. Proteins are ordered according to the ratio between CDDO-Me treated WT and 
Nrf2 KO mice, such that proteins showing the widest range of Nrf2 regulation appear at the top of the list.  
a
Protein function based on the UniProt database annotation 
(http://www.uniprot.org/). 
  Mean expression level 
relative to pool 
 Expression ratios  
Uniprot  
Accession 
Name KO WT  WT-
CDDO  
 WT  
KO 
WT-
CDDO 
WT 
WT-
CDDO   
KO 
a
Protein function 
P20852 Cytochrome P450 2A5 0.19 0.40 3.26  2.12 8.12 17.24 Cytochrome P450 exhibiting high coumarin 7-hydroxylase activity 
P19639 Glutathione S-transferase 
Mu 3 
0.33 1.33 2.11  4.04 1.58 6.39 Mediates the conjugation of GSH to a wide number of exogenous and 
endogenous electrophiles 
Q9WUZ9 Ectonucleoside 
triphosphate 
diphosphohydrolase 5 
0.47 1.05 2.15  2.22 2.04 4.55 Uridine diphosphatase that promotes protein N-glycosylation and ATP 
regulation. With CMPK1 and AK1, constitutes an ATP hydrolysis cycle 
converting ATP to AMP resulting in a compensatory increase in aerobic 
glycolysis. Plays a key role AKT1-PTEN pathway by promoting glycolysis in 
proliferating cells in response to PI3K signalling. 
O70475 UDP-glucose 6-
dehydrogenase 
0.45 1.19 1.87  2.64 1.57 4.14 Involved in the biosynthesis of UDPGA, glycosaminoglycans, hyaluronan, 
chondroitin sulfate, and heparan sulphate 
Q9D379 Epoxide hydrolase 1 0.63 1.25 1.86  2.00 1.48 2.96 Enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to 
less reactive and more water soluble dihydrodiols by the trans addition of 
water. 
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5.3.6 Western immunoblotting validation of regulation of CYP2A5 and ENTPD5 by Nrf2  
Western immunoblotting was performed in order to validate the differences noted in 
expression of CYP2A5 and ENTPD5 (figure 5.5).  Densitometric analysis of immunoblots 
identified a 2.4-fold induction in CYP2A5 levels in WT mice treated with CDDO-Me when 
compared to vehicle control mice, while no induction was identified in Nrf2 KO mice 
treated with the triterpenoid. Expression of the CYP2A5 was 7.4-fold lower in vehicle 
control Nrf2 KO animals when compared to their WT counterparts.   ENTPD5 expression 
was induced 2.3-fold in CDDO-Me treated WT animals, with no induction in Nrf2 KO mice.  
Furthermore, comparison of the vehicle control groups showed that ENTPD5 expression 
was reduced by 4.6-fold in Nrf2 KO animals. 
5.3.7 ACL in CDDO-Me treated mice 
In order to further investigate potential differences in fatty acid metabolism enzymes in 
control- and CDDO-Me-treated WT mice, a western immunoblot for ACL was performed 
(figure 5.6).  The results confirmed the iTRAQ analysis showing that there was no statistical 
difference in expression of the protein between WT animals in the vehicle control and 
those treated with CDDO-Me.     
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Figure 5.5: Immunoblots of liver homogenates from WT and Nrf2 KO mice treated with CDDO-Me  
or DMSO vehicle control (i.p) and culled 24 hours later.  (a) and (c) show representative 
immunoblots for CYP2A5 and ENTPD5 respectively, together with the corresponding actin 
immunoblot. (b) and (d) show densitometric analysis of immunoblots  for all animals in each group 
(n=6), with CYP2A5 and ENTPD5 expressed relative to actin. Error bars represent SEM. Statistical 
analysis was performed using an unpaired t-test (**P< 0.01; ***P<0.001).   
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Figure 5.6: Immunoblots of liver homogenates from WT mice treated with CDDO-Me or DMSO 
vehicle control (i.p) and culled 24 hours later. (a) Immunoblots for ACL and actin. (b) Densitometric 
analysis of immunoblots for all animals in each group (n=6). ACL is expressed relative to actin.  Error 
bars represent SEM. There was no statistical difference between groups. 
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5.4 Discussion 
The aim of the work described in this chapter was to define the hepatic proteomic profile 
of Nrf2 activation.  A dose of 3mg/kg (i.p) CDDO-Me was shown to result in optimal Nrf2 
activation 24 hours after dosing, as determined by NQO1 immunoblotting, and was 
subsequently used in order to dose WT and Nrf2 KO mice for iTRAQ-based hepatic protein 
analysis.  The use of the Nrf2 knockout mouse model was a particular strength of this study 
because it facilitated comparison of CDDO-Me induced protein expression changes in Nrf2 
competent and deficient mice, thus allowing any changes observed to be assigned as Nrf2 
dependent or independent effects.  
CDDO and its derivatives have been shown to affect several different intracellular signalling 
pathways, including NF-κB (Ahmad et al., 2006; Shishodia et al., 2006; Yore et al., 2006),  
JAK-STAT (Ahmad et al., 2008; Liby et al., 2006) and  PPAR-γ receptor signalling (Wang et 
al., 2000).  However, somewhat surprisingly very few of the proteins induced by CDDO-Me 
in WT mice were similarly changed in the Nrf2 KO animals, indicating that at the relatively 
low dose of CDDO-Me administered, nearly all the changes in protein expression were 
mediated via the Keap1:Nrf2 signalling pathway.   
The iTRAQ analysis identified more proteins that were differentially expressed at the basal 
level in WT versus Nrf2 KO mice than at the inducible level in WT control versus WT CDDO-
Me treated mice.  The Nrf2 KO mouse is a model of chronic Nrf2 deficiency and is therefore 
likely to have a more profound influence on protein homeostasis than a single dose of an 
Nrf2 inducer. However, the study emphasises the important role that Nrf2 plays in the 
basal regulation of protein expression, and suggests that the influence of Nrf2 may be more 
notable in the constitutive regulation of proteins than it is following acute induction. 
In work described in chapter 2 of this thesis investigating the proteomic hepatic profile of 
Nrf2-null mice, lipid metabolism featured strongly in the differentially regulated proteins, 
confirming a key role for Nrf2 in the modulation of fatty acid synthesis.  In other studies, 
both pharmacological and genetic methods of Nrf2 induction have been shown to result in 
the down-regulation of pivotal enzymes in the fatty acid synthesis pathway at the mRNA 
level (Shin et al., 2009; Yates et al., 2009), with Yates et al identifying a reduction in ACL 
and FAS mRNA after a single dose of CDDO-Im. Interestingly, results from the current study 
show that whilst WT mice clearly under-expressed these proteins when compared with 
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Nrf2-deficient mice, treatment of WT animals with CDDO-Me did not result in a further 
decrease in expression. Thus the effects observed by Yates et al at the mRNA level may not 
translate into altered expression at the protein level at least within the time-course of this 
study.  
It should be noted that in a second study by the same group, FAS mRNA levels were not 
affected by the administration of CDDO-Im to HFD-fed WT mice 3 times per week for a 21 
day period, however a significant reduction was noted after a 95 day dosing period, along 
with a reduction in triglyceride levels when compared to control animals (Shin et al., 2009). 
These results suggest that chronic administration of CDDO derivatives is required to 
achieve functional modulation of lipid metabolism pathways.  
It is clear that Nrf2 has an important role for maintenance of lipid homeostasis in the liver; 
however, the work described in this chapter suggests that Nrf2 has a more significant role 
in modulating lipid metabolism at the basal level than it does following acute induction. 
However, it remains to be determined whether Nrf2 has a greater influence on expression 
of proteins important for lipid metabolism in models of chronic induction.    
Of the proteins that were up-regulated in CDDO-Me treated WT mice, CYP2A5 was most 
significantly increased.  Nrf2-regulation of CYP2A5 has previously been documented (Abu-
Bakar et al., 2007; Lamsa et al., 2010), while studies employing human hepatocytes have 
also identified CYP2A6, the human analogue, as Nrf2 regulated (Yokota et al., 2011). 
Interestingly, CYP2A5/6 is important for the metabolism of compounds including coumarin, 
nicotine and caffeine, with products of coumarin and caffeine metabolism being employed 
as markers of enzyme activity (Hakooz et al., 2007; Satarug et al., 2004).  Consequently, 
there may be the potential to utilize CYP2A5/6 activity as a biomarker for Nrf2 activation 
through the administration of a non-toxic exogenous CYP2A5/6 substrate.  However, 
CYP2A6 has been shown to be polymorphic in a range of ethnic populations, with some 
polymorphisms resulting in functional differences in enzyme activity (Han et al., 2012; 
Nurfadhlina et al., 2006; Shimada et al., 1996).  This would therefore have to be taken into 
account were CYP2A6 activity to be used as a biomarker for Nrf2 activity in the human 
population.   
ENTPD5 was another protein that was expressed at a significantly higher level in WT mice 
treated with CDDO-Me, as well as at a constitutively lower level in Nrf2 KO animals. 
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ENTPD5 is a uridine diphosphatase that hydrolyzes uridine diphosphate (UDP) to uridine 
monophosphate (UMP).  It is important in the glycosylation and folding of proteins, as well 
as in ATP regulation.  It has been shown to play a role in regulation of the PI3K-PTEN-AKT 
signalling loop (Fang et al., 2010). Interestingly, the PI3K/AKT signalling pathway has been 
implicated in Nrf2 signalling, notably in the triterpenoid-mediated activation of Nrf2 (Liby 
et al., 2005), and this is currently the subject of further investigation within the 
department.  
The work described in this chapter has defined a list of proteins with expression that was 
induced following Nrf2 activation resulting from the administration of a single 3mg/kg dose 
of CDDO-Me. Furthermore, it has shown that the majority of changes in protein expression 
that result from such a dose are attributable to Keap1:Nrf2 pathway modulation. By 
determining the proteins that are induced on Nrf2 activation, a number of candidate 
proteins have been identified that may have utility as biomarkers for investigating Nrf2 
activity and variability in preclinical and translational models. Those proteins that were 
identified as down-regulated in Nrf2 KO when compared to WT mice, as well as up-
regulated in WT mice on CDDO-Me treatment, have significant potential because of their 
dynamic range of Nrf2-regulated expression.  
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6.1 Summary of thesis aims and major findings 
The Keap1:Nrf2 pathway plays an important and well characterised role in the 
cytoprotective response. Under conditions of oxidative stress, Keap1 is no longer able to 
target Nrf2 for degradation and the transcription factor accumulates in the nucleus, where 
it binds to the ARE in a range of genes thus mediating their expression. Nrf2 has a role in 
regulating the expression of genes encoding phase II proteins, enzymes important for 
glutathione synthesis, and antioxidants. 
Hepatotoxicity resulting from drug administration is a significant problem for the 
pharmaceutical industry. Often the mechanisms by which DILI occurs are poorly 
understood and there is a clear imperative to improve preclinical models of hepatotoxicity.  
Oxidative stress and glutathione depletion have been implicated in the toxicity associated 
with model hepatotoxins, as well as in cases of idiosyncratic DILI. Nrf2 KO mice have also 
been shown to be more susceptible to the toxicity resulting from the administration of 
compounds including paracetamol, carbon tetrachloride and cisplatin (Chan et al., 2001; 
Enomoto et al., 2001; Park et al., 2008; Xu et al., 2008).  Consequently, the Keap1:Nrf2 
system provides a potential focus for the development of novel therapeutic strategies for 
the management of DILI. Biomarkers that are indicative of Nrf2 activity may reflect 
oxidative stress levels, thus having applicability in preclinical models of hepatotoxicity.   
Biomarkers of Nrf2 activity would also have utility in studies investigating the importance 
and variability of Nrf2 levels in the human population. While Nrf2 has been widely studied 
in mouse models, the role of the transcription factor in man has received limited attention.  
However, Nrf2 induction has been investigated for its therapeutic potential, with CDDO-Me 
recently entering Phase III clinical trials for the treatment of CKD in patients with type II 
diabetes. Consequently, there is a pressing need to characterise the variability of Nrf2 
expression in the human population and explore the functional roles of the transcription 
factor in man.    
The overall aim of the work described in this thesis was to investigate the hepatic profile of 
mice in which Nrf2 signalling had been modulated in order to identify potential biomarkers 
of Nrf2 activity.  Work detailed in chapter 2 set out to characterise the basal hepatic 
proteomic profile of WT and Nrf2 KO mice.  Analysis of iTRAQ data identified lipid and 
glutathione metabolism as the processes that were most significantly differentially 
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regulated in Nrf2 KO animals. Glutathione synthesis was found to be positively regulated by 
Nrf2 and lipid metabolism was identified as a process that is negatively regulated by the 
transcription factor.   
Given the importance of Nrf2 in glutathione regulation and the association between 
glutathione depletion and drug toxicity noted in chapter 1 of this thesis, the aim of the 
work described in chapter 3 was to develop and validate an LC-MS/MS assay for the 
quantification of GSH and GSSG. The assay was employed to determine the basal levels of 
GSH and GSSG in the livers of WT and Nf2 KO mice, with levels of GSH found to be reduced 
by 21.5% in Nrf2 KO animals.   
Evidence of a role for Nrf2 in the regulation of lipid metabolism has only recently emerged 
and has yet to be definitively characterised. Lipids and other metabolites associated with 
lipid synthesis may have the potential to serve as biomarkers of Nrf2 activation.  Therefore, 
the aim of the work set out in chapter 4 of this thesis was to investigate the hepatic lipid 
profiles of WT and Nrf2 KO mice.  The fatty acid synthesis pathway was the major focus of 
the work described, as this process was noted as significantly regulated by Nrf2 in the 
proteomic analysis set out in chapter 2.  Carbohydrate restriction was employed as a tool 
to investigate how the animals responded to perturbations in the fatty acid synthesis 
pathway. The level of a number of fatty acids differed in the livers of WT and Nrf2 KO 
animals at a statistically significant level, with some of the differences exacerbated by a 
CHO-R diet.  Preliminary lipidomic analysis provided further evidence for the importance of 
Nrf2 in lipid regulation. 
The synthetic triterpenoid, CDDO-Me has been shown to be a particularly potent inducer of 
Nrf2 and was used in the studies detailed in chapter 5 in order to investigate the hepatic 
proteomic profile of Nrf2 activation in mice.  The use of both WT and Nrf2 KO animals 
allowed any changes resulting from CDDO-Me administration to be identified as Nrf2-
depndent or –independent.  iTRAQ results and subsequent MetaCore analysis highlighted 
the important role of Nrf2 in the constitutive regulation of protein expression, with 
significantly more proteins and pathways differentially regulated in WT and Nrf2 KO control 
animals when compared to the differences identified in WT control and CDDO-Me treated 
mice.  Five proteins were identified as being constitutively expressed at a lower level in 
Nrf2 KO animals when compared to their WT counterparts and also up-regulated in the 
Chapter 6 
170 
 
livers of WT animals treated with CDDO-Me.  The dynamic range of Nrf2-inducible 
expression means that these proteins have significant potential as candidate biomarkers of 
Nrf2 activity. 
6.2 The importance of Nrf2 in constitutive regulation 
In the context of drug toxicity it is often the function of the Keap1:Nrf2 pathway in the 
adaptive response to chemical stress that is the focus, whereby the interaction between 
Keap1 and Nrf2 is disrupted following oxidative insult and Nrf2 mediates the up-regulation 
of the expression of cytoprotective genes and thus synthesis of enzymes key for 
detoxification. However, Nrf2 is also known to have a role in controlling the basal 
expression of many defence genes and work described in this thesis further highlights the 
importance of Nrf2 in the regulation of the constitutive hepatic profile. The iTRAQ studies 
detailed in chapter 2 identified 127 proteins that were differentially expressed in the livers 
of WT and Nrf2 KO mice at a basal level, including many proteins with a role in 
cytoprotection.  Analysis of hepatic glutathione levels in WT and Nrf2 KO animals detailed 
in chapter 3 also showed that levels of reduced glutathione were statistically significantly 
lower in Nrf2 KO animals when compared to their WT counterparts.  Furthermore, work set 
out in chapter 5 investigating the hepatic proteomic profile of acute Nrf2 induction, 
showed that a greater proportion of proteins were regulated at the basal level by Nrf2 than 
were induced following a single dose of the synthetic triterpenoid CDDO-Me. 
The function of Nrf2 in regulating the basal expression of proteins is likely to be of 
particular significance in the initial phase of the response to acute toxic insult.  It is 
probable that the Nrf2-mediated constitutive expression of proteins including the GSTs and 
UGTs is vital in mounting a successful response to such stress.  For example, a functional 
Keap1:Nrf2 system has been shown to confer protection against drug-induced 
hepatotoxicity including damage associated with paracetamol overdose (Chan et al., 2001).  
Paracetamol toxicity is associated with hepatocellular damage in Nrf2 KO animals within 2 
hours of drug administration at doses that do not result in detectable damage in WT 
animals at the same time point (Enomoto et al., 2001). The timeframe for up-regulation of 
mRNA expression and subsequent protein synthesis cannot account for the protection 
conferred by Nrf2 in WT animals (Kitteringham et al., 2000).  While the up-regulation of 
gene expression by Nrf2 may be important for the longer term response to stress and 
contribute to the effective recovery of an animal following chemical insult, it seems unlikely 
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that this process is able to influence the crucial primary response to stress within a relevant 
time-frame.     
Given that Nrf2 has an important role in regulating the basal expression of cytoprotective 
proteins and basal glutathione levels, as highlighted by work described in this thesis, it is 
important that the constitutive variability of Nrf2 in the human population is established. 
Individuals in whom Nrf2 expression is constitutively low may be predisposed to the 
toxicity associated with oxidative stress-inducing compounds and this may be relevant for 
some cases of idiosyncratic DILI.  
6.3 A role for Nrf2 in the regulation of lipid metabolism 
While the importance of Nrf2 in the oxidative stress response is well documented, the 
study described in chapter 2 of this thesis was one of the first to identify a role for Nrf2 in 
the modulation of lipid metabolism.  In a paper published in 2008, Tanaka et al. reported 
that genes encoding enzymes key for fatty acid synthesis, including FAS and ACC1, were 
increased in livers of Nrf2 KO mice fed a HFD for 4 weeks when compared to WT animals 
(Tanaka et al., 2008). Interestingly, the feeding of a HFD also led to a 56% reduction in Nrf2 
mRNA expression in WT animals. These findings suggest a negative role for Nrf2 in the 
regulation of hepatic fatty acid metabolism and are therefore in accordance with the 
results detailed in chapter 2.   
While one subsequent study has suggested that levels of fatty acid synthesis enzymes are 
in fact higher in livers of WT mice fed a HFD when compared to Nrf2 KO animals (Huang et 
al., 2010), the majority of studies in the literature support the hypothesis that Nrf2 
negatively regulates hepatic lipid metabolism. For example, in a study investigating the 
effect of CDDO-Im administration in a HFD model, mRNA levels of FAS and ACC1 were 
reduced in animals treated with CDDO-Im 3 times weekly for a 95 day period in WT HFD fed 
and WT control diet groups.  This was not the case in Nrf2 KO groups (Shin et al., 2009).  
Furthermore, in a comprehensive study by Yates et al.  (Yates et al., 2009), lipid metabolism 
was the functional category that was most significantly altered by both genetic and 
pharmacological Nrf2 induction, with a majority of lipid metabolism-related genes down-
regulated with increasing Nrf2 activation.  Within the lipid metabolism class, genes linked 
with fatty acid biosynthesis were most notably affected and included FAS, ACC1, SREBP1c 
and ACL.  
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Such studies, together with the results from iTRAQ analysis set out in chapter 2 of this 
thesis, have provided significant evidence that the regulation of hepatic lipid metabolism is 
an important function of Nrf2.  Yates et al. suggest that Nrf2 may function to sense lipids or 
the intermediates of lipid metabolism (Yates et al., 2009), however, further studies 
investigating the role of Nrf2 in lipid regulation are required before conclusions can be 
drawn. 
The mechanism of negative regulation of lipid metabolism by Nrf2 may be the result of a 
direct or an indirect interaction. Given that the evidence for a role for microRNAs (miRNAs) 
in the regulation of lipid metabolism is growing, these small non coding RNA species may 
be hypothesised to contribute to the mechanisms by which Nrf2 regulates lipid pathways at 
a transcriptional and post-transcriptional level. miRNAs including miR122 and miR370 have 
been shown to have a role in the regulation of lipid and cholesterol homeostasis (Esau et 
al., 2006; Iliopoulos et al., 2010), while Nrf2 has been shown to have a role in the 
regulation of levels of miR29B (Chorley et al., 2012). A comprehensive study that identifies 
miRNAs that are regulated by Nrf2 and subsequently investigates the effect of modulation 
of levels of such miRNAs on lipid metabolism may provide valuable insight into Nrf2-
mediated regulation of lipid pathways.   
Given the evidence for a role for Nrf2 in the regulation of enzymes important for cytosolic 
fatty acid synthesis, the work described in chapter 4 of this thesis set out to explore the 
functional significance of the changes in enzyme expression by investigating the hepatic 
fatty acid profile of WT and Nrf2 KO animals.  While many of the differences in fatty acid 
levels that were detected were subtle, results suggest that the differences in the 
expression of enzymes including SCD may have functional consequences in terms of fatty 
acid homeostasis.  
The lipidomic analysis of livers from WT and Nrf2 KO mice also detailed in chapter 4 of this 
thesis provided preliminary evidence that the modulation of Nrf2 expression results in 
changes in the levels of some lipids, thus highlighting the potential for lipids to serve as 
biomarkers of Nrf2 activity. A comprehensive lipidomic analysis employing methods to 
identify the lipids that are altered in the absence of a functional Nrf2 gene could provide 
considerable insight.  Furthermore, the analysis of serum alongside liver homogenate could 
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result in the identification of lipids or lipid metabolites with potential as preclinical and 
translational biomarkers of Nrf2 activity.  
A number of the studies noted above employed CDDO derivatives in order to investigate 
the effect of Nrf2 induction on lipid pathways.  These studies have shown that the 
compounds reduce mRNA levels of lipid synthesis enzymes in an Nrf2-dependent manner. 
In the iTRAQ analysis of livers from mice treated with a single dose of CDDO-Me detailed in 
chapter 5 of this thesis, no statistical difference was noted in the protein level of fatty acid 
synthesis enzymes when WT control and WT CDDO-Me-treated mice were compared. 
While the HFD studies using CDDO-Im treatment involved the chronic administration of the 
compound, the study by Yates et al. identified an Nrf2-dependent reduction in mRNA levels 
of FAS and ACL after a single dose (Yates et al., 2009).  This apparent discrepancy between 
the effects at the mRNA and protein level may reflect the different time-frames of 
expression of these biomolecules: a change in mRNA that occurs within the 24 hour period 
may not translate to the protein level within this same period. Furthermore, to see a 
decrease in protein level following reduced mRNA production is a function of protein 
degradation, and it is likely that proteins involved in fundamental cellular metabolism 
would be long-lived with long half-lives. Conversely, the turnover of proteins important for 
cytoprotection is likely to occur more quickly and hence an increase in these enzymes was 
detected in the study. 
Future studies are needed in order to investigate the hepatic proteomic profile of mice 
following chronic CDDO-Me treatment. However, it may be necessary to investigate the 
use of an alternative vehicle control for the administration of the compound as evidence 
suggests that DMSO is associated with neurotoxicity (Hanslick et al., 2009) and natural killer 
T cell infiltration of the liver (Masson et al., 2008). These factors may be limiting in a 
chronic dosing study.  However, such a study would also be better suited to oral drug 
administration and consequently this leaves scope for the compound, which is insoluble in 
aqueous conditions, to be administered as a suspension.   
 The characterisation of the hepatic effects of repeat CDDO-Me dosing is important for 
further defining the role of Nrf2 in the regulation of lipid metabolism, but also in the wider 
context of investigating pathways that are modulated by chronic Nrf2 activation, as this 
may provide evidence of other potential therapeutic targets for Nrf2 activation.  
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Conversely, such a study would also have utility in identifying potential toxicity risks.  
Furthermore, It is yet to be determined whether the Nrf2 cytoprotective response is down-
regulated upon chronic stimulation of the pathway, and this would also be important were 
Nrf2 activation to be used for wider therapeutic applications or as a chemoprevention 
strategy.   
While fatty acid synthesis was the lipid metabolism-associated process that emerged as 
most notably regulated by Nrf2 following the study described in chapter 2, other aspects of 
lipid metabolism were also highlighted in the proteomic analysis.  Peroxisomal proteins 
were significantly represented amongst the proteins that were expressed at a constitutively 
higher level in Nrf2 KO mice (table 2.5) with peroxisomal straight-chain fatty acid beta-
oxidation one of the pathways that was identified by MetaCore analysis as differentially 
regulated in WT and Nrf2 KO animals.  Peroxisomes have a major role in fatty acid β-
oxidation, a process involving the breakdown of fatty acids into 2 carbon chain units, which 
are subsequently converted into acetyl CoA.  The acetyl CoA produced in the peroxisomes 
is transported back to the cytosol. Consequently, enzymes important in both the synthesis 
and breakdown of fatty acids were up-regulated in the livers of Nrf2 KO animals, further 
highlighting the complexity of the role of Nrf2 in the regulation of lipid metabolism. 
When statistically significant fold-changes in protein expression  identified by iTRAQ 
analysis in chapter 2 were considered, the protein that was expressed at the lowest level in 
Nrf2 KO mice when compared to WT was major urinary protein 6 (MUP6; 0.35 KO/WT), 
while the protein most induced in KO animals was epidermal fatty acid binding protein 
(FABP5; 2.97 KO/WT).  The major urinary proteins (MUPs) are lipid binding proteins that 
function to transport pheromones.  While the expression profile of MUPs is species and sex 
specific, most mammals have genes encoding MUPs, although there is no functional human 
MUP gene.  In male mice MUPs are employed in territorial marking, mate attraction and 
other behavioural functions.   The fatty acid binding proteins (FABPs) are involved in the 
transport, uptake and metabolism of fatty acids and are highly conserved across species.  
Interestingly, as well as functioning as lipid transport proteins, both the MUPs and FABPs 
belong to the lipocalin class of proteins.  The fact that the two proteins that were most 
disparately expressed in the presence and absence of Nrf2 have similar functions, serves to 
further emphasise the complex role that the transcription factor plays in the regulation of 
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lipid metabolism.  It may be the case that the increase in FABP5 expression was at the 
expense of MUP6 synthesis, however further work is required in order to establish the 
relationship between the two proteins and the role that Nrf2 is playing.   
6.4 Nrf2 and lipid regulation in health and disease 
The mounting evidence that Nrf2 negatively regulates hepatic lipid metabolism, together 
with the fact that chronic triterpenoid administration has been shown to attenuate the 
fatty liver associated with the feeding of a HFD to mice, means that Nrf2 induction is an 
attractive strategy for the treatment of diseases associated with fatty liver.  NAFLD and 
steatosis are conditions characterised by the accumulation of lipids in cytosolic vesicles.  
The feeding of a methionine- and choline-deficient (MCD) diet to mice is a model employed 
to stimulate the development of steatosis.  Two studies have reported that the 
development of the condition is significantly accelerated in Nrf2 KO mice fed an MCD diet 
when compared to their WT counterparts (Chowdhry et al., 2010; Sugimoto et al., 2010). A 
third study also reporting an exacerbation in steatosis in Nrf2 KO mice, further employed a 
Keap1 knockdown (K1-kd) model to investigate the effect of Nrf2 activation in the MCD diet 
model (Zhang et al., 2010).  In the study, K1-kd was protective, with animals showing 
reduced steatosis when compared to WT mice.    
However, while the evidence for the beneficial effects of Nrf2 activation in the treatment of 
lipid-associated hepatic diseases is growing, the role of the transcription factor in 
modulating lipid pathways in other tissues remains unclear.  There is evidence for Nrf2 
regulation of lipid metabolism in adipose tissue, although there is a lack of consensus as to 
whether Nrf2 promotes or inhibits lipid synthesis.  In vitro, Nrf2-dependent inhibition of 
lipid droplet accumulation has been shown in a mouse embryonic fibroblast (MEF) model 
of adipocyte differentiation (Shin et al., 2007), while in vivo evidence suggests that loss of 
Nrf2 expression promotes a low adipose tissue mass and the formation of small adipocytes, 
suggesting Nrf2 positively regulates lipid accumulation in adipose tissue (Pi et al., 2010).   
In the context of diseases associated with the perturbation of lipid homeostasis, the role of 
Nrf2 also remains unclear.  In a streptozotocin (STZ)-induced mouse model of type I 
diabetes, hyperglycaemia was more marked in Nrf2 KO mice when compared to WT, while 
glucose tolerance was also found to be significantly reduced in basal Nrf2 KO animals 
(Aleksunes et al., 2010), suggesting Nrf2 is protective in diabetes.  However, in a study 
Chapter 6 
176 
 
using an apolipoprotein (apo) E-null background to investigate atherosclerosis, Nrf2 
deficiency was suggested to be protective against the formation of atherosclerotic lesions.  
Nrf2 KO animals were reported to have lower levels of total plasma cholesterol and 
reduced expression of genes important for lipogenesis (Barajas et al., 2011).   
Results from these studies show that there is still considerable work to be done in order to 
understand the role that Nrf2 plays in the pathology of diseases in which lipid pathways are 
dysregulated, and to determine the potentially tissue-specific effects of the transcription 
factor in modulating lipid metabolism. Such work is becoming increasingly important as 
Nrf2 inducers move closer to the market.  
6.5 Mass spectrometric techniques in biomarker discovery 
iTRAQ analysis has proved to be a useful technique for hepatic proteomic profiling in the 
studies detailed in chapter 2 and chapter 5 of this thesis. The method also has great utility 
in terms of hypothesis generation, with the work described in chapter 2 resulting in the 
design of subsequent experiments to investigate the role of Nrf2 in hepatic lipid 
metabolism.  However, iTRAQ is associated with a number of limitations.  For example, 
there can be significant variation in the number of proteins detected in different runs, as 
was the case in the four runs of iTRAQ analysis 1 in chapter 2 (table 2.3). This variation can 
be the result of a range of factors associated with the preparation and storage of samples 
and sensitivity of the mass spectrometer.  Such factors may also account for the differences 
in the proteins identified as Nrf2-regulated in iTRAQ analyses 1 and 2 in that chapter.  
The high level of variability means that fold changes of less than 30% are unlikely to be 
validated as statistically significant, even though a small reduction in protein expression 
may have important biological consequences, particularly in the context of the threshold 
for toxicity.  The value of iTRAQ is however enhanced when it is employed alongside 
methods that allow the functional grouping of proteins identified as differentially regulated 
between treatment groups. This type of systems analysis can be used to integrate small 
changes in a number of proteins to reveal novel biologically relevant pathways that are 
regulated by the target of interest. 
The development of the LC-MS/MS method for the quantification of glutathione that was 
described in chapter 3 of this thesis was associated with a number of problems in the 
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accurate determination of GSSG levels. Calculations for GSSG concentrations were 
ultimately corrected based on the recovery values determined from solutions of known 
GSSG concentration.  Such a method was valid in this instance because the recovery 
samples were run in the same assay as the WT and Nrf2 KO mouse livers that were 
analysed.  However, in order for the method to be applicable to a wide range of studies it is 
important that the intra-assay precision levels are also determined.  The running of quality 
control samples could also contribute to the validation of concentrations calculated in 
different runs.   
 Validation of the assay showed that it was considerably more accurate and precise in 
terms of GSH quantification.  This suggests that there is scope to develop the assay to 
include other glutathione precursors including glycine, glutamate and the thiol containing 
amino acid, cysteine. Such a method could be used in order to further investigate the 
impact of Nrf2 modulation on the glutathione synthesis. Given the importance of Nrf2 in 
the regulation of glutathione, the pathway has the potential to provide biomarkers of Nrf2 
activity as is highlighted by a paper detailing the use of the GSH analogue, ophthalmic acid 
as an oxidative stress biomarker (Soga et al., 2006).   
6.6 The identification of potential biomarkers 
While biomarkers that are reflective of Nrf2 activity remain to be definitively characterised, 
some of the Nrf2 regulated proteins and processes that have been identified by work 
described in this thesis have the potential to fulfil the criteria defining an ideal biomarker 
that were set out in chapter 1 of this thesis. One of the key characteristics of a biomarker 
that can be used in the human population is that it can be assessed in a non-invasive 
manner.  While the levels of proteins and lipids have been determined in liver 
homogenates in all of the investigations detailed in this thesis, there is the potential for the 
knowledge of Nrf2 hepatic protein regulation to translate into an assay that can be carried 
out in urine or serum samples.  For example, the regulation of CYP2A5 by Nrf2 means that 
non-toxic substrates of the enzyme such as caffeine could be administered and the 
production of a metabolite assessed in urine in order to determine Nrf2 activity.  Such 
assays can be implemented in both preclinical and clinical settings and are relatively cost 
effective.   
Chapter 6 
178 
 
The fact that the expression of proteins including CYP2A5 and ENTPD5 is regulated by Nrf2 
at a constitutive and inducible level is particularly important in the context of biomarker 
discovery because it means that their levels of expression cover a wide dynamic range and 
so changes in their expression, or alterations in metabolites produced from a reaction 
catalysed by the enzyme, are likely to be easily detected. 
The specificity and selectivity of a given biomarker is also an important factor to consider. 
While expression of proteins such as CYP2A5 is not liver specific, the relative contribution 
of the enzyme in different tissues to the metabolism of particular substrate could be 
characterised and the information used to validate the use of the biomarker.  Given the 
important role of the liver in lipid homeostasis, lipid metabolites may have a greater 
propensity towards hepatic specificity however, this remains to be determined.   
The work described in this thesis has investigated a range of Nrf2-regulated targets 
including proteins important for cytoprotection, glutathione levels and lipid metabolism 
pathways.  Each of the processes that are regulated by Nrf2 has the potential to yield 
further markers of Nrf2 activity that can be used in preclinical models of oxidative stress 
and have potential applications in defining the importance of variability of Nrf2 in the 
human population.   
6.7 Concluding remarks 
In summary, the work described in this thesis has sought to identify potential candidate 
biomarkers of Nrf2 activity through the characterisation of the hepatic profile of mice in 
which the Keap1:Nrf2 pathway has been modulated.  This aim has been achieved by 
addressing a series of key questions: 
How do the constitutive hepatic proteomic profiles of WT and Nrf2 KO mice differ?   
Can GSH and GSSG be reliable quantified in the livers of WT and Nrf2 KO animals, and given 
the differences noted in glutathione metabolism pathways in proteomic analysis, do levels 
of glutathione also differ in the livers of WT and Nrf2 KO animals? 
Do the differences identified in levels of proteins related to lipid metabolism in chapter 2 
translate to a functional difference in the hepatic lipid profile of WT and Nrf2 KO animals?  
How does acute Nrf2 activation affect the hepatic proteomic profile of mice? 
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In seeking to answer each of these questions, the work detailed in this thesis has 
highlighted the important role that Nrf2 plays in regulating the constitutive hepatic 
phenotype and contributed to the growing evidence of a role for Nrf2 in the regulation of 
lipid metabolism.  Ultimately, the most promising candidates for biomarker development 
that have emerged are those proteins that have been shown to be down-regulated in Nrf2 
KO mouse livers, while also being up-regulated following acute Nrf2 activation because 
they have the greatest dynamic range of expression and are therefore likely to result in 
differences that are quantifiable.  The need to define the importance of Nrf2 in the human 
population is becoming more pressing as Nrf2 inducers move closer to the market and 
research into the functions of Nrf2 identify further potential therapeutic applications for 
the modulation of Nrf2.  It is hoped that the biomarkers of Nrf2 activity and the pathways 
identified as Nrf2-regulated in this thesis can contribute to understanding the role of Nrf2 
in man and the importance of oxidative stress in drug safety.  
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